[go: up one dir, main page]

US20100075953A1 - Substituted piperazines, (1,4) diazepines, and 2,5-diazabicyclo (2.2.1) heptanes as histamine h1 and/or h3 antagonists or histamine h3 reverse antagonists - Google Patents

Substituted piperazines, (1,4) diazepines, and 2,5-diazabicyclo (2.2.1) heptanes as histamine h1 and/or h3 antagonists or histamine h3 reverse antagonists Download PDF

Info

Publication number
US20100075953A1
US20100075953A1 US12/562,285 US56228509A US2010075953A1 US 20100075953 A1 US20100075953 A1 US 20100075953A1 US 56228509 A US56228509 A US 56228509A US 2010075953 A1 US2010075953 A1 US 2010075953A1
Authority
US
United States
Prior art keywords
phenyl
oxy
piperidinyl
piperazine
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/562,285
Inventor
Rachael Ancliff
Colin David Eldred
Ashley Paul Hancock
Thomas Daniel Heightman
Heather Hobbs
Simon Teanby Hodgson
David Matthew Wilson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Priority to US12/562,285 priority Critical patent/US20100075953A1/en
Publication of US20100075953A1 publication Critical patent/US20100075953A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
    • C07D213/46—Oxygen atoms
    • C07D213/50—Ketonic radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/40—Nitrogen atoms attached in position 8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C07D215/46—Nitrogen atoms attached in position 4 with hydrocarbon radicals, substituted by nitrogen atoms, attached to said nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/50—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/08—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/06—1,2,3-Thiadiazoles; Hydrogenated 1,2,3-thiadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/192—Radicals derived from carboxylic acids from aromatic carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/215—Radicals derived from nitrogen analogues of carbonic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/26—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/84—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D307/85—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78—Ring systems having three or more relevant rings
    • C07D311/80—Dibenzopyrans; Hydrogenated dibenzopyrans
    • C07D311/82—Xanthenes
    • C07D311/84—Xanthenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 9
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Definitions

  • the present invention relates to novel piperazine and azepine derivatives having pharmacological activity, processes for their preparation, to compositions containing them and to their use in the treatment of neurodegenerative disorders including Alzheimer's disease.
  • WO 02/76925 (Eli Lilly) describes a series of compounds which are claimed to be histamine H3 antagonists.
  • WO 02/055496 (GlaxoSmithKline) describes a series of piperidine and piperazine derivatives which are claimed to be inducers of LDL-receptor expression.
  • WO 02/12214 (Ortho McNeil Pharmaceutical Inc.) describes a series of substituted aryloxyalkylamines which are claimed to be histamine H3 antagonists.
  • the histamine H3 receptor is expressed in both the mammalian central nervous system (CNS), and in peripheral tissues (Leurs et al., (1998), Trends Pharmacol. Sci. 19, 177-183). Activation of H3 receptors by selective agonists or histamine results in the inhibition of neurotransmitter release from a variety of different nerve populations, including histaminergic, adrenergic and cholinergic neurons (Schlicker et al., (1994), Fundam. Clin. Pharmacol. 8, 128-137).
  • H3 antagonists can facilitate neurotransmitter release in brain areas such as the cerebral cortex and hippocampus, relevant to cognition (Onodera et al., (1998), In: The Histamine H3 receptor, ed Leurs and Timmerman, pp 255-267, Elsevier Science B.V.).
  • H3 antagonists e.g. thioperamide, clobenpropit, ciproxifan and GT-2331
  • rodent models including the five choice task, object recognition, elevated plus maze, acquisition of novel task and passive avoidance (Giovanni et al., (1999), Behav. Brain Res. 104, 147-155).
  • the present invention provides, in a first aspect, a compound of formula (I):
  • R 1 represents hydrogen, —C 1-6 alkyl, —C 1-6 alkoxy, —C 3-8 cycloalkyl, —C 1-6 alkyl-C 3-8 cycloalkyl, aryl, heterocyclyl, heteroaryl, —C 1-6 alkyl-aryl, —C 1-6 alkyl-heteroaryl, —C 1-6 alkyl-heterocyclyl, -aryl-aryl, -aryl-heteroaryl, -aryl-heterocyclyl, -heteroaryl-aryl, -heteroaryl-heteroaryl, -heteroaryl-heterocyclyl, -heterocyclyl-aryl, -heterocyclyl-aryl, -heterocyclyl-heteroaryl, -heterocyclyl-aryl, -heterocyclyl-heteroaryl, -heterocycly
  • R 11 and R 12 independently represent C 1-6 alkyl or C 3-8 cycloalkyl or together with the nitrogen atom to which they are attached represent an N-linked nitrogen containing heterocyclyl group optionally substituted by one or more R 17 groups;
  • R 13 represents hydrogen, C 1-6 alkyl, —C 1-6 alkyl-C 1-6 alkoxy, C 3-8 cycloalkyl, —C 1-6 alkyl-C 3-8 cycloalkyl, —C 1-6 alkyl-aryl or heterocyclyl;
  • R 14 and R 17 independently represent halogen, C 1-6 alkyl, haloalkyl, OH, diC 1-6 alkylamino, C 1-6 alkoxy or heterocyclyl;
  • f and k independently represent 0, 1 or 2;
  • g is 0, 1 or 2 and h is 0, 1, 2 or 3, such that g and h cannot both be 0; with the proviso that when m represents 1, n and r both represent 0
  • R 1 represents a group other than hydrogen, —C 1-6 alkoxy or —C 1-6 alkyl-C 3-8 cycloalkyl; and R 1 is optionally substituted by one or more substituents other than COOR 15 , —C 1-6 alkyl-cyano, C 1-6 alkyl substituted by a COOR 15 group), C 2-6 alkenyl (optionally substituted by a COOR 15 group), C 2-6 alkynyl (optionally substituted by a COOR 15 group), C 1-6 alkoxy (optionally substituted by a COOR 15 group), C 2-6 alkenoxy, aryl, arylC 1-6 alkyl, —CO-aryl (optionally substituted by a halogen atom), —CO-heteroaryl, —C 1-6 alkyl-CO-aryl or C 3-7 cycloalkyl; and R 15 and R 16 independently represent a group other than C 3-8 cycloalkyl or together may be fused to form an
  • Alkyl groups may be straight chain or branched and the groups alkoxy and alkanoyl shall be interpreted similarly.
  • Alkyl moieties are more preferably C 1-4 alkyl, eg. methyl or ethyl.
  • halogen is used herein to describe, unless otherwise stated, a group selected from fluorine, chlorine, bromine or iodine.
  • aryl includes single and fused rings wherein at least one ring is aromatic, for example, phenyl, naphthyl, tetrahydronaphthalenyl, indanyl or fluorenyl.
  • heterocyclyl is intended to mean a 4-7 membered monocyclic saturated or partially unsaturated ring or a 4-7 membered saturated or partially unsaturated ring fused to a benzene ring containing 1 to 3 heteroatoms selected from oxygen, nitrogen or sulphur.
  • monocyclic rings include pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, tetrahydrofuranyl, diazepanyl, azepanyl and azocanyl.
  • Suitable examples of benzofused heterocyclic rings include indolinyl, isoindolinyl, benzodioxolyl and dihydroisoquinolinyl.
  • nitrogen containing heterocyclyl is intended to represent any heterocyclyl group as defined above which contains a nitrogen atom.
  • heteroaryl is intended to mean a 5-7 membered monocyclic aromatic or a fused 8-11 membered bicyclic aromatic ring containing 1 to 3 heteroatoms selected from oxygen, nitrogen and sulphur.
  • monocyclic aromatic rings include thienyl, furyl, pyrrolyl, triazolyl, imidazolyl, oxazolyl, thiazolyl, oxadiazolyl, isothiazolyl, isoxazolyl, thiadiazolyl, pyrazolyl, pyrimidyl, pyridazinyl, pyrazinyl and pyridyl.
  • fused aromatic rings include furopyridinyl and benzofused aromatic rings such as quinolinyl, isoquinolinyl, quinazolinyl, quinoxalinyl, cinnolinyl, naphthyridinyl, indolyl, indazolyl, pyrrolopyridinyl, benzofuranyl, benzothienyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzothiazolyl, benzisothiazolyl, benzoxadiazolyl, benzothiadiazolyl and the like.
  • Compounds of formula (I) and their pharmaceutically acceptable salts have affinity for and are antagonists and/or inverse agonists of the histamine H3 receptor and are believed to be of potential use in the treatment of neurological diseases including Alzheimer's disease, dementia, age-related memory dysfunction, mild cognitive impairment, cognitive dysfunction, epilepsy, neuropathic pain, inflammatory pain, migraine, Parkinson's disease, multiple sclerosis, stroke and sleep disorders including narcolepsy; psychiatric disorders including schizophrenia, attention deficit hypereactivity disorder, depression and addiction; and other diseases including obesity, asthma, allergic rhinitis, nasal congestion, chronic obstructive pulmonary disease and gastro-intestinal disorders.
  • neurological diseases including Alzheimer's disease, dementia, age-related memory dysfunction, mild cognitive impairment, cognitive dysfunction, epilepsy, neuropathic pain, inflammatory pain, migraine, Parkinson's disease, multiple sclerosis, stroke and sleep disorders including narcolepsy; psychiatric disorders including schizophrenia, attention deficit hypereactivity disorder, depression and addiction; and other diseases including obesity,
  • the invention also provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, for use as a therapeutic substance in the treatment or prophylaxis of the above disorders, in particular cognitive impairments in diseases such as Alzheimer's disease and related neurodegenerative disorders.
  • R 1 represents:
  • R 1 represents unsubstituted phenyl.
  • R 1 represents:
  • R 1 is optionally substituted by one or more (eg. 1, 2 or 3): halogen (eg. chlorine, fluorine or bromine); trifluoromethyl; —C 1-6 alkyl (eg. methyl, ethyl, isopropyl, propyl or t-butyl) optionally substituted by COOR 15 (eg. COOH, COOMe or COOEt); —C 1-6 alkoxy (eg. methoxy, butoxy, —OCH(Me) 2 or —OC(Me) 3 ) optionally substituted by COOR 15 (eg.
  • COOH or COOMe hydroxy; oxo; cyano; —C 1-6 alkyl-cyano (eg. —CH 2 —CN); C 1-6 alkenyl (eg. ethenyl) optionally substituted by COOR 15 (eg. COOMe); C 3-7 cycloalkyl (eg. cyclopentyl); C 1-6 alkylsulfonyl (eg. SO 2 Me); C 1-6 alkenoxy (eg. —OCH 2 CH ⁇ CH 2 ); C 1-6 alkylthio (eg. —S-ethyl); NR 15 R 16 (eg. N(Me) 2 ); —C 1-6 alkyl-aryl (eg.
  • benzyl aryl (eg. phenyl); —CO-aryl (eg. —CO-phenyl) optionally substituted by halogen (eg. chlorine); —CO-heteroaryl (eg. —CO-azetidinyl); —CO-heterocyclyl (eg. —CO-tetrahydropyranyl); —COOR 15 (eg. COOH, COOMe or COOt-butyl); —COR 15 (eg.
  • C 1-6 alkyl eg. methyl
  • halogen eg. fluorine
  • R 1 is optionally substituted by one or more (eg. 1, 2 or 3): halogen (eg. fluorine); oxo; cyano; —CONR 15 R 16 (eg. —CO-pyrrolidinyl) or —COR 15 (eg. —CO-isopropyl, —CO-cyclopropyl or —CO-cyclobutyl).
  • halogen eg. fluorine
  • oxo cyano
  • CONR 15 R 16 eg. —CO-pyrrolidinyl
  • COR 15 eg. —CO-isopropyl, —CO-cyclopropyl or —CO-cyclobutyl.
  • Z represents a bond, CO or CONR 10 . More preferably, Z represents bond or CO, especially CO.
  • R 10 represents hydrogen or C 1-6 alkyl.
  • m is 0 or 2, more preferably 0.
  • n is 0 or 1, more preferably n is 0.
  • R 2 is preferably halogen (eg. chlorine, bromine or fluorine), trifluoromethyl, cyano or C 1-6 alkyl (eg. methyl).
  • halogen eg. chlorine, bromine or fluorine
  • trifluoromethyl e.g. cyano or C 1-6 alkyl (eg. methyl).
  • r is 0.
  • R 2 is preferably C 1-6 alkyl (eg. methyl) or two R 4 groups together form a bridged CH 2 group.
  • p is 1.
  • R 3 represents —(CH 2 ) q —NR 11 R 12 .
  • R 3 represents a group of formula (I), preferably f is 0 or 1, g is 2, h is 1, k is 0 and R 13 represents hydrogen, optionally substituted C 1-6 alkyl (eg. ethyl, methylpropyl, isopropyl or methoxyethyl), C 3-8 cycloalkyl (eg. cyclopropyl, cyclobutyl or cyclopentyl) or —C 1-6 alkyl-C 3-8 cycloalkyl (eg. —CH 2 -cyclopropyl).
  • C 1-6 alkyl eg. ethyl, methylpropyl, isopropyl or methoxyethyl
  • C 3-8 cycloalkyl eg. cyclopropyl, cyclobutyl or cyclopentyl
  • —C 1-6 alkyl-C 3-8 cycloalkyl eg. —CH 2 -cyclopropy
  • R 3 represents a group of formula (I), more preferably f is 0, g is 2, h is 1, k is 0 and R 13 represents C 1-6 alkyl (eg. isopropyl) or C 3-8 cycloalkyl (eg. cyclopropyl or cyclobutyl).
  • q is 2 or 3, more preferably 3.
  • R 11 and R 12 independently represent C 1-6 alkyl (eg. methyl) or C 3-8 cycloalkyl (eg. cyclopentyl) or NR 11 R 12 represents a heterocyclic group (eg. piperidinyl, pyrrolidinyl, thiomorpholinyl, azepanyl or azocanyl optionally substituted by one or more halogen (eg. fluorine) or C 1-6 alkyl (eg. methyl or ethyl).
  • halogen eg. fluorine
  • NR 11 R 12 represents pyrrolidinyl, piperidinyl, azepanyl or azocanyl optionally substituted by one or more C 1-6 alkyl (eg. methyl or ethyl), especially unsubstituted piperidine.
  • —O—R 3 is present at the para position of the phenyl group with respect to the rest of the compound.
  • Preferred compounds according to the invention include examples E1-E503 as shown below, or a pharmaceutically acceptable salt thereof.
  • Compounds of formula (I) may form acid addition salts with acids, such as conventional pharmaceutically acceptable acids, for example maleic, hydrochloric, hydrobromic, phosphoric, acetic, fumaric, salicylic, sulphuric, citric, lactic, mandelic, tartaric and methanesulphonic. Salts, solvates and hydrates of compounds of formula (I) therefore form an aspect of the invention.
  • acids such as conventional pharmaceutically acceptable acids, for example maleic, hydrochloric, hydrobromic, phosphoric, acetic, fumaric, salicylic, sulphuric, citric, lactic, mandelic, tartaric and methanesulphonic. Salts, solvates and hydrates of compounds of formula (I) therefore form an aspect of the invention.
  • Certain compounds of formula (I) are capable of existing in stereoisomeric forms. It will be understood that the invention encompasses all geometric and optical isomers of these compounds and the mixtures thereof including racemates. Tautomers also form an aspect of the invention. For example, when R 3 represents (CH 2 ) q NR 11 R 12 and NR 11 R 12 represents a nitrogen containing heterocyclyl group substituted by one or more C 1-6 alkyl groups it will be appreciated that the present invention extends to cover diastereomeric and enantiomeric compounds.
  • the present invention also provides a process for the preparation of a compound of formula (I) or a pharmaceutically acceptable salt thereof, which process comprises:
  • R 1 , Z, R 4 , p, m, r, R 2 and n are as defined above, with a compound of formula R 3′ -L 1 , wherein R 3′ is as defined above for R 3 or a group convertible thereto and L 1 represents a suitable leaving group such as a halogen atom (eg. bromine or chlorine) or an optionally activated hydroxyl group; or (b) preparing a compound of formula (I) wherein Z represents CO by reacting a compound of formula (III)
  • R 4 , r, p, m, R 2 , n and R 3 are as defined above, with a compound of formula R 1 —COX, wherein R 1 is as defined above and X represents a suitable leaving group such as an activated hydroxy group, a suitable halogen atom or benzotriazolyl; or (c) preparing a compound of formula (I) wherein Z represents SO 2 by reacting a compound of formula (III) as defined above with a compound of formula R 1 —SO 2 Cl, wherein R 1 is as defined above; or (d) preparing a compound of formula (I) wherein Z represents NR 10 CO by reacting a compound of formula (III) as defined above with a compound of formula R 1 —N ⁇ C ⁇ O, wherein R 1 is as defined above; or (e) preparing a compound of formula (I) wherein Z represents CONR 10 by reacting a compound of formula (III) as defined above, sequentially with phosgene in
  • R 4 , r, R 2 , n, R 3 , R 1 , Z and p are as defined above under reducing conditions; or (g) deprotecting a compound of formula (I) which is protected; and (h) interconversion to other compounds of formula (I).
  • process (a) typically comprises the use of a suitable base, such as potassium carbonate in an appropriate solvent such as 2-butanone optionally in the presence of an activating reagent such as potassium iodide at an appropriate temperature such as reflux.
  • a suitable base such as potassium carbonate
  • an appropriate solvent such as 2-butanone
  • an activating reagent such as potassium iodide
  • process (a) typically comprises an alkylation reaction using analogous conditions to those described above.
  • process (a) typically comprises the use of a phosphine such as triphenylphosphine in a suitable solvent such as tetrahydrofuran, followed by addition of an azodicarboxylate such as diethylazodicarboxylate at a suitable temperature such as room temperature.
  • a phosphine such as triphenylphosphine
  • a suitable solvent such as tetrahydrofuran
  • Process (b) typically comprises the use of an appropriate solvent such as dichloromethane optionally in the presence of an organic or inorganic base such as potassium carbonate or in the presence of a suitable coupling agent such as 1,3-dicyclohexylcarbodiimide and 1-hydroxybenzotriazole.
  • an appropriate solvent such as dichloromethane
  • an organic or inorganic base such as potassium carbonate
  • a suitable coupling agent such as 1,3-dicyclohexylcarbodiimide and 1-hydroxybenzotriazole.
  • Processes (c) and (d) typically comprise the use of a suitable solvent such as 2-butanone.
  • Process (e) typically comprises the use of a suitable base, such as triethylamine.
  • Process (f) comprises the use of reductive conditions (such as treatment with a borohydride eg. sodium triacetoxyborohydride), optionally in the presence of an acid, such as acetic acid, followed by optional deprotection in the event that the compound of formula (XI) is a protected derivative.
  • reductive conditions such as treatment with a borohydride eg. sodium triacetoxyborohydride
  • an acid such as acetic acid
  • Suitable amine protecting groups include sulphonyl (e.g. tosyl), acyl (e.g. acetyl, 2′,2′,2′-trichloroethoxycarbonyl, benzyloxycarbonyl or t-butoxycarbonyl) and arylalkyl (e.g. benzyl), which may be removed by hydrolysis (e.g. using an acid such as hydrochloric acid in dioxan or trifluoroacetic acid in dichloromethane) or reductively (e.g.
  • hydrolysis e.g. using an acid such as hydrochloric acid in dioxan or trifluoroacetic acid in dichloromethane
  • reductively e.g.
  • Suitable amine protecting groups include trifluoroacetyl (—COCF 3 ) which may be removed by base catalysed hydrolysis or a solid phase resin bound benzyl group, such as a Merrifield resin bound 2,6-dimethoxybenzyl group (Ellman linker), which may be removed by acid catalysed hydrolysis, for example with trifluoroacetic acid.
  • Process (h) may be performed using conventional interconversion procedures such as epimerisation, oxidation, reduction, alkylation, nucleophilic or electrophilic aromatic substitution, ester hydrolysis or amide bond formation.
  • compounds of formula (I) wherein R 3 represents a group of formula (I) may be interconverted at the R 13 position by reaction with an alkyl halide such as 1-chloro-2-methoxyethane in the presence of a base such as potassium carbonate in a suitable solvent such as 2-butanone optionally in the presence of a transfer reagent such as potassium iodide.
  • Such interconversion may also be carried out by reductive amination, for example, with acetone in the presence of a borohydride such as sodium triacetoxyborohydride and optionally an acid such as acetic acid in a suitable solvent such as dichloromethane.
  • a borohydride such as sodium triacetoxyborohydride
  • an acid such as acetic acid
  • a suitable solvent such as dichloromethane
  • R 4 , r, R 2 , n, R 3 , p are as defined above and the compound of formula (V) may be optionally protected.
  • Step (i) may be performed in an analogous manner to that described for process (f) above.
  • R 4 , r, p, R 2 , n and R 3 are as defined above and P 1 represents a suitable protecting group (such as Boc).
  • Step (i) may be performed when P 1 represents Boc by reacting a compound of formula (IX) with di-t-butyl carbonate in the presence of a suitable base (eg. triethylamine) in the presence of a suitable solvent (eg. dichloromethane) at a suitable temperature (eg. room temperature).
  • a suitable base eg. triethylamine
  • a suitable solvent eg. dichloromethane
  • Step (ii) may be performed in an analogous manner to the procedures shown below for the preparation of compounds of formula (IV).
  • Step (iii) typically comprises a deprotection reaction, for example, when P 1 represents Boc, deprotection may typically comprise reaction of a compound of formula (III) P' with hydrochloric acid in dioxan or trifluoroacetic acid in dichloromethane.
  • R 2 , R 3 , R 4 , n, p, r are as defined above
  • P 2 represents a suitable protecting group such as Boc
  • L 5 represents a suitable leaving group such as a halogen atom (eg. bromine).
  • Step (i) typically comprises reaction of a compound of formula (XII) with a compound of formula (XIII) in the presence of an inert solvent such as dimethylformamide or acetonitrile.
  • Step (ii) typically comprises a deprotection reaction, for example, when P 2 represents Boc, deprotection may typically comprise reaction of a compound of formula (III) pii with hydrochloric acid in dioxan or trifluoroacetic acid in dichloromethane.
  • R 2 , n, q, R 11 , R 12 are as defined above and L 1 , L 2 , L 3 and L 4 represent suitable leaving groups (eg. halogen atoms, such as bromine or chlorine).
  • Steps (i), (ii) and (iii) may be performed using similar conditions to those described for process (a) above.
  • L 4 represents a suitable leaving group such as a halogen atom or a hydroxyl group and R 13a is as defined above for R 13 or a protecting group such as t-butoxycarbonyl, followed by optional deprotection.
  • Step (i) may be performed using similar conditions to those described for process (a) above.
  • Compounds of formula (XI) wherein Z represents a bond may be prepared by reacting a compound of formula R 1 -L 6 (wherein R 1 is as defined above and L 6 represents a suitable leaving group, eg. a bromine atom) with a compound of formula (XII), such as 1-BOC-piperazine, in the presence of a palladium catalyst, such as tris(dibenzylideneacetone) dipalladium, and a ligand such as 2-cyclohexylphosphino-2′-(N,N-dimethylamino)biphenyl, in an inert solvent such as tetrahydrofuran and in the presence of a base such as lithium bis(trimethylsilyl)amide in an inert atmosphere (nitrogen) and at elevated temperature such as 80° C., according to the procedure of Buchwald, Organic Letters, 2002, 4, 2885-2888.
  • a palladium catalyst such as tris(dibenzylideneacetone
  • Histamine H1 receptors are widely distributed throughout the CNS and periphery, and are involved in wakefulness and acute inflammatory processes [Hill et al, Pharmacol. Rev. 49:253-278 (1997)]. Seasonal allergic rhinitis, and other allergic conditions, are associated with the release of histamine from mast cells. The activation of H1 receptors in blood vessels and nerve endings are responsible for many of the symptoms of allergic rhinitis, which include itching, sneezing, and the production of watery rhinorrhea. Antihistamine compounds, i.e.
  • drugs which are selective H1 receptor antagonists such as chlorphenyramine and cetirizine, are effective in treating the itching, sneezing and rhinorrhea associated with allergic rhinitis, but are not very effective in treating the nasal congestion symptoms [Aaronson, Ann. Allergy, 67:541-547, (1991)].
  • H3 receptor agonists are known to inhibit the effect of sympathetic nerve activation on vascular tone in porcine nasal mucosa [Varty & Hey. Eur. J. Pharmacol., 452:339-345, (2002)].
  • H3 receptor agonists inhibit the decrease in nasal airway resistance produced by sympathetic nerve activation [Hey et al, Arzneim-Forsch Drug Res., 48:881-888 (1998)].
  • H3 receptor antagonists in combination with histamine H1 receptor antagonists reverse the effects of mast cell activation on nasal airway resistance and nasal cavity volume, an index of nasal congestion [McLeod et al, Am. J. Rhinol., 13: 391-399, (1999)].
  • a combined histamine H1 and H3 receptor antagonist, such as the series described herein, would be effective in the treatment of both the nasal congestion and the sneezing, itching and rhinorrhea associated with both seasonal and perennial allergic rhinitis.
  • examples of disease states in which dual histamine H1 and H3 antagonists have potentially beneficial anti-inflammatory effects include diseases of the respiratory tract such as asthma (including allergic and non-allergic), allergic rhinitis, sinusitis, bronchitis (including chronic bronchitis), bronchiectasis, chronic obstructive pulmonary disease (COPD) and cystic fibrosis.
  • diseases of the respiratory tract such as asthma (including allergic and non-allergic), allergic rhinitis, sinusitis, bronchitis (including chronic bronchitis), bronchiectasis, chronic obstructive pulmonary disease (COPD) and cystic fibrosis.
  • disease states in which dual histamine H1 and H3 antagonists have potentially beneficial effects include diseases of the gastrointestinal tract such as intestinal inflammatory diseases including inflammatory bowel disease (e.g. Crohn's disease or ulcerative colitis) and intestinal inflammatory diseases secondary to radiation exposure or allergen exposure.
  • intestinal inflammatory diseases including inflammatory bowel disease (e.g. Crohn's disease or ulcerative colitis) and intestinal inflammatory diseases secondary to radiation exposure or allergen exposure.
  • Dual histamine H1 and H3 antagonists of the present invention may also be of use in the treatment of sleep/wake disorders, arousal/vigilance disorders, migraine, dementia, mild cognitive impairment (pre-dementia), cognitive dysfunction, Alzheimer's disease, epilepsy, narcolepsy, eating disorders, motion sickness, vertigo, attention deficit hyperactivity disorders, learning disorders, memory retention disorders, schizophrenia, depression, manic disorders, bipolar disorders and diabetes.
  • Diseases of principal interest for a dual histamine H1 and H3 antagonist include asthma, COPD and inflammatory diseases of the upper respiratory tract involving seasonal and perennial allergic rhinitis, non-allergic rhinitis, and the specific symptoms associated with these diseases including nasal congestion, rhinorrhoea, sneezing, cough and itching (pruritis) of eyes, ears, nose and throat.
  • Other diseases of principal interest include cough, chronic urticaria, allergic conjunctivitis, nasal polyposis, sinusitis, psoriasis, eczema and allergic dermatoses (including urticaria, atopic dermatitis, contact dermatitis, drug rashes and insect bites).
  • Diseases of principal interest include asthma, COPD, cognitive disorders and inflammatory diseases of the upper respiratory tract involving seasonal and perennial rhinitis.
  • Preferred diseases of principal interest include asthma, cognitive disorders and inflammatory diseases of the upper respiratory tract involving seasonal and perennial rhinitis.
  • Further diseases also of principal interest include inflammatory diseases of the gastrointestinal tract such as inflammatory bowel disease.
  • the invention also provides a dual histamine H1 and H3 antagonist compound of formula (I) or a pharmaceutically acceptable salt thereof, for use as a therapeutic substance in the treatment or prophylaxis of the above disorders, in particular allergic rhinitis.
  • Preferred dual histamine H1 and H3 antagonist compounds of formula (I) are those wherein:
  • R 1 represents aryl (eg. phenyl, naphthyl or tetrahydronaphthyl) or heteroaryl (eg. benzofuranyl, indolyl or quinolinyl); R 1 is optionally substituted by one or more (eg. 1, 2 or 3): halogen (eg. chlorine, fluorine or bromine); trifluoromethyl; —C 1-6 alkyl (eg. methyl, ethyl, isopropyl, propyl or t-butyl) optionally substituted by COOR 15 (eg. COOEt); —C 1-6 alkoxy (eg. methoxy) optionally substituted by COOR 15 (eg.
  • COOMe C 1-6 alkenyl (eg. ethenyl); NR 15 R 16 (eg. N(Me) 2 ); or C 1-6 alkylthio (eg. —S-ethyl) groups; Z is a bond or CO; m is 0 or 2; n is 0; r is 0; p is 1.
  • R 3 represents —(CH 2 ) q —NR 11 R 12 ; q represents 3; and NR 11 R 12 represents pyrrolidinyl, piperidinyl, azepanyl or azocanyl optionally substituted by one or more C 1-6 alkyl (eg. methyl or ethyl), more preferably piperidinyl substituted by one or two methyl or ethyl groups.
  • the invention further provides a method of treatment or prophylaxis of the above disorders, in mammals including humans, which comprises administering to the sufferer a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof.
  • the invention provides the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for use in the treatment of the above disorders.
  • the compounds of formula (I) are usually formulated in a standard pharmaceutical composition.
  • Such compositions can be prepared using standard procedures.
  • the present invention further provides a pharmaceutical composition for use in the treatment of the above disorders which comprises the compound of formula (I) or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
  • the present invention further provides a pharmaceutical composition which comprises the compound of formula (I) or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
  • compositions according to the invention may also be used in combination with other therapeutic agents, for example anti-inflammatory agents (such as corticosteroids (e.g. fluticasone propionate, beclomethasone dipropionate, mometasone furoate, triamcinolone acetonide or budesonide) or NSAIDs (eg.
  • corticosteroids e.g. fluticasone propionate, beclomethasone dipropionate, mometasone furoate, triamcinolone acetonide or budesonide
  • NSAIDs eg.
  • chemokine antagonists e.g CCR3, CCR1, CCR2, CXCR1, CXCR2
  • iNOS inhibitors e.g. CCR3, CCR1, CCR2, CXCR1, CXCR2
  • iNOS inhibitors e.g. CCR3, CCR1, CCR2, CXCR1, CXCR2
  • beta-2 integrin antagonists and adenosine 2a agonists beta adrenergic agents
  • beta adrenergic agents such as salmeterol, salbutamol, formoterol, fenoterol or terbutaline and salts thereof
  • sympathomimetics e.g pseudoephedrine or oxymetazoline
  • other antagonists at the histamine receptor e.g H4
  • cholinesterase inhibitors e.g. cholinergic antagonists
  • antiinfective agents eg. antibiotics, antivirals.
  • a pharmaceutical composition of the invention which may be prepared by admixture, suitably at ambient temperature and atmospheric pressure, is usually adapted for oral, topical, parenteral or rectal administration and, as such, may be in the form of tablets, capsules, oral liquid preparations, powders, granules, lozenges, reconstitutable powders, injectable or infusible solutions or suspensions or suppositories. Orally administrable compositions are generally preferred.
  • Tablets and capsules for oral administration may be in unit dose form, and may contain conventional excipients, such as binding agents, fillers, tabletting lubricants, disintegrants and acceptable wetting agents.
  • the tablets may be coated according to methods well known in normal pharmaceutical practice.
  • Oral liquid preparations may be in the form of, for example, aqueous or oily suspension, solutions, emulsions, syrups or elixirs, or may be in the form of a dry product for reconstitution with water or other suitable vehicle before use.
  • Such liquid preparations may contain conventional additives such as suspending agents, emulsifying agents, non-aqueous vehicles (which may include edible oils), preservatives, and, if desired, conventional flavourings or colorants.
  • fluid unit dosage forms are prepared utilising a compound of the invention or pharmaceutically acceptable salt thereof and a sterile vehicle.
  • the compound depending on the vehicle and concentration used, can be either suspended or dissolved in the vehicle.
  • the compound can be dissolved for injection and filter sterilised before filling into a suitable vial or ampoule and sealing.
  • adjuvants such as a local anaesthetic, preservatives and buffering agents are dissolved in the vehicle.
  • the composition can be frozen after filling into the vial and the water removed under vacuum.
  • Parenteral suspensions are prepared in substantially the same manner, except that the compound is suspended in the vehicle instead of being dissolved, and sterilisation cannot be accomplished by filtration.
  • the compound can be sterilised by exposure to ethylene oxide before suspension in a sterile vehicle.
  • a surfactant or wetting agent is included in the composition to facilitate uniform distribution of the compound.
  • the composition may contain from 0.1% to 99% by weight, preferably from 10 to 60% by weight, of the active material, depending on the method of administration.
  • the dose of the compound used in the treatment of the aforementioned disorders will vary in the usual way with the seriousness of the disorders, the weight of the sufferer, and other similar factors.
  • suitable unit doses may be 0.05 to 1000 mg, more suitably 1.0 to 200 mg, and such unit doses may be administered more than once a day, for example two or three a day. Such therapy may extend for a number of weeks or months.
  • the title compound (D6) was prepared from 4-(4-formyl-phenoxy)-piperidine-1-carboxylic acid tert-butyl ester (D5) and piperazine using the method described in Description 1 (D1).
  • the title compound (D7) was prepared from 4-(4-piperazin-1-ylmethyl-phenoxy)-piperidine-1-carboxylic acid tert-butyl ester (D6) and benzoyl chloride using the method described in Example 24 (E24). MS(ES+) m/e 480 [M+H] + .
  • Methyl 3-bromo-4-ethyl-benzoate (D44) (5 g) in NMP (180 mL) was treated with copper (I) cyanide (3.69 g). The mixture was then heated at reflux for 5 h, under argon. After cooling to 20° C. the reaction mixture was diluted with water, then filtered through kieselguhr, washing well with water and EtOAc. The organic layer was washed with water, brine and dried over MgSO 4 .
  • Methyl 3-cyano-4-ethyl-benzoate (D45) (1.92 g) was dissolved in MeOH (50 mL) before adding 1M NaOH solution (15.24 mL) and stirring the resulting mixture overnight at room temperature, under argon.
  • the reaction mixture was diluted with water, and extracted with EtOAc.
  • the aqueous layer was acidified to pH1 using 2M HCl before extracting with EtOAc.
  • the combined extracts were washed with brine, dried over MgSO 4 and the solvent evaporated to dryness in vacuo to afford the title compound (1.63 g).
  • 1 H NMR (CDCl 3 ) ⁇ 1.35 (3H, t), 2.97 (2H, q), 7.49 (1H, d), 8.24 (1H, dd), 8.36 (1H, d).
  • LCMS was conducted on a Supelcosil LCABZ+PLUS column (3.3 cm ⁇ 4.6 mm ID) eluting with 0.1% formic acid and 0.01 M ammonium acetate in water (solvent A) and 0.05% formic acid and 5% water in acetonitrile (solvent B), using the following elution gradient 0.0-7 min 0% B, 0.7-4.2 min 100% B, 4.2-5.3 min 0% B, 5.3-5.5 min 0% B at a flow rate of 3 mL/min.
  • the mass spectra were recorded on a Fisons VG Platform spectrometer using electrospray positive and negative mode (ES+ve and ES ⁇ ve).
  • Preparative mass directed HPLC was conducted on a Waters FractionLynx system comprising of a Waters 600 pump with extended pump heads, Waters 2700 autosampler, Waters 996 diode array and Gilson 202 fraction collector on a 10 cm ⁇ 2.54 cm ID ABZ+column, eluting with 0.1% formic acid in water (solvent A) and 0.1% formic acid in acetonitrile (solvent B), using an appropriate elution gradient, at a flow rate of 20 ml/min and detecting at 200-320 nm at room temperature.
  • Mass spectra were recorded on Micromass ZMD mass spectrometer using electrospray positive and negative mode, alternate scans. The software used was MassLynx 3.5 with OpenLynx and FractionLynx options.
  • N-Cyclohexylcarbodiimide, N-methyl polystyrene HL (200-400 mesh) 1.8 mMol/g (650 mg, 1.172 mmol) was suspended in a (1:1) mixture of dichloromethane and dimethylformamide and treated sequentially with benzoic acid (72 mg, 0.58 mmol), 1-hydroxybenzotriazole hydrate (80 mg, 0.58 mmol) and stirred for 10 minutes at room temperature.
  • Examples 2-11 were prepared from Description 2 (D2) using an analogous method to that described in Example 1 (E1) by substituting benzoic acid for the appropriate acid indicated in the table.
  • Examples 13-15 were prepared from Description 4 (D4) using an analogous method to that described in Example 12 (E12) by substituting benzo[1,3]dioxole-5-carboxylic acid for the appropriate acid indicated in the table.
  • Examples 16-23 were prepared from Description 4 (D4) using an analogous method to that described in Example 12 (E12) by substituting benzo[1,3]dioxole-5-carboxylic acid for the appropriate acid indicated in the table followed by further purification by column chromatography on silica gel eluting with a mixture of 0.880 ammonia/methanol/dichloromethane (0.5:4.5:95).
  • Examples 26-28 were prepared from Description 4 (D4) using an analogous method to that described in Example 25 (E25) by substituting benzenesulfonyl chloride for the appropriate sulfonyl chloride indicated in the table.
  • Examples 29-31 were prepared from Description 4 (D4) using an analogous method to that described in Example 25 (E25) by substituting benzenesulfonyl chloride for the appropriate sulfonyl chloride indicated in the table followed by further purification by column chromatography on silica gel eluting with a mixture of 0.880 ammonia/methanol/dichloromethane (0.5:4.5:95).
  • Examples 38-39 were prepared from 1-[3-(3-piperidin-1-yl-propoxy)-phenyl]-piperazine (D15) using the same procedure as described in Examples 36 and 37, respectively.
  • Examples 43-45 were prepared from 1-[3-(3-piperidin-1-yl-propoxy)-phenyl]-piperazine (D15) using the same procedure as described in Examples 40, 41 and 42, respectively.
  • Examples 49-50 were prepared from 1-[3-(3-piperidin-1-yl-propoxy)-phenyl]-piperazine (D15) using the same procedure as described in Examples 46 and 47, respectively.
  • Tris(dibenzylidineacetone) di palladium (0) (5 mol %; 23 mg) was added to a mixture of 1-[4-(3-piperidin-1-yl-propoxy)-phenyl]-piperazine (D11) (150 mg; 0.49 mmol), 3,4-dichloro bromo benzene (160 mg; 1.2 eq), sodium tert-butoxide (71 mg; 1.1 eq) and racemic 2,2′-bis(diphenylphosphino)-1,1′-binaphthyl (7.5 mol %; 24 mg) in dry toluene (3 ml). The resulting mixture was heated at reflux under argon for 18 hours.
  • the title compound (E52) was prepared from 1-[3-(3-piperidin-1-yl-propoxy)-phenyl]-piperazine (D15) using the same method as described in Example 51 (E51).
  • Examples 64-75 were prepared in an array format using the same method described in Example 63c from 1-[4-(3-chloropropoxy)phenyl]-4-(1-naphthoyl)piperazine (0.067 mmol), the appropriate secondary amine (5.0 eq), potassium carbonate (5.0 eq), and potassium iodide (5.0 eq) in 2-butanone (2 ml).
  • the products were purified by mass directed auto-preparative HPLC to provide the compounds as TFA salts.
  • 1,1-Dimethylethyl 4- ⁇ 4-[(3-chloropropyl)oxy]phenyl ⁇ -1-piperazinecarboxylate (D9) (1.6 g), was dissolved in 2-butanone (10 ml). Potassium carbonate (1.38 g) and a catalytic amount of potassium iodide were added, followed by 2-methylpiperidine (0.99 g). The mixture was heated at reflux for 72 h under nitrogen. The reaction mixture was diluted with water and extracted with dichloromethane. The organic phases were separated using a hydrophobic frit, combined and evaporated in vacuo.
  • Examples 77 to 224 were prepared in an array format in vials using a solution of the appropriate carboxylic acid (0.1 mmol) in DMF (0.5 ml) and a solution of O-(1H-benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium tetrafluoroborate (TBTU) (0.15 mmol) in DMF (0.5 ml) and diisopropylethylamine (0.2 mmol).
  • TBTU O-(1H-benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium tetrafluoroborate
  • TBTU O-(1H-benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium tetrafluoroborate
  • TBTU O-(1H-benzotriazol-1-yl)-N,N,N′,N′-te
  • E226a 4-(4-Acetylpiperazin-1-yl)-3-bromophenyl acetate
  • the dichloromethane layer was diluted (1 L) and separated, washed with an equal volume of water, dried, evaporated and purified by chromatography on Biotage (800 g cartridge) eluting with ethyl acetate-hexane (3:1) to give the title compound. (34.8 g) mp 75° C.
  • E229a 1,1-Dimethylethyl 4-(8-quinolinyl)-1-piperazinecarboxylate
  • Examples 230-236 were prepared in an analogous manner to that described for E229d from known starting materials and those indicated in the table below:
  • Examples 238-244 were prepared in an analogous manner to that described for E229d from known starting materials and those indicated in the table below:
  • Polystyryl-carbodiimide (450 mmol) was treated with a solution of 9H-xanthene-9-carboxylic acid (34 mg) in DMF (2 ml) and shaken for 5 min then treated with a solution of 1-[4-(3-piperidin-1-ylpropoxy)phenyl]piperazine (D11) (30 mg) in DMF (1 ml) and shaken at room temperature for 20 h.
  • Polystyryl-isocyanate (100 mmol) was added and the mixture shaken for a further 24 h. The mixture was then filtered and the filtrate loaded onto a SCX cartridge.
  • Examples 248-251 were prepared according to the procedure for Example 247.
  • E253b 1-[4-(Methoxycarbonylmethoxy)naphth-1-oyl]-4-[4-(3-piperidin-1-ylpropoxy)phenyl]piperazine
  • Step 2 1,1-Dimethylethyl 4-[(4- ⁇ 4-[(4-fluorophenyl)carbonyl]-1-piperazinyl ⁇ phenyl)oxy]-1-piperidinecarboxylate
  • Di-tert-butyl azodicarboxylate (2.4 g, 10.3 mmol) was added to a mixture of 4- ⁇ 4-[(4-fluorophenyl)carbonyl]-1-piperazinyl ⁇ phenol (2.57 g, 8.6 mmol), triphenyl phospine (2.7 g, 10.3 mmol) and 1,1-dimethylethyl 4-hydroxy-1-piperidinecarboxylate (2 g, 10.3 mmol) in tetrahydrofuran (30 ml). The mixture was stirred at room temperature for 18 hours. The reaction was diluted with ethyl acetate and washed with 2 molar sodium hydroxide solution.
  • Step 4 1-[(4-Fluorophenyl)carbonyl]-4-(4- ⁇ [1-(1-methylethyl)-4-piperidinyl]oxy ⁇ phenyl)piperazine
  • Examples 256-259 were prepared in the same manner as Example 255 using the appropriate ketone or aldehyde as indicated in the table:
  • Examples 261-262 may be prepared in an analogous manner to that described in Example 255, step 4 from pentan-3-one and the product of Example 255, step 3.
  • Di-tert-butyl azodicarboxylate (5.9 g, 25.8 mmol) was added to a mixture of 4-iodophenol (4.72 g, 21.5 mmol), triphenyl phospine (6.8 g, 25.8 mmol) and 1,1-dimethylethyl 4-hydroxy-1-piperidinecarboxylate (5.18 g, 25.8 mmol) in tetrahydrofuran (100 ml). The mixture was stirred at room temperature for 18 hours. The reaction was diluted with ethyl acetate and washed with 2 molar sodium hydroxide solution. The organic portion was dried (sodium sulphate) and evaporated.
  • Step 4 1,1-Dimethylethyl 4-(4- ⁇ [1-(1-methylethyl)-4-piperidinyl]oxy ⁇ phenyl)-1-piperazinecarboxylate
  • Step 6 1-(4- ⁇ [1-(1-Methylethyl)-4-piperidinyl]oxy ⁇ phenyl)-4-(tetrahydro-2H-pyran-4-ylcarbonyl)piperazine
  • Examples 264 to 268 were prepared in the same manner as Example 263 using the appropriate acid highlighted in the table below:
  • Step 1 4-(4- ⁇ [3-(1-Piperidinyl)propyl]oxy ⁇ phenyl)-1-piperazinecarbonyl chloride hydrochloride salt
  • Step 2 4- ⁇ [4-(4- ⁇ [3-(1-Piperidinyl)propyl]oxy ⁇ phenyl)-1-piperazinyl]carbonyl ⁇ morpholine
  • Morpholine (75 ⁇ l, 1.1 mmol) was added to a mixture of the product of Step 1 (4-(4- ⁇ [3-(1-piperidinyl)propyl]oxy ⁇ phenyl)-1-piperazinecarbonyl chloride hydrochloride salt) (170 mg, 0.42 mmol) and triethylamine (126 ⁇ l, 0.88 mmol) in dichloromethane (5 ml).
  • Examples 270 to 282 were prepared in the same manner as Example 269 using the appropriate amine highlighted in the table below.
  • Step 1 Phenylmethyl 4- ⁇ 4-[(1- ⁇ [(1,1-dimethylethyl)oxy]carbonyl ⁇ -4-piperidinyl)oxy]phenyl ⁇ -1-piperazinecarboxylate
  • Step 5 4-[(4- ⁇ 4-[(1-Cyclobutyl-4-piperidinyl)oxy]phenyl ⁇ -1-piperazinyl)carbonyl]morpholine
  • Example 294 was Prepared in the Same Manner as Example 293 from Piperidine.
  • Triphenylphosphine (2.79 g, 10.6 mmol) was added to a mixture of iodine (2.59 g, 10.2 mmol) in toluene (90 ml). After 5 minutes, pyridine (1.65 ml, 20.4 mmol) followed by the product from Step 1 was added. The resulting mixture was heated under reflux for 3 hours. The cooled reaction mixture was filtered and the filtrate was washed with saturated sodium thiosulfate and brine, dried under magnesium sulphate, filtered and concentrated in vacuo.
  • Step 4 1,1-Dimethylethyl 4[( ⁇ 4-[4-(phenylcarbonyl)-1-piperazinyl]phenyl ⁇ oxy)methyl]-1-piperidine carboxylate
  • step 2 The product from step 2 (1.83 g, 5.63 mmol), the product from step 3 (1.59 g, 5.63 mmol), potassium carbonate (1.86 g, 13.5 mmol) and potassium iodide (2.24 g, 13.5 mmol) were added together in 2-butanone (70 ml) and the mixture heated under reflux for 24 hours. The mixture was allowed to cool to room temperature, treated with sodium thiosulfate (1M, 15 ml) and extracted with ethyl acetate. The organic layer was separated, washed with water and brine, dried under magnesium sulphate and evaporated in vacuo. The title compound (0.30 g) was obtained by silica gel chromatography eluting with a mixture of ethyl acetate:hexane (1:1). MS (ES+) m/e 480 [M+H] + .
  • step 4 The product from step 4 (0.30 g, 0.63 mmol) was dissolved in dichloromethane (3 ml), treated with trifluoroacetic acid (2 ml) and stirred at room temperature under argon for 2 hours. The solvent was removed in vacuo and the residue dissolved in methanol and passed down an SCX ion exchange column (5 g) eluting with methanol followed by a mixture of 0.880 ammonia:methanol (1:9). The basic fractions were combined and concentrated in vacuo to afford the title compound (0.1 g); MS (ES+) m/e 380 [M+H] + .
  • Step 6 1-[4-( ⁇ [1-(1-Methylethyl)-4-piperidinyl]methyl ⁇ oxy)phenyl]-4-(phenylcarbonyl)piperazine
  • step 5 The product of step 5 (90 mg, 0.24 mmol) in dry dichloromethane (4 ml) was treated with acetone (0.06 ml, 0.72 mmol) and glacial acetic acid (1 drop) and stirred at ambient temperature for 15 minutes. Sodium triacetoxyborohydride (152 mg, 0.72 mmol) was added and the reaction mixture stirred at ambient temperature under argon for 36 hours. The reaction mixture was diluted with methanol and passed down an SCX ion exchange column (5 g) eluting with methanol followed by a mixture of 0.880 ammonia:methanol (1:9). The basic fractions were combined and concentrated in vacuo to afford the title compound (98 mg); MS (ES+) m/e 422 [M+H] + .
  • Step 3 1,1-Dimethylethyl (3S)-3-[( ⁇ 4-[4-(phenylcarbonyl)-1-piperazinyl]phenyl ⁇ oxy)methyl]-1-piperidinecarboxylate
  • Step 4 1-(Phenylcarbonyl)-4-(4- ⁇ [(3S)-3-piperidinylmethyl]oxy ⁇ phenyl)piperazine
  • Step 5 1-[4-( ⁇ [(3S)-1-(1-Methylethyl)-3-piperidinyl]methyl ⁇ oxy)phenyl]-4-(phenylcarbonyl)piperazine
  • Example 296 Step 4 The following examples were prepared from the product of Example 296 Step 4 using the method of Example 295 Step 6 with the appropriate ketone or aldehyde as indicated in the table below.
  • Step 3 1,1-Dimethylethyl (3R)-3-[( ⁇ 4-[4-(phenylcarbonyl)-1-piperazinyl]phenyl ⁇ oxy)methyl]-1-piperidinecarboxylate
  • Step 5 1-[4-( ⁇ [(3R)-1-(1-Methylethyl)-3-piperidinyl]methyl ⁇ oxy)phenyl]-4-(phenylcarbonyl)piperazine
  • Example 300 Step 4 The following examples were prepared from the product of Example 300 Step 4 using the method of Example 295 Step 6 using the appropriate aldehyde or ketone as indicated.
  • Step 2 1,1-Dimethylethyl (3S)-3- ⁇ [(4- ⁇ 4-[(4-cyanophenyl)carbonyl]-1-piperazinyl ⁇ phenyl)oxy]methyl ⁇ -1-piperidinecarboxylate
  • Step 3 4- ⁇ [4-(4- ⁇ [(3S)-3-Piperidinylmethyl]oxy ⁇ phenyl)-1-piperazinyl]carbonyl ⁇ benzonitrile
  • Step 4 4-( ⁇ 4-[4-( ⁇ [(3S)-1-Cyclopentyl-3-piperidinyl]methyl ⁇ oxy)phenyl]-1-piperazinyl ⁇ carbonyl)benzonitrile
  • step 1 The product from step 1 was dissolved in 2-butanone (30 ml), treated with 1-(3-chloropropyl)piperidine hydrochloride (0.72 g, 3.63 mmol), potassium carbonate (1.17 g, 8.48 mmol) and sodium iodide (0.15 g, 0.91 mmol) and heated under reflux for 18 hours. The mixture was allowed to cool to ambient temperature, diluted with ethyl acetate and washed with water. The organic layer was separated, dried under magnesium sulphate and evaporated in vacuo.
  • Step 3 1,1-Dimethylethyl 4-[4- ⁇ [3-(1-piperidinyl)propyl]oxy ⁇ -2-(trifluoromethyl)phenyl]-1-piperazinecarboxylate
  • Step 4 1-[4- ⁇ [3-(1-Piperidinyl)propyl]oxy ⁇ -2-(trifluoromethyl)phenyl]piperazine
  • Step 5 4-( ⁇ 4-[4- ⁇ [3-(1-Piperidinyl)propyl]oxy ⁇ -2-(trifluoromethyl)phenyl]-1-piperazinyl ⁇ carbonyl)benzonitrile
  • Step 3 1,1-Dimethylethyl 4-(2-cyano-4- ⁇ [3-(1-piperidinyl)propyl]oxy ⁇ phenyl)-1-piperazinecarboxylate
  • Step 5 2-[4-(Phenylcarbonyl)-1-piperazinyl]-5- ⁇ [3-(1-piperidinyl)propyl]oxy ⁇ benzonitrile
  • Example 306 Step 4 The following examples were prepared from the product of Example 306 Step 4 and the appropriate carboxylic acid indicated in table below using the method of Example 305 Step 5.
  • Step 2 1,1-Dimethylethyl 4-(2-fluoro-4- ⁇ [3-(1-piperidinyl)propyl]oxy ⁇ phenyl)-1-piperazinecarboxylate
  • Step 4 1-(2-Fluoro-4- ⁇ [3-(1-piperidinyl)propyl]oxy ⁇ phenyl)-4-(phenylcarbonyl)piperazine
  • Example 310 Step 3 The following examples were prepared from the product of Example 310 Step 3 and the appropriate carboxylic acid indicated in the table below using the method of Example 305 Step 5.
  • Example 310 step 3 The product from Example 310 step 3 (150 mg, 0.47 mmol) was dissolved in dry dichloromethane (5 ml), treated with diethylaminomethyl polystyrene (3.2 mmol/g, 294 mg, 0.94 mmol) and morpholine carbonyl chloride (0.11 ml, 0.94 mmol) and stirred at ambient temperature under argon for 1 hour.
  • the reaction mixture was diluted with methanol and passed down an SCX ion exchange column (5 g) eluting with methanol followed by a mixture of 0.880 ammonia:methanol (1:9).
  • the basic fractions were combined and evaporated in vacuo.
  • the residue was purified by column chromatography eluting with a mixture of 0.880 ammonia:methanol:dichloromethane (0.5:4.5:95) to give the title compound (84 mg).
  • step 1 The product from step 1 (4.67 g, 12.5 mmol) was dissolved in dry dichloromethane (30 ml), treated with trifluoroacetic acid (20 ml) and stirred at ambient temperature for 2 hours. The solvent was removed in vacuo and the residue made basic by addition of aqueous sodium hydroxide solution (2M). The resulting mixture was extracted with dichloromethane ( ⁇ 2). The organic layers were combined, washed with brine, dried under magnesium sulphate and concentrated in vacuo. The residue was purified by column chromatography eluting with a mixture of 0.880 ammonia:methanol:dichloromethane (1:9:90) to give the title compound (2.13 g). MS (ES+) m/e 275 [M+H] +
  • Step 3 4-[(4-Bromo-3-fluorophenyl)oxy]-1-(1-methylethyl)piperidine
  • Step 4 1,1-Dimethylethyl 4-(2-fluoro-4- ⁇ [1-(1-methylethyl)-4-piperidinyl]oxy ⁇ phenyl)-1-piperazinecarboxylate
  • Step 6 4- ⁇ [4-(2-Fluoro-4- ⁇ [1-(1-methylethyl)-4-piperidinyl]oxy ⁇ phenyl)-1-piperazinyl]carbonyl ⁇ morpholine
  • Step 2 (3R,5S)-3,5-Dimethyl-1-(4- ⁇ [3-(1-piperidinyl)propyl]oxy ⁇ phenyl)piperazine
  • Step 3 4- ⁇ [(2R,6S)-2,6-Dimethyl-4-(4- ⁇ [3-(1-piperidinyl)propyl]oxy ⁇ phenyl)-1-piperazinyl]carbonyl ⁇ benzonitrile
  • step 2 The product from step 2 (249 mg, 0.75 mmol) was dissolved in dry dichloromethane (5 ml), treated with triethylamine (0.21 ml, 1.50 mmol) and 4-cyanobenzoyl chloride (248 mg, 1.50 mmol) and the resulting mixture was stirred at ambient temperature under argon for 2 hours. Methanol was added and the mixture passed down an SCX ion exchange column (5 g) eluting with methanol followed by a mixture of 0.880 ammonia:methanol (1:9). The basic fractions were combined and evaporated in vacuo.
  • Step 2 4- ⁇ [(2S)-2-Methyl-4-(4- ⁇ [3-(1-piperidinyl)propyl]oxy ⁇ phenyl)-1-piperazinyl]carbonyl ⁇ benzonitrile
  • Example 318 Step 1 The following compounds were prepared from the product of Example 318 Step 1 with the appropriate carboxylic acid indicated in the table below using the procedure of Example 305 Step 5.
  • Step 1 1,1-Dimethylethyl (3R)-3-methyl-4-(4- ⁇ [3-(1-piperidinyl)propyl]oxy ⁇ phenyl)-1-piperazinecarboxylate
  • Step 3 4- ⁇ [(3R)-3-Methyl-4-(4- ⁇ [3-(1-piperidinyl)propyl]oxy ⁇ phenyl)-1-piperazinyl]carbonyl ⁇ benzonitrile
  • Example 325 Step 2 The following compounds were prepared from the product of Example 325 Step 2 with the appropriate carboxylic acid indicated in the table below using the procedure of Example 305 Step 5.
  • E332 to E342 were prepared from 1-(4- ⁇ [3-(1-piperidinyl)propyl]oxy ⁇ phenyl)piperazine (D11) with the appropriate acid chloride indicated in the table below using the procedure of Example 331
  • E344 to E374 were prepared from 1-(4- ⁇ [3-(1-piperidinyl)propyl]oxy ⁇ phenyl)piperazine (D11) with the appropriate carboxylic acid indicated in the table below using the procedure of Example 343.
  • E376 to E431 were prepared from 1-(4- ⁇ [3-(1-piperidinyl)propyl]oxy ⁇ phenyl)piperazine (D11) with the appropriate carboxylic acid indicated in the table below using the procedure of Example 375.
  • Methyl 4-chlorocarbonylbenzoate (3.6 g, 18.12 mM) was added to a solution of 1-[4-(3-Piperidin-1-yl-propoxy)-phenyl]-piperazine (D11) (5 g, 16.48 mM) and triethylamine (2.53 ml, 18.12 mM) in dichloromethane (25 ml), and the resulting solution stirred at room temperature for 16 hours. A saturated aqueous solution of sodium bicarbonate (25 ml) was added to the reaction and stirred for 1 hour. The organic phase was separated, washed with water, dried over anhydrous sodium sulfate and evaporated in vacuo to afford the title compound (7.46 g); MS (ES+) m/e 466 [M+H] + .
  • Step 1 1,1-Dimethylethyl 4-[(4- ⁇ [4-(4- ⁇ [3-(1-piperidinyl)propyl]oxy ⁇ phenyl)-1-piperazinyl]carbonyl ⁇ phenyl)carbonyl]-1-piperazinecarboxylate
  • N-Cyclohexylcarbodiimide, N-methyl polystyrene HL (200-400 mesh) 1.9 mMol/g (530 mg, 1 mM) was suspended in dichloromethane (10 ml) and treated sequentially with 4- ⁇ [4-(4- ⁇ [3-(1-piperidinyl)propyl]oxy ⁇ phenyl)-1-piperazinyl]carbonyl ⁇ benzoic acid (E433) (225 mg, 1 mM), 1-hydroxybenzotriazole hydrate (135 mg, 1 mM) and tert-butyl 1-piperazinecarboxylate (93 mg, 0.5 mM) and stirred at room temperature for 16 hours.
  • Step 2 1- ⁇ [4-(1-piperazinylcarbonyl)phenyl]carbonyl ⁇ -4-(4- ⁇ [3-(1-piperidinyl)propyl]oxy ⁇ phenyl)piperazine
  • E435 to E445 were prepared from 4- ⁇ [4-(4- ⁇ [3-(1-piperidinyl)propyl]oxy ⁇ phenyl)-1-piperazinyl]carbonyl ⁇ benzoic acid (E433) with the appropriate amine indicated in the table below using the procedure of Example 434 step 1.
  • Step 2 1,1-Dimethylethyl 4-(3-fluoro-4- ⁇ [3-(1-piperidinyl)propyl]oxy ⁇ phenyl)-1-piperazinecarboxylate
  • step 1 The product of step 1 (632 mg, 2 mmol), sodium tert-butoxide (538 mg, 5.6 mmol), tert-butyl 1-piperazinecarboxylate (894 mg, 4.8 mmol), tris(dibenzylidineacetone)dipalladium(0) (18 mg, 0.01 mmol) and tris(o-tolyl)phosphine (24 mg, 0.08 mmol) were heated at reflux in toluene (10 ml) for 16 hours. The solution was loaded directly on to a SCX ion exchange resin eluting with methanol and then a mixture of 0.88 ammonia solution:methanol (1:9).
  • step 2 The product of step 2 (468 mg, 1.1 mmol) was dissolved in 1:1 TFA:DCM (10 ml) at 0° C. and stirred to room temperature over 2 hours. The solution was concentrated in vacuo and co-evaporated three times with dichloromethane. The residue was passed through a SCX ion exchange resin eluting with methanol and then a mixture of 0.88 ammonia solution:methanol (1:9).
  • Step 4 1-(3-Fluoro-4- ⁇ [3-(1-piperidinyl)propyl]oxy ⁇ phenyl)-4-(phenylcarbonyl)piperazine
  • step 3 The product of step 3 (320 mg, 1 mmol) and triethylamine (140 ⁇ L, 1 mmol) were dissolved in dichloromethane (5 ml), and treated with benzoyl chloride (115 ⁇ L, 1 mmol) added. The solution was stirred at room temperature overnight and concentrated in vacuo to a crude solid. The solid was purified by silica gel chromatography eluting with dichloromethane then a mixture of 0.880 ammonia:ethanol:dichoromethane (1:9:90) to afford the title compound (354 mg, 83%); MS (ES+) m/e 426 [M+H] + .
  • Step 2 1-[3-(4-Bromo-naphthalen-1-yl oxy)-propyl]-piperidine
  • step 1 The product from step 1 (0.85 g, 3.83 mMol) in 2-Butanone (30 ml), was treated with 1-(3-Chloro-propyl)-piperidine (0.74 g, 4.59 mMol), potassium carbonate (1.2 g, 9.19 mMol), followed by potassium iodide (1.5 g, 9.19 mMol) and heated under reflux for 6 hours. After cooling to room temperature, the reaction mixture was treated with sodium thiosulphate (1M, 10 ml) the product was extracted into ethyl acetate, washed with water ( ⁇ 3), brine ( ⁇ 1), dried over magnesium sulphate and concentrated in vacuo.
  • Step 3 4-[4-(3-Piperidin-1-yl-propoxy)-naphthalen-1-yl]-piperazine-1-carboxylic acid tert-butyl ester
  • Step 1 1-[4-(3-Piperidin-1-yl-propoxy)-naphthalene-1-yl]-piperazine
  • Step 2 4-(1- ⁇ 4-[4-(3-Piperidin-1-yl-propoxy)-naphthalen-1-yl]-piperazin-1-yl ⁇ -methanoyl)-benzonitrile
  • Step 1 4-[4-(3-Piperidin-1-yl-propoxy)-phenyl]-[1,4]diazepane-1-carboxylic acid tert butyl ester
  • a mixture of the product from Example 316, step 1 (1-[3-(4-Iodo-phenoxy)-propyl]-piperidine) (2 g, 5.8 mMol), [1,4] Diazepane-1-carboxylic acid tert butyl ester (2.7 g. 13.9 mMol), tris(dibenzylidenacetone) dipalladium(0) (0.03 g, 0.03 mMol), tri-ortho-tolyl-phosphane (0.04 g, 0.02 mMol) in dioxane (20 ml) was heated at reflux for 20 hours.
  • Step 3 1-Phenyl-1- ⁇ 4-[4-(3-piperidin-1-yl-propoxy)-phenyl-[1,4]diazepan-1-yl ⁇ -methanone
  • E450 to E453 were prepared from Example 449 step 2 with the appropriate carboxylic acids indicated in the table below using the procedure detailed in Example 375.
  • step 1 (1-[3-(4-iodo-phenoxy)-propyl]-piperidine) (0.5 g, 1.45 mmol) pre-dissolved in toluene (5 ml), (2S,5R)-2,5-dimethyl-piperazine (0.20 g 1.74 mmol) predissolved in toluene (5 ml), followed by sodium tert-butoxide (0.20 g, 2.02 mmol). The mixture was heated at 100° C. for 6 hours. After cooling to room temperature the reaction mixture was diluted with ethyl acetate, washed with water ( ⁇ 3), brine ( ⁇ 1), dried over magnesium sulphate and concentrated in vacuo.
  • Step 2 4-(1- ⁇ (2S,5R)-2,5-Dimethyl-4-[4-(3-piperidin-1-yl-propoxy)-phenyl]-piperazin-1-yl ⁇ -methanoyl)-benzonitrile
  • E455 to E458 were prepared from Example 454 step 1 with the appropriate carboxylic acids indicated in the table below using the procedure detailed in Example 375.
  • Step 1 5-[4-(3-Piperidin-1-yl-propoxy)-phenyl]-2,5-diaza-bicyclo[2.2.1] heptane-carboxylic acid tert butyl ester
  • the title compound was prepared from example 316, step 1 (1-[3-(4-Iodo-phenoxy)-propyl]-piperidine) (0.25 g, 0.72 mmol) and 2,5-Diaza-bicyclo[2.2.1] heptane carboxylic acid tert butyl ester (0.17 g 0.87 mmol) using the procedure described for example 454, step 1(0.313 g, 84%); MS (ES+) m/e 416 [M+H] + .
  • Step 2 2-[4-(3-Piperidin-1-yl-propoxy)-phenyl]-2,5-diaza-bicyclo[2.2.1] heptane
  • Step 3 4-(1- ⁇ 5-[4-(3-Piperidin-1-yl-propoxy)-phenyl]-2,5-diaza-bicyclo[2.2.1] hept-2-yl ⁇ -methanoyl)benzonitrile
  • Step 2 4-[2-Chloro-4-(3-piperidin-1-yl-propoxy)-phenyl]-piperazine-1-carboxylic acid tert-butyl ester
  • Step 4 4-(1- ⁇ 4-[2-Chloro-4-(3-piperidin-1-yl-propoxy)-phenyl]-piperazin-1-yl ⁇ -methanoyl)-benzonitrile
  • Step 1 1- ⁇ 4-[4-(3-Chloro-propoxy)-phenyl]-piperazin-1-yl ⁇ -1-phenyl-methanone
  • Step 2 1-Phenyl-1- ⁇ 4-[4-(3-pyrrolidin-1-yl-propoxy)-phenyl]-piperazin-1-yl ⁇ -methanone
  • E463 to E464 were prepared from Example 462 step 1 with the appropriate amine indicated in the table below using the procedure detailed in Description 10.
  • E465a 1-(1-Naphthalenylcarbonyl)-4-(2- ⁇ 4-[(phenylmethyl)oxy]phenyl ⁇ ethyl) piperazine
  • E465c 1-(2- ⁇ 4-[(3-Chloropropyl)oxy]phenyl ⁇ ethyl)-4-(1-naphthalenylcarbonyl) piperazine
  • E475a 1-(2- ⁇ 4-[(2-Chloroethyl)oxy]phenyl ⁇ ethyl)-4-(1-naphthalenylcarbonyl)piperazine
  • E475b 1-(1-Naphthalenylcarbonyl)-4-[2-(4- ⁇ [2-(1-piperidinyl)ethyl]oxy ⁇ phenyl)ethyl]piperazine
  • Examples 476-479 were prepared in an array format using the same method described in Example 465d from 1-(2- ⁇ 4-[(2-chloroethyl)oxy]phenyl ⁇ ethyl)-4-(1-naphthalenylcarbonyl)piperazine (0.0544 mmol), the appropriate secondary amine (6 eq), potassium carbonate (6 eq) and potassium iodide (5 eq) in 2-butanone (2 ml). The products were purified by mass directed auto-preparative HPLC to provide the compounds as formate salts.
  • Examples 480-499 were prepared in an analogous manner to the procedure described for Example 62
  • a membrane preparation containing histamine H3 receptors may be prepared in accordance with the following procedures:
  • DNA encoding the human histamine H3 gene was cloned into a holding vector, pcDNA3.1 TOPO (InVitrogen) and its cDNA was isolated from this vector by restriction digestion of plasmid DNA with the enzymes BamH1 and Not-1 and ligated into the inducible expression vector pGene (InVitrogen) digested with the same enzymes.
  • the GeneSwitchTM system (a system where in transgene expression is switched off in the absence of an inducer and switched on in the presence of an inducer) was performed as described in U.S. Pat. Nos.
  • Ligated DNA was transformed into competent DH5 ⁇ E. coli host bacterial cells and plated onto Luria Broth (LB) agar containing ZeocinTM (an antibiotic which allows the selection of cells expressing the sh ble gene which is present on pGene and pSwitch) at 50 ⁇ g ml ⁇ 1 . Colonies containing the re-ligated plasmid were identified by restriction analysis. DNA for transfection into mammalian cells was prepared from 250 ml cultures of the host bacterium containing the pGeneH3 plasmid and isolated using a DNA preparation kit (Qiagen Midi-Prep) as per manufacturers guidelines (Qiagen).
  • CHO K1 cells previously transfected with the pSwitch regulatory plasmid (InVitrogen) were seeded at 2 ⁇ 10e6 cells per T75 flask in Complete Medium, containing Hams F12 (GIBCOBRL, Life Technologies) medium supplemented with 10% v/v dialysed foetal bovine serum, L-glutamine, and hygromycin (100 ⁇ g ml ⁇ 1 ), 24 hours prior to use. Plasmid DNA was transfected into the cells using Lipofectamine plus according to the manufacturer's guidelines (InVitrogen). 48 hours post transfection cells were placed into complete medium supplemented with 500 ⁇ g ml ⁇ 1 ZeocinTM.
  • nM Mifepristone 10-14 days post selection 10 nM Mifepristone (InVitrogen), was added to the culture medium to induce the expression of the receptor. 18 hours post induction cells were detached from the flask using ethylenediamine tetra-acetic acid (EDTA; 1:5000; InVitrogen), following several washes with phosphate buffered saline pH 7.4 and resuspended in Sorting Medium containing Minimum Essential Medium (MEM), without phenol red, and supplemented with Earles salts and 3% Foetal Clone II (Hyclone).
  • EDTA ethylenediamine tetra-acetic acid
  • Positively stained cells were sorted as single cells into 96-well plates, containing Complete Medium containing 500 ⁇ g ml ⁇ 1 ZeocinTM and allowed to expand before reanalysis for receptor expression via antibody and ligand binding studies.
  • the cell pellet is resuspended in 10 volumes of buffer A2 containing 50 mM N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid (HEPES) (pH 7.40) supplemented with 10e-4M leupeptin (acetyl-leucyl-leucyl-arginal; Sigma L2884), 25 ⁇ g/ml bacitracin (Sigma B0125), 1 mM ethylenediamine tetra-acetic acid (EDTA), 1 mM phenylmethylsulfonyl fluoride (PMSF) and 2 ⁇ 10e-6M pepstain A (Sigma).
  • HEPES N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid
  • the cells are then homogenised by 2 ⁇ 15 second bursts in a 1 litre glass Waring blender, followed by centrifugation at 500 g for 20 minutes. The supernatant is then spun at 48,000 g for 30 minutes. The pellet is resuspended in 4 volumes of buffer A2 by vortexing for 5 seconds, followed by homogenisation in a Dounce homogeniser (10-15 strokes). At this point the preparation is aliquoted into polypropylene tubes and stored at ⁇ 70° C.
  • the human H1 receptor was cloned using known procedures described in the literature [Biochem. Biophys. Res. Commun. 1994, 201(2), 894]. Chinese hamster ovary cells stably expressing the human H1 receptor were generated according to known procedures described in the literature [Br. J. Pharmacol. 1996, 117(6), 1071].
  • test compound or 100 of iodophenpropit (a known histamine H3 antagonist) at a final concentration of 10 mM) diluted to the required concentration in 10% DMSO;
  • the plate is shaken for 5 minutes and then allowed to stand at room temperature for 3-4 hours prior to reading in a Wallac Microbeta counter on a 1 minute normalised tritium count protocol. Data was analysed using a 4-parameter logistic equation.
  • test compound or 100 of guanosine 5′-triphosphate (GTP) (Sigma) as non-specific binding control
  • assay buffer 20 mM N-2-Hydroxyethylpiperazine-N′-2-ethanesulfonic acid (HEPES)+100 mM NaCl+10 mM MgCl 2 , pH7.4 NaOH
  • HEPES N-2-Hydroxyethylpiperazine-N′-2-ethanesulfonic acid
  • 600 bead/membrane/GDP mix prepared by suspending wheat germ agglutinin-polyvinyltoluene (WGA-PVT) scintillation proximity assay (SPA) beads at 100 mg/ml in assay buffer followed by mixing with membrane (prepared in accordance with the methodology described above) and diluting in assay buffer to give a final volume of 600 which contains 10′4 protein and 0.5 mg bead per well-mixture is pre-mixed
  • the plate is incubated at room temperature to equilibrate antagonist with receptor/beads by shaking for 30 minutes followed by addition of:
  • Wells are then washed with Tyrodes buffer using a EMBLA cell washer system, leaving 400 buffer in each well, and then treated with 10 ⁇ l of test compound in Tyrodes buffer. Each plate is incubated for 30 min to allow equilibration of the test compound with the receptor. Each well is then treated with 10 ⁇ l of histamine solution in Tyrodes buffer.
  • Functional antagonism is indicated by a suppression of histamine induced increase in fluorescence, as measured by the FLIPR system (Molecular Devices). By means of concentration effect curves, functional potencies are determined using standard pharmacological mathematical analysis.
  • Examples E1-260, 263-479 and E499-503 were tested in the histamine H3 functional antagonist assay and exhibited antagonism>6.5 pK b . More particularly, the compounds of Examples E1, E3, E10, E12-14, E16-20, E21, E23, E24, E31, E33, E35-37, E40-42, E46-48, E51, E255-256, E258-260, E263, E265-267, E268-271, E273-274, E277-280, E284-288, E290-293, E295, E309, E311, E314-315, E317, E319-329, E331, E333, E342, E344, E346-348, E350, E352, E354-355, E361-363, E368, E374, E378, E380, E384, E386, E389, E391-393, E396-E399, E405, E407, E410-411
  • the compounds of Examples E53-254, E465-479 and E499-503 were tested in the histamine H1 functional antagonist assay and exhibited antagonism>6.5 pK b . More particularly, the compounds of Examples E60, E64-65, E67, E70, E84, E87, E91, E93, E95, E98, E100, E108-110, E112, E114-115, E135-136, E162, E171, E188-189, E195, E199, E206-212, E214-219, E224, E229, E231, E235, E242, E244, E466, E468-474 and E500-503 exhibited antagonism>7.3 pK b .

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyrrole Compounds (AREA)
  • Indole Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Furan Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

The present invention relates to novel piperazine and azepine derivatives having pharmacological activity, processes for their preparation, to compositions containing them and to their use in the treatment of neurodegenerative disorders including Alzheimer's disease.

Description

  • The present application is a continuation application of U.S. Ser. No. 10/531,758, filed 14 Apr. 2005, now allowed, which was a 35 U.S.C. §371 United States National Phase Application of International Application No. PCT/EP2003/011423 filed 14 Oct. 2003, which claims priority from GB0224084.4 filed 16 Oct. 2002.
  • The present invention relates to novel piperazine and azepine derivatives having pharmacological activity, processes for their preparation, to compositions containing them and to their use in the treatment of neurodegenerative disorders including Alzheimer's disease.
  • WO 02/76925 (Eli Lilly) describes a series of compounds which are claimed to be histamine H3 antagonists. WO 02/055496 (GlaxoSmithKline) describes a series of piperidine and piperazine derivatives which are claimed to be inducers of LDL-receptor expression. WO 02/12214 (Ortho McNeil Pharmaceutical Inc.) describes a series of substituted aryloxyalkylamines which are claimed to be histamine H3 antagonists.
  • The histamine H3 receptor is expressed in both the mammalian central nervous system (CNS), and in peripheral tissues (Leurs et al., (1998), Trends Pharmacol. Sci. 19, 177-183). Activation of H3 receptors by selective agonists or histamine results in the inhibition of neurotransmitter release from a variety of different nerve populations, including histaminergic, adrenergic and cholinergic neurons (Schlicker et al., (1994), Fundam. Clin. Pharmacol. 8, 128-137). Additionally, in vitro and in vivo studies have shown that H3 antagonists can facilitate neurotransmitter release in brain areas such as the cerebral cortex and hippocampus, relevant to cognition (Onodera et al., (1998), In: The Histamine H3 receptor, ed Leurs and Timmerman, pp 255-267, Elsevier Science B.V.). Moreover, a number of reports in the literature have demonstrated the cognitive enhancing properties of H3 antagonists (e.g. thioperamide, clobenpropit, ciproxifan and GT-2331) in rodent models including the five choice task, object recognition, elevated plus maze, acquisition of novel task and passive avoidance (Giovanni et al., (1999), Behav. Brain Res. 104, 147-155). These data suggest that novel H3 antagonists and/or inverse agonists such as the current series could be useful for the treatment of cognitive impairments in neurological diseases such as Alzheimer's disease and related neurodegenerative disorders.
  • The present invention provides, in a first aspect, a compound of formula (I):
  • Figure US20100075953A1-20100325-C00001
  • wherein:
    R1 represents hydrogen, —C1-6 alkyl, —C1-6 alkoxy, —C3-8 cycloalkyl, —C1-6 alkyl-C3-8 cycloalkyl, aryl, heterocyclyl, heteroaryl, —C1-6 alkyl-aryl, —C1-6 alkyl-heteroaryl, —C1-6 alkyl-heterocyclyl, -aryl-aryl, -aryl-heteroaryl, -aryl-heterocyclyl, -heteroaryl-aryl, -heteroaryl-heteroaryl, -heteroaryl-heterocyclyl, -heterocyclyl-aryl, -heterocyclyl-heteroaryl, -heterocyclyl-heterocyclyl,
    wherein R1 may be optionally substituted by one or more substituents which may be the same or different, and which are selected from the group consisting of halogen, hydroxy, COOR15, cyano, —C1-6 alkyl-cyano, nitro, oxo, trifluoromethyl, trifluoromethoxy, fluoromethoxy, difluoromethoxy, C1-6 alkyl (optionally substituted by a COOR15 group), C2-6 alkenyl (optionally substituted by a COOR15 group), C2-6 alkynyl (optionally substituted by a COOR15 group), C1-6 alkoxy (optionally substituted by a COOR15 group), pentafluoroethyl, C1-6 alkoxy, C2-6 alkenoxy, aryl, arylC1-6 alkyl, —CO-aryl (optionally substituted by a halogen atom), —CO-heteroaryl, —C1-6 alkyl-CO-aryl, arylC1-6 alkoxy, C1-6 alkylthio, C1-6 alkoxyC1-6 alkyl, C3-7 cycloalkyl, C3-7 cycloalkylC1-6 alkoxy, C1-6 alkoxycarbonyl, C1-6 alkylsulfonyl, C1-6 alkylsulfinyl, C1-6 alkylsulfonyloxy, C1-6 alkylsulfonylC1-6 alkyl, sulfonyl, arylsulfonyl, arylsulfonyloxy, arylsulfonylC1-6 alkyl, aryloxy, C1-6 alkylsulfonamido, C1-6 alkylamido, C1-6 alkylsulfonamidoC1-6 alkyl, C1-6 alkylamidoC1-6 alkyl, arylsulfonamido, arylcarboxamido, arylsulfonamidoC1-6 alkyl, arylcarboxamidoC1-6 alkyl, aroyl, aroylC1-6 alkyl, arylC1-6 alkanoyl, or a group —COR15, —NR15R16, —CONR15R16, —NR15COR16, —NR15SO2R16, or —SO2NR15R16,
    wherein R15 and R16 independently represent hydrogen, C1-6 alkyl or C3-8 cycloalkyl or together may be fused to form a 5- to 7-membered non-aromatic heterocyclic ring optionally interrupted by an O or S atom and optionally substituted by a halogen, C1-6 alkyl or —C1-6 alkylC1-6 alkoxy group;
    Z represents a bond, CO, N(R10)CO or SO2, such that when R1 represents hydrogen, Z represents NR10CO;
    p is 1 or 2;
    m, n and r independently represent 0, 1 or 2;
    R2 represents halogen, C1-6 alkyl, C1-6 alkoxy, cyano, amino or trifluoromethyl, such that when n represents 2, two R2 groups may instead be linked to form a phenyl ring;
    R4 represents C1-6 alkyl, or when r represents 2, two R4 groups may instead together form a bridged CH2, (CH2)2 or (CH2)3 group;
    R10 represents hydrogen or C1-6 alkyl, or R10, together with the nitrogen to which it is attached and R1 forms a nitrogen containing heterocyclic group;
    R3 represents —(CH2)q—NR11R12 or a group of formula (I):
  • Figure US20100075953A1-20100325-C00002
  • wherein q is 2, 3 or 4;
    R11 and R12 independently represent C1-6 alkyl or C3-8 cycloalkyl or together with the nitrogen atom to which they are attached represent an N-linked nitrogen containing heterocyclyl group optionally substituted by one or more R17 groups;
    R13 represents hydrogen, C1-6 alkyl, —C1-6 alkyl-C1-6 alkoxy, C3-8 cycloalkyl, —C1-6 alkyl-C3-8 cycloalkyl, —C1-6 alkyl-aryl or heterocyclyl;
    R14 and R17 independently represent halogen, C1-6 alkyl, haloalkyl, OH, diC1-6 alkylamino, C1-6 alkoxy or heterocyclyl;
    f and k independently represent 0, 1 or 2;
    g is 0, 1 or 2 and h is 0, 1, 2 or 3, such that g and h cannot both be 0; with the proviso that when m represents 1, n and r both represent 0 and R3 represents —(CH2)3—N-piperidine or —(CH2)3—N(ethyl)2, R1-Z represents a group other than methyl, —CO—O—C(CH3)3 or benzyl;
    and with the proviso that when m, n and r all represent 0, p represents 1, R3 represents —(CH2)3—N-pyrrolidine or —(CH2)3—N-piperidine, R1 represents benzyl, Z represents a group other than a bond;
    and with the proviso that when m, n and r all represent 0, p represents 1, R3 represents —(CH2)3—N-piperidine, R1 represents isopropyl, Z represents a group other than a bond;
    and with the proviso that when m represents 1, n and r both represent 0, p represents 1, R3 represents —(CH2)3—N-piperidine, R1 represents methyl, isopropyl, aryl or benzyl, Z represents a group other than a bond;
    and with the proviso that when m and n both represent 0, R3 represents —(CH2)3—N(ethyl)2, p represents 1, r represents 2 and R1 and R4 both represent methyl, Z represents a group other than a bond;
    or a pharmaceutically acceptable salt thereof.
  • In one particular aspect of the present invention, there is provided a compound of formula (I) as defined above wherein:
  • R1 represents a group other than hydrogen, —C1-6 alkoxy or —C1-6 alkyl-C3-8 cycloalkyl; and
    R1 is optionally substituted by one or more substituents other than COOR15, —C1-6 alkyl-cyano, C1-6 alkyl substituted by a COOR15 group), C2-6 alkenyl (optionally substituted by a COOR15 group), C2-6 alkynyl (optionally substituted by a COOR15 group), C1-6 alkoxy (optionally substituted by a COOR15 group), C2-6 alkenoxy, aryl, arylC1-6 alkyl, —CO-aryl (optionally substituted by a halogen atom), —CO-heteroaryl, —C1-6 alkyl-CO-aryl or C3-7 cycloalkyl; and
    R15 and R16 independently represent a group other than C3-8 cycloalkyl or together may be fused to form an unsubstituted 5- to 7-membered non-aromatic heterocyclic ring optionally interrupted by an O or S atom; and
    r represents 0; and
    two R2 groups are not linked to form a phenyl ring; and
    R11 and R12 independently represent a group other than C3-8 cycloalkyl; and
    R13 represents a group other than —C1-6 alkyl-C3-8 cycloalkyl.
  • In a second particular aspect of the present invention, there is provided a compound of formula (I) as defined above wherein m represents 0 or 2.
  • In a further particular aspect of the present invention, there is provided a compound of formula (I) as defined above wherein Z represents CO, CONR10 or SO2.
  • Alkyl groups, whether alone or as part of another group, may be straight chain or branched and the groups alkoxy and alkanoyl shall be interpreted similarly. Alkyl moieties are more preferably C1-4 alkyl, eg. methyl or ethyl. The term ‘halogen’ is used herein to describe, unless otherwise stated, a group selected from fluorine, chlorine, bromine or iodine.
  • The term “aryl” includes single and fused rings wherein at least one ring is aromatic, for example, phenyl, naphthyl, tetrahydronaphthalenyl, indanyl or fluorenyl.
  • The term “heterocyclyl” is intended to mean a 4-7 membered monocyclic saturated or partially unsaturated ring or a 4-7 membered saturated or partially unsaturated ring fused to a benzene ring containing 1 to 3 heteroatoms selected from oxygen, nitrogen or sulphur. Suitable examples of such monocyclic rings include pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, tetrahydrofuranyl, diazepanyl, azepanyl and azocanyl. Suitable examples of benzofused heterocyclic rings include indolinyl, isoindolinyl, benzodioxolyl and dihydroisoquinolinyl.
  • The term “nitrogen containing heterocyclyl” is intended to represent any heterocyclyl group as defined above which contains a nitrogen atom.
  • The term “heteroaryl” is intended to mean a 5-7 membered monocyclic aromatic or a fused 8-11 membered bicyclic aromatic ring containing 1 to 3 heteroatoms selected from oxygen, nitrogen and sulphur. Suitable examples of such monocyclic aromatic rings include thienyl, furyl, pyrrolyl, triazolyl, imidazolyl, oxazolyl, thiazolyl, oxadiazolyl, isothiazolyl, isoxazolyl, thiadiazolyl, pyrazolyl, pyrimidyl, pyridazinyl, pyrazinyl and pyridyl. Suitable examples of such fused aromatic rings include furopyridinyl and benzofused aromatic rings such as quinolinyl, isoquinolinyl, quinazolinyl, quinoxalinyl, cinnolinyl, naphthyridinyl, indolyl, indazolyl, pyrrolopyridinyl, benzofuranyl, benzothienyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzothiazolyl, benzisothiazolyl, benzoxadiazolyl, benzothiadiazolyl and the like.
  • Compounds of formula (I) and their pharmaceutically acceptable salts have affinity for and are antagonists and/or inverse agonists of the histamine H3 receptor and are believed to be of potential use in the treatment of neurological diseases including Alzheimer's disease, dementia, age-related memory dysfunction, mild cognitive impairment, cognitive dysfunction, epilepsy, neuropathic pain, inflammatory pain, migraine, Parkinson's disease, multiple sclerosis, stroke and sleep disorders including narcolepsy; psychiatric disorders including schizophrenia, attention deficit hypereactivity disorder, depression and addiction; and other diseases including obesity, asthma, allergic rhinitis, nasal congestion, chronic obstructive pulmonary disease and gastro-intestinal disorders.
  • Thus the invention also provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, for use as a therapeutic substance in the treatment or prophylaxis of the above disorders, in particular cognitive impairments in diseases such as Alzheimer's disease and related neurodegenerative disorders.
  • Preferably, R1 represents:
      • hydrogen;
      • C1-6 alkyl (eg. methyl, methylbutyl, or propyl);
      • C1-6 alkoxy (eg. —OC(CH3)3);
      • aryl (eg. phenyl, naphthyl, tetrahydronaphthyl, indanyl or fluorenyl);
      • heteroaryl (eg. benzofuranyl, indolyl, pyrazinyl, benzoxadiazolyl, thiadiazolyl, thienyl, pyrazolopyrimidinyl, pyrazolopyridinyl, benzothiazolyl, furopyridinyl, pyridyl, quinolinyl, isoquinolinyl, quinoxalinyl, cinnolinyl, thiazolyl, triazolyl, isoxazolyl, pyrimidinyl, naphthyridinyl, benzisoxazolyl or benzisothiazolyl);
      • heterocyclyl (eg. benzodioxolyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, tetrahydrothiopyranyl, thiopyranyl, tetrahydropyranyl, dihydrobenzofuranyl, dihydrochromenyl and xanthenyl);
      • C3-8 cycloalkyl (eg. cyclopropyl, cyclopentyl or cyclohexyl);
      • —C1-6 alkyl-aryl (eg. benzyl);
      • —C1-6 alkyl-C3-8 cycloalkyl (eg. —CH2-cyclopropyl);
      • —C1-6 alkyl-heteroaryl (eg. —CH2-pyridyl, —CH2-tetrazolyl, —CH2-triazolyl, —CH2-isothiazolyl, —CH2-thienyl or —CH2-furanyl);
      • -aryl-heterocyclyl (eg. phenyl-pyrrolidinyl);
      • -aryl-aryl (eg. -biphenyl);
      • -aryl-heteroaryl (eg. -phenyl-pyridyl, -phenyl-pyrrolyl or -phenyl-tetrazolyl); or
      • -heteroaryl-aryl (eg. pyridyl-phenyl).
  • More preferably, R1 represents unsubstituted phenyl.
  • Also more preferably, R1 represents:
      • aryl (eg. phenyl); or
      • heterocyclyl (eg. piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl or tetrahydropyranyl).
  • Preferably, R1 is optionally substituted by one or more (eg. 1, 2 or 3): halogen (eg. chlorine, fluorine or bromine); trifluoromethyl; —C1-6 alkyl (eg. methyl, ethyl, isopropyl, propyl or t-butyl) optionally substituted by COOR15 (eg. COOH, COOMe or COOEt); —C1-6 alkoxy (eg. methoxy, butoxy, —OCH(Me)2 or —OC(Me)3) optionally substituted by COOR15 (eg. COOH or COOMe); hydroxy; oxo; cyano; —C1-6 alkyl-cyano (eg. —CH2—CN); C1-6 alkenyl (eg. ethenyl) optionally substituted by COOR15 (eg. COOMe); C3-7 cycloalkyl (eg. cyclopentyl); C1-6 alkylsulfonyl (eg. SO2Me); C1-6 alkenoxy (eg. —OCH2CH═CH2); C1-6 alkylthio (eg. —S-ethyl); NR15R16 (eg. N(Me)2); —C1-6 alkyl-aryl (eg. benzyl); aryl (eg. phenyl); —CO-aryl (eg. —CO-phenyl) optionally substituted by halogen (eg. chlorine); —CO-heteroaryl (eg. —CO-azetidinyl); —CO-heterocyclyl (eg. —CO-tetrahydropyranyl); —COOR15 (eg. COOH, COOMe or COOt-butyl); —COR15 (eg. —CO-methyl, —CO-ethyl, —CO-isopropyl, —CO-cyclopropyl, —CO-cyclobutyl, —CO-cyclopentyl or —CO-cyclohexyl); —CONR15R16 (eg. —CONH2, —CO-pyrrolidinyl, —CO-morpholinyl, —CO-piperazinyl, —CO-piperidinyl, —CO-thiomorpholinyl) optionally substituted by C1-6 alkyl (eg. methyl), halogen (eg. fluorine) or —C1-6 alkylC1-6 alkoxy (eg. —CH2—OMe); or —C1-6 alkyl-CO-aryl (eg. —CH2COphenyl) groups.
  • More preferably, R1 is optionally substituted by one or more (eg. 1, 2 or 3): halogen (eg. fluorine); oxo; cyano; —CONR15R16 (eg. —CO-pyrrolidinyl) or —COR15 (eg. —CO-isopropyl, —CO-cyclopropyl or —CO-cyclobutyl).
  • Preferably, Z represents a bond, CO or CONR10. More preferably, Z represents bond or CO, especially CO.
  • Preferably, R10 represents hydrogen or C1-6 alkyl.
  • Preferably, m is 0 or 2, more preferably 0.
  • Preferably, n is 0 or 1, more preferably n is 0.
  • When n represents 1, R2 is preferably halogen (eg. chlorine, bromine or fluorine), trifluoromethyl, cyano or C1-6 alkyl (eg. methyl).
  • Preferably, r is 0.
  • When r represents 1 or 2, R2 is preferably C1-6 alkyl (eg. methyl) or two R4 groups together form a bridged CH2 group.
  • Preferably, p is 1.
  • Preferably, R3 represents —(CH2)q—NR11R12.
  • When R3 represents a group of formula (I), preferably f is 0 or 1, g is 2, h is 1, k is 0 and R13 represents hydrogen, optionally substituted C1-6 alkyl (eg. ethyl, methylpropyl, isopropyl or methoxyethyl), C3-8 cycloalkyl (eg. cyclopropyl, cyclobutyl or cyclopentyl) or —C1-6 alkyl-C3-8 cycloalkyl (eg. —CH2-cyclopropyl).
  • When R3 represents a group of formula (I), more preferably f is 0, g is 2, h is 1, k is 0 and R13 represents C1-6 alkyl (eg. isopropyl) or C3-8 cycloalkyl (eg. cyclopropyl or cyclobutyl).
  • Preferably, q is 2 or 3, more preferably 3.
  • Preferably, R11 and R12 independently represent C1-6 alkyl (eg. methyl) or C3-8 cycloalkyl (eg. cyclopentyl) or NR11R12 represents a heterocyclic group (eg. piperidinyl, pyrrolidinyl, thiomorpholinyl, azepanyl or azocanyl optionally substituted by one or more halogen (eg. fluorine) or C1-6 alkyl (eg. methyl or ethyl).
  • More preferably NR11R12 represents pyrrolidinyl, piperidinyl, azepanyl or azocanyl optionally substituted by one or more C1-6 alkyl (eg. methyl or ethyl), especially unsubstituted piperidine.
  • Preferably, —O—R3 is present at the para position of the phenyl group with respect to the rest of the compound.
  • Preferred compounds according to the invention include examples E1-E503 as shown below, or a pharmaceutically acceptable salt thereof.
  • Compounds of formula (I) may form acid addition salts with acids, such as conventional pharmaceutically acceptable acids, for example maleic, hydrochloric, hydrobromic, phosphoric, acetic, fumaric, salicylic, sulphuric, citric, lactic, mandelic, tartaric and methanesulphonic. Salts, solvates and hydrates of compounds of formula (I) therefore form an aspect of the invention.
  • Certain compounds of formula (I) are capable of existing in stereoisomeric forms. It will be understood that the invention encompasses all geometric and optical isomers of these compounds and the mixtures thereof including racemates. Tautomers also form an aspect of the invention. For example, when R3 represents (CH2)qNR11R12 and NR11R12 represents a nitrogen containing heterocyclyl group substituted by one or more C1-6 alkyl groups it will be appreciated that the present invention extends to cover diastereomeric and enantiomeric compounds.
  • The present invention also provides a process for the preparation of a compound of formula (I) or a pharmaceutically acceptable salt thereof, which process comprises:
  • (a) reacting a compound of formula (II)
  • Figure US20100075953A1-20100325-C00003
  • wherein R1, Z, R4, p, m, r, R2 and n are as defined above, with a compound of formula R3′-L1, wherein R3′ is as defined above for R3 or a group convertible thereto and L1 represents a suitable leaving group such as a halogen atom (eg. bromine or chlorine) or an optionally activated hydroxyl group; or
    (b) preparing a compound of formula (I) wherein Z represents CO by reacting a compound of formula (III)
  • Figure US20100075953A1-20100325-C00004
  • or a protected derivative thereof, wherein R4, r, p, m, R2, n and R3 are as defined above, with a compound of formula R1—COX, wherein R1 is as defined above and X represents a suitable leaving group such as an activated hydroxy group, a suitable halogen atom or benzotriazolyl; or
    (c) preparing a compound of formula (I) wherein Z represents SO2 by reacting a compound of formula (III) as defined above with a compound of formula R1—SO2Cl, wherein R1 is as defined above; or
    (d) preparing a compound of formula (I) wherein Z represents NR10CO by reacting a compound of formula (III) as defined above with a compound of formula R1—N═C═O, wherein R1 is as defined above; or
    (e) preparing a compound of formula (I) wherein Z represents CONR10 by reacting a compound of formula (III) as defined above, sequentially with phosgene in a solvent such as toluene followed by a compound of formula R10R1—NH, in a solvent such as dichloromethane, wherein R1 and R10 are as defined above; or
    (f) preparing a compound of formula (I) wherein m represents 1 by reacting a compound of formula (IV)
  • Figure US20100075953A1-20100325-C00005
  • with a compound of formula (XI)
  • Figure US20100075953A1-20100325-C00006
  • or an optionally protected derivative thereof, wherein R4, r, R2, n, R3, R1, Z and p are as defined above under reducing conditions; or
    (g) deprotecting a compound of formula (I) which is protected; and
    (h) interconversion to other compounds of formula (I).
  • When R3 represents —(CH2)q—NR11R12, process (a) typically comprises the use of a suitable base, such as potassium carbonate in an appropriate solvent such as 2-butanone optionally in the presence of an activating reagent such as potassium iodide at an appropriate temperature such as reflux.
  • When a group R3′ convertible to R3 represents, for example, L2-(CH2)q—, process (a) typically comprises an alkylation reaction using analogous conditions to those described above.
  • When R3 represents a group of formula (I) and L1 represents an optionally activated hydroxyl group, process (a) typically comprises the use of a phosphine such as triphenylphosphine in a suitable solvent such as tetrahydrofuran, followed by addition of an azodicarboxylate such as diethylazodicarboxylate at a suitable temperature such as room temperature.
  • Process (b) typically comprises the use of an appropriate solvent such as dichloromethane optionally in the presence of an organic or inorganic base such as potassium carbonate or in the presence of a suitable coupling agent such as 1,3-dicyclohexylcarbodiimide and 1-hydroxybenzotriazole.
  • Processes (c) and (d) typically comprise the use of a suitable solvent such as 2-butanone.
  • Process (e) typically comprises the use of a suitable base, such as triethylamine.
  • Process (f) comprises the use of reductive conditions (such as treatment with a borohydride eg. sodium triacetoxyborohydride), optionally in the presence of an acid, such as acetic acid, followed by optional deprotection in the event that the compound of formula (XI) is a protected derivative.
  • In process (g), examples of protecting groups and the means for their removal can be found in T. W. Greene ‘Protective Groups in Organic Synthesis’ (J. Wiley and Sons, 1991). Suitable amine protecting groups include sulphonyl (e.g. tosyl), acyl (e.g. acetyl, 2′,2′,2′-trichloroethoxycarbonyl, benzyloxycarbonyl or t-butoxycarbonyl) and arylalkyl (e.g. benzyl), which may be removed by hydrolysis (e.g. using an acid such as hydrochloric acid in dioxan or trifluoroacetic acid in dichloromethane) or reductively (e.g. hydrogenolysis of a benzyl group or reductive removal of a 2′,2′,2′-trichloroethoxycarbonyl group using zinc in acetic acid) as appropriate. Other suitable amine protecting groups include trifluoroacetyl (—COCF3) which may be removed by base catalysed hydrolysis or a solid phase resin bound benzyl group, such as a Merrifield resin bound 2,6-dimethoxybenzyl group (Ellman linker), which may be removed by acid catalysed hydrolysis, for example with trifluoroacetic acid.
  • Process (h) may be performed using conventional interconversion procedures such as epimerisation, oxidation, reduction, alkylation, nucleophilic or electrophilic aromatic substitution, ester hydrolysis or amide bond formation. For example, compounds of formula (I) wherein R3 represents a group of formula (I) may be interconverted at the R13 position by reaction with an alkyl halide such as 1-chloro-2-methoxyethane in the presence of a base such as potassium carbonate in a suitable solvent such as 2-butanone optionally in the presence of a transfer reagent such as potassium iodide. Such interconversion may also be carried out by reductive amination, for example, with acetone in the presence of a borohydride such as sodium triacetoxyborohydride and optionally an acid such as acetic acid in a suitable solvent such as dichloromethane.
  • Compounds of formula (II) and (III) wherein m is 1 or 2 may be prepared in accordance with the following scheme:
  • Figure US20100075953A1-20100325-C00007
  • wherein R4, r, R2, n, R3, p are as defined above and the compound of formula (V) may be optionally protected.
  • Step (i) may be performed in an analogous manner to that described for process (f) above.
  • Compounds of formula (III) wherein m is 0 may be prepared in accordance with the following scheme:
  • Figure US20100075953A1-20100325-C00008
  • wherein R4, r, p, R2, n and R3 are as defined above and P1 represents a suitable protecting group (such as Boc).
  • Step (i) may be performed when P1 represents Boc by reacting a compound of formula (IX) with di-t-butyl carbonate in the presence of a suitable base (eg. triethylamine) in the presence of a suitable solvent (eg. dichloromethane) at a suitable temperature (eg. room temperature).
  • Step (ii) may be performed in an analogous manner to the procedures shown below for the preparation of compounds of formula (IV).
  • Step (iii) typically comprises a deprotection reaction, for example, when P1 represents Boc, deprotection may typically comprise reaction of a compound of formula (III) P' with hydrochloric acid in dioxan or trifluoroacetic acid in dichloromethane.
  • Compounds of formula (III) wherein m is 2 may be prepared in accordance with the following scheme:
  • Figure US20100075953A1-20100325-C00009
  • wherein R2, R3, R4, n, p, r are as defined above, P2 represents a suitable protecting group such as Boc and L5 represents a suitable leaving group such as a halogen atom (eg. bromine).
  • Step (i) typically comprises reaction of a compound of formula (XII) with a compound of formula (XIII) in the presence of an inert solvent such as dimethylformamide or acetonitrile.
  • Step (ii) typically comprises a deprotection reaction, for example, when P2 represents Boc, deprotection may typically comprise reaction of a compound of formula (III)pii with hydrochloric acid in dioxan or trifluoroacetic acid in dichloromethane.
  • Compounds of formula (IV) wherein R3 represents —(CH2)q—NR11R12 may be prepared in accordance with the following scheme:
  • Figure US20100075953A1-20100325-C00010
  • wherein R2, n, q, R11, R12 are as defined above and L1, L2, L3 and L4 represent suitable leaving groups (eg. halogen atoms, such as bromine or chlorine).
  • Steps (i), (ii) and (iii) may be performed using similar conditions to those described for process (a) above.
  • Compounds of formula (IV) wherein R3 represents a group of formula (I) as defined above may be prepared in accordance with the following scheme:
  • Figure US20100075953A1-20100325-C00011
  • wherein R2, n, f, g, h, k, are as defined above, L4 represents a suitable leaving group such as a halogen atom or a hydroxyl group and R13a is as defined above for R13 or a protecting group such as t-butoxycarbonyl, followed by optional deprotection.
  • Step (i) may be performed using similar conditions to those described for process (a) above.
  • Compounds of formula (II) wherein m is 0 may be prepared by a deprotection reaction of a compound of formula (IX) as defined above, followed by an analogous process to those described in processes (b), (c), (d) and (e) above, optionally followed by hydrolysis treatment to re-generate the free hydroxyl group of formula (II).
  • Compounds of formula (II) wherein m is 1 or 2 may be prepared from a compound of formula (IV) as defined above in an analogous process to that defined above to prepare compounds of formula (III)a followed by an analogous process to those described in processes (b), (c), (d) and (e) above, optionally followed by hydrolysis treatment to re-generate the free hydroxyl group of formula (II).
  • Compounds of formula (XI) may be prepared from the corresponding piperazine or diazepane by analogous procedures to those described in processes (b), (c), (d) and (e) above.
  • Compounds of formula (XI) wherein Z represents a bond may be prepared by reacting a compound of formula R1-L6 (wherein R1 is as defined above and L6 represents a suitable leaving group, eg. a bromine atom) with a compound of formula (XII), such as 1-BOC-piperazine, in the presence of a palladium catalyst, such as tris(dibenzylideneacetone) dipalladium, and a ligand such as 2-cyclohexylphosphino-2′-(N,N-dimethylamino)biphenyl, in an inert solvent such as tetrahydrofuran and in the presence of a base such as lithium bis(trimethylsilyl)amide in an inert atmosphere (nitrogen) and at elevated temperature such as 80° C., according to the procedure of Buchwald, Organic Letters, 2002, 4, 2885-2888.
  • Compounds of formula (V), (VI), (VIII), (IX), (XII) and (XIII) are either known or may be prepared in accordance with known procedures.
  • Certain compounds of formula (I), and their pharmaceutically acceptable salts have also been found to have affinity for the histamine H1 receptor.
  • Histamine H1 receptors are widely distributed throughout the CNS and periphery, and are involved in wakefulness and acute inflammatory processes [Hill et al, Pharmacol. Rev. 49:253-278 (1997)]. Seasonal allergic rhinitis, and other allergic conditions, are associated with the release of histamine from mast cells. The activation of H1 receptors in blood vessels and nerve endings are responsible for many of the symptoms of allergic rhinitis, which include itching, sneezing, and the production of watery rhinorrhea. Antihistamine compounds, i.e. drugs which are selective H1 receptor antagonists such as chlorphenyramine and cetirizine, are effective in treating the itching, sneezing and rhinorrhea associated with allergic rhinitis, but are not very effective in treating the nasal congestion symptoms [Aaronson, Ann. Allergy, 67:541-547, (1991)].
  • H3 receptor agonists are known to inhibit the effect of sympathetic nerve activation on vascular tone in porcine nasal mucosa [Varty & Hey. Eur. J. Pharmacol., 452:339-345, (2002)]. In vivo, H3 receptor agonists inhibit the decrease in nasal airway resistance produced by sympathetic nerve activation [Hey et al, Arzneim-Forsch Drug Res., 48:881-888 (1998)]. Furthermore, H3 receptor antagonists in combination with histamine H1 receptor antagonists reverse the effects of mast cell activation on nasal airway resistance and nasal cavity volume, an index of nasal congestion [McLeod et al, Am. J. Rhinol., 13: 391-399, (1999)]. A combined histamine H1 and H3 receptor antagonist, such as the series described herein, would be effective in the treatment of both the nasal congestion and the sneezing, itching and rhinorrhea associated with both seasonal and perennial allergic rhinitis.
  • Therefore, examples of disease states in which dual histamine H1 and H3 antagonists have potentially beneficial anti-inflammatory effects include diseases of the respiratory tract such as asthma (including allergic and non-allergic), allergic rhinitis, sinusitis, bronchitis (including chronic bronchitis), bronchiectasis, chronic obstructive pulmonary disease (COPD) and cystic fibrosis.
  • Other examples of disease states in which dual histamine H1 and H3 antagonists have potentially beneficial effects include diseases of the gastrointestinal tract such as intestinal inflammatory diseases including inflammatory bowel disease (e.g. Crohn's disease or ulcerative colitis) and intestinal inflammatory diseases secondary to radiation exposure or allergen exposure.
  • Dual histamine H1 and H3 antagonists of the present invention may also be of use in the treatment of sleep/wake disorders, arousal/vigilance disorders, migraine, dementia, mild cognitive impairment (pre-dementia), cognitive dysfunction, Alzheimer's disease, epilepsy, narcolepsy, eating disorders, motion sickness, vertigo, attention deficit hyperactivity disorders, learning disorders, memory retention disorders, schizophrenia, depression, manic disorders, bipolar disorders and diabetes.
  • Diseases of principal interest for a dual histamine H1 and H3 antagonist include asthma, COPD and inflammatory diseases of the upper respiratory tract involving seasonal and perennial allergic rhinitis, non-allergic rhinitis, and the specific symptoms associated with these diseases including nasal congestion, rhinorrhoea, sneezing, cough and itching (pruritis) of eyes, ears, nose and throat. Other diseases of principal interest include cough, chronic urticaria, allergic conjunctivitis, nasal polyposis, sinusitis, psoriasis, eczema and allergic dermatoses (including urticaria, atopic dermatitis, contact dermatitis, drug rashes and insect bites).
  • Diseases of principal interest include asthma, COPD, cognitive disorders and inflammatory diseases of the upper respiratory tract involving seasonal and perennial rhinitis. Preferred diseases of principal interest include asthma, cognitive disorders and inflammatory diseases of the upper respiratory tract involving seasonal and perennial rhinitis. Further diseases also of principal interest include inflammatory diseases of the gastrointestinal tract such as inflammatory bowel disease.
  • Thus the invention also provides a dual histamine H1 and H3 antagonist compound of formula (I) or a pharmaceutically acceptable salt thereof, for use as a therapeutic substance in the treatment or prophylaxis of the above disorders, in particular allergic rhinitis.
  • Preferred dual histamine H1 and H3 antagonist compounds of formula (I) are those wherein:
  • R1 represents aryl (eg. phenyl, naphthyl or tetrahydronaphthyl) or heteroaryl (eg. benzofuranyl, indolyl or quinolinyl);
    R1 is optionally substituted by one or more (eg. 1, 2 or 3): halogen (eg. chlorine, fluorine or bromine); trifluoromethyl; —C1-6 alkyl (eg. methyl, ethyl, isopropyl, propyl or t-butyl) optionally substituted by COOR15 (eg. COOEt); —C1-6 alkoxy (eg. methoxy) optionally substituted by COOR15 (eg. COOMe); C1-6 alkenyl (eg. ethenyl); NR15R16 (eg. N(Me)2); or C1-6 alkylthio (eg. —S-ethyl) groups;
    Z is a bond or CO;
    m is 0 or 2;
    n is 0;
    r is 0;
    p is 1.
    R3 represents —(CH2)q—NR11R12;
    q represents 3; and
    NR11R12 represents pyrrolidinyl, piperidinyl, azepanyl or azocanyl optionally substituted by one or more C1-6 alkyl (eg. methyl or ethyl), more preferably piperidinyl substituted by one or two methyl or ethyl groups.
  • The invention further provides a method of treatment or prophylaxis of the above disorders, in mammals including humans, which comprises administering to the sufferer a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof.
  • In another aspect, the invention provides the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for use in the treatment of the above disorders.
  • When used in therapy, the compounds of formula (I) are usually formulated in a standard pharmaceutical composition. Such compositions can be prepared using standard procedures.
  • Thus, the present invention further provides a pharmaceutical composition for use in the treatment of the above disorders which comprises the compound of formula (I) or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
  • The present invention further provides a pharmaceutical composition which comprises the compound of formula (I) or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
  • The pharmaceutical compositions according to the invention may also be used in combination with other therapeutic agents, for example anti-inflammatory agents (such as corticosteroids (e.g. fluticasone propionate, beclomethasone dipropionate, mometasone furoate, triamcinolone acetonide or budesonide) or NSAIDs (eg. sodium cromoglycate, nedocromil sodium, PDE-4 inhibitors, leukotriene antagonists, lipoxygenase inhibitors, chemokine antagonists (e.g CCR3, CCR1, CCR2, CXCR1, CXCR2), iNOS inhibitors, tryptase and elastase inhibitors, beta-2 integrin antagonists and adenosine 2a agonists)) or beta adrenergic agents (such as salmeterol, salbutamol, formoterol, fenoterol or terbutaline and salts thereof), or sympathomimetics (e.g pseudoephedrine or oxymetazoline), or other antagonists at the histamine receptor (e.g H4), or cholinesterase inhibitors, or cholinergic antagonists, or antiinfective agents (eg. antibiotics, antivirals).
  • A pharmaceutical composition of the invention, which may be prepared by admixture, suitably at ambient temperature and atmospheric pressure, is usually adapted for oral, topical, parenteral or rectal administration and, as such, may be in the form of tablets, capsules, oral liquid preparations, powders, granules, lozenges, reconstitutable powders, injectable or infusible solutions or suspensions or suppositories. Orally administrable compositions are generally preferred.
  • Tablets and capsules for oral administration may be in unit dose form, and may contain conventional excipients, such as binding agents, fillers, tabletting lubricants, disintegrants and acceptable wetting agents. The tablets may be coated according to methods well known in normal pharmaceutical practice.
  • Oral liquid preparations may be in the form of, for example, aqueous or oily suspension, solutions, emulsions, syrups or elixirs, or may be in the form of a dry product for reconstitution with water or other suitable vehicle before use. Such liquid preparations may contain conventional additives such as suspending agents, emulsifying agents, non-aqueous vehicles (which may include edible oils), preservatives, and, if desired, conventional flavourings or colorants.
  • For parenteral administration, fluid unit dosage forms are prepared utilising a compound of the invention or pharmaceutically acceptable salt thereof and a sterile vehicle. The compound, depending on the vehicle and concentration used, can be either suspended or dissolved in the vehicle. In preparing solutions, the compound can be dissolved for injection and filter sterilised before filling into a suitable vial or ampoule and sealing. Advantageously, adjuvants such as a local anaesthetic, preservatives and buffering agents are dissolved in the vehicle. To enhance the stability, the composition can be frozen after filling into the vial and the water removed under vacuum. Parenteral suspensions are prepared in substantially the same manner, except that the compound is suspended in the vehicle instead of being dissolved, and sterilisation cannot be accomplished by filtration. The compound can be sterilised by exposure to ethylene oxide before suspension in a sterile vehicle. Advantageously, a surfactant or wetting agent is included in the composition to facilitate uniform distribution of the compound.
  • The composition may contain from 0.1% to 99% by weight, preferably from 10 to 60% by weight, of the active material, depending on the method of administration. The dose of the compound used in the treatment of the aforementioned disorders will vary in the usual way with the seriousness of the disorders, the weight of the sufferer, and other similar factors. However, as a general guide suitable unit doses may be 0.05 to 1000 mg, more suitably 1.0 to 200 mg, and such unit doses may be administered more than once a day, for example two or three a day. Such therapy may extend for a number of weeks or months.
  • The following Descriptions and Examples illustrate the preparation of compounds of the invention.
    • Description 1 4-[4-(3-Piperidin-1-yl-propoxy)-benzyl]-piperazine-1-carboxylic acid tert-butyl ester (D1)
  • To a solution of 4-(3-(piperidin-1-yl)propoxy)benzaldehyde (WO 02/12214 A2) (1.90 g, 7.68 mmol) in dichloromethane (25 ml) was added 1-N tert butoxy carbonyl piperazine (1.57 g, 8.45 mmol) followed by acetic acid (1 ml), and the reaction stirred for 1 hour at room temperature, then treated with sodium triacetoxy borohydride (2 g, 9.61 mmol) and stirred for 16 hours at room temperature. The reaction was then diluted with saturated sodium bicarbonate solution and extracted with dichloromethane. The dichloromethane was then washed sequentially with water and brine, dried over anhydrous sodium sulfate and evaporated in vacuo to yield a residue which was purified using silica gel chromatography eluting with a mixture of 0.880 ammonia:methanol:dichloromethane (0.5:4.5:95) to afford the title compound (1.586 g, 50%); MS (ES+), m/e 418 [M+H]+.
    • Description 2 1-[4-(3-Piperidin-1-yl-propoxy)-benzyl]-piperazine trihydrochloride (D2)
  • To a solution of 4-[4-(3-piperidin-1-yl-propoxy)-benzyl]-piperazine-1-carboxylic acid tert-butyl ester (D1) (1.576 g, 3.76 mmol) in a (1:1) mixture of dichloromethane and methanol (20 ml) was added a 1M solution of hydrogen chloride in diethyl ether (20 ml) and the reaction stirred for 5 hours at room temperature. The solvent was then evaporated in vacuo and the resulting residue triturated with diethyl ether to afford the title compound (1.5 g, 93%); MS (ES+), m/e 318 [M+H]+.
    • Description 3 4-[4-(3-Piperidin-1-yl-propoxy)-benzyl]-[1,4]diazepane-1-carboxylic acid tert-butyl ester (D3)
  • Figure US20100075953A1-20100325-C00012
  • The title compound (D3) was prepared from [1,4]diazepane-1-carboxylic acid tert-butyl ester using the method of Description 1 (D1).
  • MS (ES+) m/e 432 [M+H]+.
    • Description 4 1-[4-(3-Piperidin-1-yl-propoxy)-benzyl]-[1,4]diazepane (D4)
  • Figure US20100075953A1-20100325-C00013
  • 4-[4-(3-Piperidin-1-yl-propoxy)-benzyl]-[1,4]diazepane-1-carboxylic acid tert-butyl ester (D3) (2.27 g, 5.27 mmol) was dissolved in dichloromethane (10 ml), treated with trifluoroacetic acid (5 ml) and stirred at room temperature under argon for 2 hours. The solvent was removed in vacuo and the residue dissolved in methanol and passed down an SCX column (10 g) eluting with methanol followed by 0.88 ammonia/methanol (1:9). The basic fractions were combined and concentrated in vacuo to afford the title compound (1.57 g).
  • MS (ES+) m/e 332 [M+H]+.
    • Description 5 4-(4-Formyl-phenoxy)-piperidine-1-carboxylic acid tert-butyl ester (D5)
  • 4-Hydroxybenzaldehyde (2.0 g, 16.4 mmol) was dissolved in tetrahydrofuran (20 ml) and treated with 4-hydroxy-piperidine-1-carboxylic acid tert-butyl ester (4.1 g, 20.5 mmol) and triphenylphosphine (5.4 g, 20.5 mmol). The mixture was cooled in an ice bath, treated with diethyl azodicarboxylate (3.2 ml, 20.5 mmol) and allowed to stir at room temperature for 36 hours. The reaction mixture was diluted with ethyl acetate, washed with sodium hydroxide solution (2M), sodium bicarbonate solution and brine. The organic layer was dried under magnesium sulphate, filtered and the solvent removed in vacuo. The title compound (1.85 g) was obtained by column chromatography eluting with ethyl acetate/hexane (1:4).
  • 1H NMR (CDCl3) δ 9.88 (1H, s), 7.85-7.82 (2H, d), 7.02-6.99 (2H, d), 4.65-4.59 (1H, m), 3.74-3.65 (2H, m), 3.43-3.33 (2H, m), 2.04-1.92 (2H, m), 1.82-1.77 (2H, m), 1.47 (9H, s).
    • Description 6 4-(4-piperazin-1-ylmethyl-phenoxy)-piperidine-1-carboxylic acid tert-butyl ester (D6)
  • The title compound (D6) was prepared from 4-(4-formyl-phenoxy)-piperidine-1-carboxylic acid tert-butyl ester (D5) and piperazine using the method described in Description 1 (D1).
  • MS (ES+) m/e 376 [M+H]+.
    • Description 7 4-{4-[4-(1-Phenyl-methanoyl)-piperazin-1-ylmethyl]-phenoxy}-piperidine-1-carboxylic acid tert-butyl ester (D7)
  • The title compound (D7) was prepared from 4-(4-piperazin-1-ylmethyl-phenoxy)-piperidine-1-carboxylic acid tert-butyl ester (D6) and benzoyl chloride using the method described in Example 24 (E24). MS(ES+) m/e 480 [M+H]+.
    • Description 8 4-(4-Hydroxy-phenyl)-piperazine-1-carboxylic acid tert-butyl ester (D8)
  • Di-tert-butyl dicarbonate (10.1 g; 1.1 eq) was added portion wise to 4-piperazin-1-yl-phenol (Chem. Pharm. Bull. 49(10), 1314 (2001)) (7.5 g; 42.1 mM) and triethylamine (6.4 ml; 1.1 eq) in dichloromethane (150 ml). The resulting mixture was stirred at room temperature for 18 hours
  • The reaction was washed with water (2×100 ml), dried (sodium sulphate) and the solvent removed by evaporation in vacuo. The residue was purified by column chromatography on silica eluting with 4-1 hexane-ethyl acetate to afford the title compound as an off-white solid (4.71 g)
  • MS (ES+) m/e 279 [M+H]+.
    • Description 9 4-[4-(3-Chloro-propoxy)-phenyl]-piperazine-1-carboxylic acid tert-butyl ester (D9)
  • A mixture of 4-(4-hydroxy-phenyl)-piperazine-1-carboxylic acid tert-butyl ester (D8) (4.0 g; 14.4 mM), 1-bromo-3-chloro propane (1.70 ml; 1.2 eq) and potassium carbonate (4.0 g; 2 eq) in butan-2-one (100 ml) was heated at reflux for 18 hours. The mixture was allowed to cool to room temperature, filtered and evaporated. The residue was purified by column chromatography on silica eluting with 4-1 hexane-ethyl acetate to afford the title compound as a colourless viscous oil (3.8 g)
  • MS (ES+) m/e 355 [M+H]+.
    • Description 10 4-[4-(3-Piperidin-1-yl-propoxy)-phenyl]-piperazine-1-carboxylic acid tert-butyl ester (D10)
  • A mixture of 4-[4-(3-chloro-propoxy)-phenyl]-piperazine-1-carboxylic acid tert-butyl ester (D9) (4.0 g; 11.3 mM), piperidine (2.23 ml; 2 eq), potassium carbonate (3.73 g; 2.4 eq) and potassium iodide (3.74 g; 2 eq) in butan-2-one (100 ml) was heated at reflux for 3 days. The mixture was allowed to cool to room temperature, filtered and evaporated to give the title compound as a pale yellow solid (4.6 g)
  • MS (ES+) m/e 404 [M+H]+.
    • Description 11 1-[4-(3-Piperidin-1-yl-propoxy)-phenyl]-piperazine (D11)
  • A solution of 4-[4-(3-piperidin-1-yl-propoxy)-phenyl]-piperazine-1-carboxylic acid tert-butyl ester (D10) (1.0 g; 2.48 mM) in trifluoroacetic acid (5 ml) was stirred at room temperature for 60 minutes. The resulting mixture was purified on an SCX ion exchange cartridge to afford the title compound as a colourless crystalline solid (0.76 g)
  • MS (ES+) m/e 304 [M+H]+.
    • Description 12 4-(3-Hydroxy-phenyl)-piperazine-1-carboxylic acid tert-butyl ester (D12)
  • Prepared from 3-piperazin-1-yl-phenol (Chem. Pharm. Bull. 49(10), 1314 (2001)) using the same method described in Description 8 (D8).
  • MS (ES+) m/e 279 [M+H]+.
    • Description 13 4-[3-(3-Chloro-propoxy)-phenyl]-piperazine-1-carboxylic acid tert-butyl ester (D13)
  • Prepared from 4-(3-hydroxy-phenyl)-piperazine-1-carboxylic acid tert-butyl ester (D12) using the same method described in Description 9 (D9).
  • MS (ES+) m/e 355 [M+H]+.
    • Description 14 4-[3-(3-Piperidin-1-yl-propoxy)-phenyl]-piperazine-1-carboxylic acid tert-butyl ester (D14)
  • Prepared from 4-[3-(3-chloro-propoxy)-phenyl]-piperazine-1-carboxylic acid tert-butyl ester (D13) using the same method described in Description 10 (D10).
  • MS (ES+) m/e 404 [M+H]+.
    • Description 15 1-[3-(3-Piperidin-1-yl-propoxy)-phenyl]-piperazine (D15)
  • Prepared from 4-[3-(3-piperidin-1-yl-propoxy)-phenyl]piperazine-1-carboxylic acid tert-butyl ester (D14) using the same method described in Description 11 (D11).
  • MS (ES+) m/e 304 [M+H]+.
    • Description 16 4-Bromo-1-methyl-1H-indole (D16)
  • Figure US20100075953A1-20100325-C00014
  • A solution of 4-bromo-1H-indole (6.7 g) in tetrahydrofuran (75 ml) was treated with sodium hydride (1.24 g) and stirred for 0.5 h at room temperature. The resulting suspension was treated with a solution of iodomethane (2.34 ml) in tetrahydrofuran (35 ml) at 0° C. and allowed to warm to room temperature over 1 h, whilst stirring. The reaction mixture was poured onto water and partitioned between dichloromethane and water. The organic phase was dried over (MgSO4) and concentrated in vacuo to afford the title compound (7.2 g). TLC Silica (cyclohexane-ethyl acetate [1:1]), Rf=0.55.
    • Description 17 4-Bromo-1-methyl-1H-indole-3-carboxylic acid (D17)
  • Figure US20100075953A1-20100325-C00015
  • A solution of 4-bromo-1-methyl-1H-indole (D16) (7.0 g) in tetrahydrofuran (50 ml) was treated with a solution of trifluoroacetic anhydride (5.65 ml) in tetrahydrofuran (20 ml) at 0° C. The reaction mixture was allowed to warm to room temperature over 6 h, whilst stirring. The reaction mixture was concentrated in vacuo and then re-suspended in ethanol (25 ml). The solution was treated with 5N sodium hydroxide solution (50 ml) and heated under reflux for 18 h. The reaction mixture was washed with diethyl ether and the aqueous phase acidified with 5N hydrochloric acid solution. The precipitate was filtered, washed with water and concentrated in vacuo to afford the title compound (4.88 g). TLC, Silica (cyclohexane-ethyl acetate-acetic acid [3:1:0.1]), Rf=0.35.
    • Descriptions 18-23
  • Descriptions 18-23 were prepared using analogous methods to Example 76b by substituting 2-methylpiperidine with the appropriate amine.
  • Mass Ion
    Description Structure RT (min) (M + H)+
    18
    Figure US20100075953A1-20100325-C00016
         		1.64 332
    19
    Figure US20100075953A1-20100325-C00017
         		0.65 304
    20
    Figure US20100075953A1-20100325-C00018
         		1.77 346
    21
    Figure US20100075953A1-20100325-C00019
         		1.45 318
    22
    Figure US20100075953A1-20100325-C00020
         		1.57 332
    23
    Figure US20100075953A1-20100325-C00021
         		1.61 318
    • Descriptions 24-32
  • Descriptions 24-32 were prepared by analogous methods to those indicated in the below table:
  • Prepared
    Descrip- analogously RT
    tion Name to (min)
    24 1,1-Dimethylethyl 4-(2-naphthalenyl)- E229a from 3.74
    1-piperazinecarboxylate known
    starting
    materials
    25 1,1-Dimethylethyl 4-(4-quinolinyl)-1- E229a from 2.18
    piperazinecarboxylate and 1,1- known &
    dimethylethyl 4-(3-quinolinyl)-1- starting 3.02
    piperazinecarboxylate (1:1) materials
    26 1-(2-Naphthalenyl)piperazine E229b from 2.00
    known
    starting
    materials
    27 4-(1-Piperazinyl)quinoline and 3-(1- E229b from 1.18
    piperazinyl)quinoline (1:1) D25
    28 3-{[4-(2-Naphthalenyl)-1- E229c from 2.39
    piperazinyl]methyl}phenol D24
    29 3-{[4-(1-Naphthalenyl)-1- E229c from 2.41
    piperazinyl]methyl}phenol D26
    30 4-{[4-(8-Quinolinyl)-1- E229c from 1.78
    piperazinyl]methyl}phenol E229b
    31 4-{[4-(4-Quinolinyl)-1- E229c from 1.91
    piperazinyl]methyl}phenol and 3-{[4- D27
    (3-quinolinyl)-1-
    piperazinyl]methyl}phenol (1:1)
    32 4-{[4-(1-Naphthalenyl)-1- E229c from 2.46
    piperazinyl]methyl}phenol D26
    • Descriptions 33-42
  • Descriptions 33-42 were prepared by analogous methods to those indicated in the below table:
  • Prepared
    Descrip- analogously RT
    tion Name to (min)
    33 2-Methyl-4-[4-(2-{4- E237a from 2.20
    [(phenylmethyl)oxy]phenyl}ethyl)-1- known
    piperazinyl]quinoline starting
    materials
    34 2-Methyl-4-[4-(2-{3- E237a from 2.11
    [(phenylmethyl)oxy]phenyl}ethyl)-1- known
    piperazinyl]quinoline starting
    materials
    35 1-(1-Naphthalenyl)-4-(2-{4- E237a from 2.91
    [(phenylmethyl)oxy]phenyl}ethyl) known
    piperazine starting
    materials
    36 1-(1-Naphthalenyl)-4-(2-{3- E237a from 2.82
    [(phenylmethyl)oxy]phenyl}ethyl) known
    piperazine starting
    materials
    37 1-Phenyl-4-(2-{4- E237a from 2.55
    [(phenylmethyl)oxy]phenyl}ethyl) known
    piperazine starting
    materials
    38 4-{2-[4-(2-Methyl-4-quinolinyl)-1- E237b from 1.69
    piperazinyl]ethyl}phenol D33
    39 3-{2-[4-(2-Methyl-4-quinolinyl)-1- E237b from 4.56
    piperazinyl]ethyl}phenol D34
    40 4-{2-[4-(1-Naphthalenyl)-1- E237b from 2.28
    piperazinyl]ethyl}phenol D35
    41 3-{2-[4-(1-Naphthalenyl)-1- E237b from 2.32
    piperazinyl]ethyl}phenol D36
    42 4-[2-(4-Phenyl-1- E237b from 2.02
    piperazinyl)ethyl]phenol D37
    • Description 43 3-Bromo-4-ethyl-benzoic acid (D43)
  • Figure US20100075953A1-20100325-C00022
  • To a mixture of conc. HNO3 (66 mL), glacial AcOH (300 mL) and water (50 mL), 4-ethyl-benzoic acid (15 g) was added, stirring vigorously, before treating with bromine (5.67 mL). Finally a solution of AgNO3 (16.97 g) in water (50 mL) was added dropwise and the mixture was stirred vigorously for 2 h. The precipitate was collected by filtration, washed well with water, before being extracted with hot, saturated K2CO3 solution, and then treated with charcoal. The hot solution was filtered through kieselguhr and the solution was acidified to pH1 using conc. HCl. The resulting white precipitate was collected by filtration and dried in the vacuum oven overnight at 60° C. to afford the title compound (19.46 g).
  • NMR (CDCl3) δ 1.26 (3H, t), 2.83 (2H, q), 7.34 (1H, d), 7.97 (1H, dd), 8.27 (1H, dd)
    • Description 44 Methyl 3-bromo-4-ethyl-benzoate (D44)
  • Figure US20100075953A1-20100325-C00023
  • 3-Bromo-4-ethyl-benzoic acid (D43) (19.40 g) was dissolved in MeOH (200 mL) and then treated with conc. H2SO4 (1 mL). The mixture was heated at reflux overnight, and then concentrated under reduced pressure. The residue was partitioned between EtOAc and saturated aqueous NaHCO3 solution, extracting again with EtOAc. The combined extracts were then washed with brine, dried (MgSO4). The solvent was evaporated in vacuo to afford the title compound (15.8 g). 1H NMR (CDCl3) δ 1.24 (3H, t), 2.79 (2H, q), 3.91 (3H, s), 7.29 (1H, d), 7.89 (1H, dd), 8.19 (1H, d).
    • Description 45 Methyl 3-cyano-4-ethyl-benzoate (D45)
  • Figure US20100075953A1-20100325-C00024
  • Methyl 3-bromo-4-ethyl-benzoate (D44) (5 g) in NMP (180 mL) was treated with copper (I) cyanide (3.69 g). The mixture was then heated at reflux for 5 h, under argon. After cooling to 20° C. the reaction mixture was diluted with water, then filtered through kieselguhr, washing well with water and EtOAc. The organic layer was washed with water, brine and dried over MgSO4. The solvent was evaporated to dryness in vacuo and the residue was purified by chromatography on silica eluting with EtOAc-Hexane (1:9) to give the title compound (1.9 g) 1H NMR (CDCl3) δ 1.33 (3H, t), 2.94 (2H, q), 3.94 (3H, s), 7.43 (1H, d), 8.17 (1H, dd), 8.28 (1H, d).
    • Description 46 3-Cyano-4-ethyl benzoic acid (D461
  • Figure US20100075953A1-20100325-C00025
  • Methyl 3-cyano-4-ethyl-benzoate (D45) (1.92 g) was dissolved in MeOH (50 mL) before adding 1M NaOH solution (15.24 mL) and stirring the resulting mixture overnight at room temperature, under argon. The reaction mixture was diluted with water, and extracted with EtOAc. The aqueous layer was acidified to pH1 using 2M HCl before extracting with EtOAc. The combined extracts were washed with brine, dried over MgSO4 and the solvent evaporated to dryness in vacuo to afford the title compound (1.63 g). 1H NMR (CDCl3) δ 1.35 (3H, t), 2.97 (2H, q), 7.49 (1H, d), 8.24 (1H, dd), 8.36 (1H, d).
  • Analysis of the Examples was performed as follows:
  • LCMS was conducted on a Supelcosil LCABZ+PLUS column (3.3 cm×4.6 mm ID) eluting with 0.1% formic acid and 0.01 M ammonium acetate in water (solvent A) and 0.05% formic acid and 5% water in acetonitrile (solvent B), using the following elution gradient 0.0-7 min 0% B, 0.7-4.2 min 100% B, 4.2-5.3 min 0% B, 5.3-5.5 min 0% B at a flow rate of 3 mL/min. The mass spectra were recorded on a Fisons VG Platform spectrometer using electrospray positive and negative mode (ES+ve and ES−ve).
  • Preparative mass directed HPLC was conducted on a Waters FractionLynx system comprising of a Waters 600 pump with extended pump heads, Waters 2700 autosampler, Waters 996 diode array and Gilson 202 fraction collector on a 10 cm×2.54 cm ID ABZ+column, eluting with 0.1% formic acid in water (solvent A) and 0.1% formic acid in acetonitrile (solvent B), using an appropriate elution gradient, at a flow rate of 20 ml/min and detecting at 200-320 nm at room temperature. Mass spectra were recorded on Micromass ZMD mass spectrometer using electrospray positive and negative mode, alternate scans. The software used was MassLynx 3.5 with OpenLynx and FractionLynx options.
    • EXAMPLE 1 1-Phenyl-1-{4-[4-(3-piperidin-1-yl-propoxy)-benzyl]-piperazin-1-yl}-methanone (E1)
  • Figure US20100075953A1-20100325-C00026
  • N-Cyclohexylcarbodiimide, N-methyl polystyrene HL (200-400 mesh) 1.8 mMol/g (650 mg, 1.172 mmol) was suspended in a (1:1) mixture of dichloromethane and dimethylformamide and treated sequentially with benzoic acid (72 mg, 0.58 mmol), 1-hydroxybenzotriazole hydrate (80 mg, 0.58 mmol) and stirred for 10 minutes at room temperature. A solution of 1-[4-(3-piperidin-1-yl-propoxy)-benzyl]-piperazine trihydrochloride (D2) (125 mg, 0.29 mmol) in dichloromethane (1 ml) and triethylamine (0.13 ml, 0.87 mmol) was then added to the reaction and stirred at room temperature for 16 hours. After filtration, the filtrate was applied to a Mega Bond elute SCX ion exchange column washing sequentially with water and methanol, followed by 0.880 ammonia/methanol (1:10) to elute the crude reaction mixture. Purification by silica gel chromatography eluting with a mixture of 0.880 ammonia:methanol:dichloromethane (0.5:4.5:95) to afford the title product (95 mg, 77%); MS (ES+), m/e 422 [M+H]+.
    • EXAMPLES 2-11
  • Examples 2-11 (E2-E11) were prepared from Description 2 (D2) using an analogous method to that described in Example 1 (E1) by substituting benzoic acid for the appropriate acid indicated in the table.
  • Example Acid Mass Spectrum
    1-Benzo[1,3]dioxol-5-yl-1-{4-[4-(3- piperonylic acid MS (ES+) m/e
    piperidin-1-yl-propoxy)-benzyl]-piperazin-1- 466 [M + H]+
    yl}-methanone (E2)
    1-Naphthalen-2-yl-1-{4-[4-(3-piperidin-1-yl- 2-naphthoic acid MS (ES+) m/e
    propoxy)-benzyl]-piperazin-1-yl}- 472 [M + H]+
    methanone (E3)
    1-(3,5-Dichloro-phenyl)-1-{4-[4-(3- 3,5- MS (ES+) m/e
    piperidin-1-yl-propoxy)-benzyl]-piperazin-1- dichlorobenzoic 491/493 [M + H]+
    yl}-methanone (E4) acid
    1-(4-Bromo-3-methyl-phenyl)-1-{4-[4-(3- 3-methyl, 4-bromo MS (ES+) m/e
    piperidin-1-yl-propoxy)-benzyl]-piperazin-1- benzoic acid 515/517 [M + H]+
    yl}-methanone (E5)
    1-(2-Methoxy-phenyl)-1-{4-[4-(3-piperidin- 2-methoxy benzoic MS (ES+) m/e
    1-yl-propoxy)-benzyl]-piperazin-1-yl}- acid 452 [M + H]+
    methanone (E6)
    1-(3,4-Dichloro-phenyl)-1-{4-[4-(3- 3,4-dichloro MS (ES+) m/e
    piperidin-1-yl-propoxy)-benzyl]-piperazin-1- benzoic acid 491/493/495
    yl}-methanone (E7) [M + H]+
    4-(1-{4-[4-(3-Piperidin-1-yl-propoxy)- 4-cyano benzoic MS (ES+) m/e
    benzyl]-piperazin-1-yl}-methanoyl)- acid 447 [M + H]+
    benzonitrile (E8)
    1-(4-Fluoro-phenyl)-1-{4-[4-(3-piperidin-1- 4-fluoro benzoic MS (ES+) m/e
    yl-propoxy)-benzyl]-piperazin-1-yl}- acid 440 [M + H]+
    methanone (E9)
    1-(4-Bromo-phenyl)-1-{4-[4-(3-piperidin-1- 4-bromo benzoic MS (ES+) m/e
    yl-propoxy)-benzyl]-piperazin-1-yl}- acid 500/502 [M + H]+
    methanone (E10)
    1-Benzofuran-2-yl-1-{4-[4-(3-piperidin-1-yl- 2-benzofuran MS (ES+) m/e
    propoxy)-benzyl]-piperazin-1-yl}- carboxylic acid 462 [M + H]+
    methanone (E11)
    • EXAMPLE 12 1-Benzo[1,3]dioxol-5-yl-1-{4-[4-(3-piperidin-1-yl-propoxy)-benzyl]-[1,4]diazepan-1-yl}-methanone (E12)
  • Figure US20100075953A1-20100325-C00027
  • 1-[4-(3-Piperidin-1-yl-propoxy)-benzyl]-[1,4]diazepane (D4) (100 mg, 0.30 mmol) was dissolved in dichloromethane (5 ml) and treated sequentially with benzo[1,3]dioxole-5-carboxylic acid (125 mg, 0.75 mmol), 1,3-dicyclohexylcarbodiimide (155 mg, 0.75 mmol) and 1-hydroxybenzotriazole hydrate (101 mg, 0.75 mmol). The mixture was allowed to stir at room temperature under argon for 12 hours, diluted with methanol and passed down an SCX ion exchange column (2 g) eluting with methanol followed by 0.880 ammonia/methanol (1:9). The basic fractions were combined and concentrated in vacuo to afford the title compound (127 mg). MS (ES+) m/e 480 [M+H]+.
    • EXAMPLES 13-15
  • Examples 13-15 (E13-E15) were prepared from Description 4 (D4) using an analogous method to that described in Example 12 (E12) by substituting benzo[1,3]dioxole-5-carboxylic acid for the appropriate acid indicated in the table.
  • Example Carboxylic acid Mass Spectrum
    1-Phenyl-1-{4-[4-(3-piperidin-1-yl-propoxy)- Benzoic acid MS(ES+) m/e
    benzyl]-[1,4]diazepan-1-yl}-methanone (E13) 436 [M + H]+
    1-Naphthalen-2-yl-1-{4-[4-(3-piperidin-1-yl-propoxy)- Naphthalene-2- MS(ES+) m/e
    benzyl]-[1,4]diazepan-1-yl}-methanone (E14) carboxylic acid 486 [M + H]+
    1-(3,5-Dichloro-phenyl)-1-{4-[4-(3-piperidin-1-yl- 3,5-Dichloro-benzoic MS(ES+) m/e
    propoxy)-benzyl]-[1,4]diazepan-1-yl}-methanone (E15) acid 505 [M + H]+
    • EXAMPLES 16-23
  • Examples 16-23 (E16-E23) were prepared from Description 4 (D4) using an analogous method to that described in Example 12 (E12) by substituting benzo[1,3]dioxole-5-carboxylic acid for the appropriate acid indicated in the table followed by further purification by column chromatography on silica gel eluting with a mixture of 0.880 ammonia/methanol/dichloromethane (0.5:4.5:95).
  • Example Carboxylic acid Mass Spectrum
    1-(4-Bromo-3-methyl-phenyl)-1-{4-[4-(3-piperidin-1-yl- 4-Bromo-3-methyl- MS(ES+) m/e
    propoxy)-benzyl]-[1,4]diazepan-1-yl}-methanone (E16) benzoic acid 529 [M + H]+
    1-(2-Methoxy-phenyl)-1-{4-[4-(3-piperidin-1-yl-propoxy)- 2-Methoxy-benzoic MS(ES+) m/e
    benzyl]-[1,4]diazepan-1-yl}-methanone (E17) acid 466 [M + H]+
    4-(1-{4-[4-(3-Piperidin-1-yl-propoxy)-benzyl]- 4-Cyano-benzoic acid MS(ES+) m/e
    [1,4]diazepan-1-yl}-methanoyl)-benzonitrile (E18) 461 [M + H]+
    1-(4-Fluoro-phenyl)-1-{4-[4-(3-piperidin-1-yl-propoxy)- 4-Fluoro-benzoic acid MS(ES+) m/e
    benzyl]-[1,4]diazepan-1-yl}-methanone (E19) 454 [M + H]+
    1-(4-Bromo-phenyl)-1-{4-[4-(3-piperidin-1-yl-propoxy)- 4-Bromo-benzoic acid MS(ES+) m/e
    benzyl]-[1,4]diazepan-1-yl}-methanone (E20) 515 [M + H]+
    1-Benzofuran-2-yl-1-{4-[4-(3-piperidin-1-yl-propoxy)- Benzofuran-2- MS(ES+) m/e
    benzyl]-[1,4]diazepan-1-yl}-methanone (E21) carboxylic acid 476 [M + H]+
    1-(3,4-Dichloro-phenyl)-1-{4-[4-(3-piperidin-1-yl- 3,4-Dichloro- MS(ES+) m/e
    propoxy)-benzyl]-[1,4]diazepan-1-yl}-methanone (E22) benzoic acid 505 [M + H]+
    1-Cyclopropyl-1 -{4-[4-(3-piperidin-1-yl-propoxy)- Cyclopropane MS(ES+) m/e
    benzyl]-[1,4]diazepan-1-yl}-methanone (E23) carboxylic acid 400 [M + H]+
    • EXAMPLE 24 1-Cyclopentyl-1-{4-[4-(3-piperidin-1-yl-propoxy)-benzyl]-[1,4]diazepan-1-yl}-methanone (E24)
  • Figure US20100075953A1-20100325-C00028
  • 1-[4-(3-Piperidin-1-yl-propoxy)-benzyl]-[1,4]diazepane (D4) (100 mg, 0.30 mmol) was dissolved in dichloromethane (5 ml), treated with cyclopentyl acid chloride (80 mg, 0.60 mmol), potassium carbonate (83 mg, 0.60 mmol) and allowed to stir at room temperature under argon for 12 hours. The reaction mixture was diluted with methanol and passed down an SCX column (2 g) eluting with methanol followed by ammonia/methanol (1:9). The basic fractions were combined and concentrated in vacuo to afford the title compound (56 mg).
  • MS (ES+) m/e 428 [M+H]+.
    • EXAMPLE 25 1-Benzenesulfonyl-4-[4-(3-piperidin-1-yl-propoxy)-benzyl]-[1,4]diazepane (E25)
  • Figure US20100075953A1-20100325-C00029
  • 1-[4-(3-Piperidin-1-yl-propoxy)-benzyl]-[1,4]diazepane (D4) (100 mg, 0.30 mmol) was dissolved in 2-butanone (5 ml), treated with benzene sulfonyl chloride (57 mg, 0.32 mmol) and allowed to stir at room temperature under argon for 2 hours. The reaction mixture was diluted with methanol and passed down an SCX column (2 g) eluting with methanol followed by ammonia/methanol (1:9). The basic fractions were combined and concentrated in vacuo to afford the title compound (91 mg). MS (ES+) m/e 472 [M+H]+.
    • EXAMPLES 26-28
  • Examples 26-28 (E26-E28) were prepared from Description 4 (D4) using an analogous method to that described in Example 25 (E25) by substituting benzenesulfonyl chloride for the appropriate sulfonyl chloride indicated in the table.
  • Example Sulfonyl Chloride Mass Spectrum
    1-(Naphthalene-2-sulfonyl)-4-[4-(3- Naphthalene-2- MS(ES+) m/e
    piperidin-1-yl-propoxy)-benzyl]- sulfonyl chloride 522 [M + H]+
    [1,4]diazepane (E26)
    1-(4-Fluoro-benzenesulfonyl)-4-[4-(3- 4-Fluoro- MS(ES+) m/e
    piperidin-1-yl-propoxy)-benzyl]- benzenesulfonyl 490 [M + H]+
    [1,4]diazepane (E27) chloride
    1-(4-Bromo-benzenesulfonyl)-4-[4-(3- 4-Bromo- MS(ES+) m/e
    piperidin-1-yl-propoxy)-benzyl]- benzenesulfonyl 552 [M + H]+
    [1,4]diazepane (E28) chloride
    • EXAMPLES 29-31
  • Examples 29-31 (E29-E31) were prepared from Description 4 (D4) using an analogous method to that described in Example 25 (E25) by substituting benzenesulfonyl chloride for the appropriate sulfonyl chloride indicated in the table followed by further purification by column chromatography on silica gel eluting with a mixture of 0.880 ammonia/methanol/dichloromethane (0.5:4.5:95).
  • Example Sulfonyl Chloride Mass Spectrum
    1-(3,5-Dichloro-benzenesulfonyl)- 3,5-Dichloro- MS(ES+) m/e
    4-[4-(3-piperidin-1-yl-propoxy)- benzenesulfonyl 540 [M + H]+
    benzyl]-[1,4]diazepane (E29) chloride
    1-(3,4-Dichloro-benzenesulfonyl)- 3,4-Dichloro- MS(ES+) m/e
    4-[4-(3-piperidin-1-yl-propoxy)- benzenesulfonyl 540 [M + H]+
    benzyl]-[1,4]diazepane (E30) chloride
    4-{4-[4-(3-Piperidin-1-yl-propoxy)- 4-Cyano- MS(ES+) m/e
    benzyl]-[1,4]diazepane-1- benzenesulfonyl 497 [M + H]+
    sulfonyl}-benzonitrile (E31) chloride
    • EXAMPLE 32 1-Phenyl-1-{4-[4-(piperidin-4-yloxy)-benzyl]-piperazin-1-yl}-methanone (E32)
  • Figure US20100075953A1-20100325-C00030
  • The title compound (E32) was prepared from 4-{4-[4-(1-phenyl-methanoyl)-piperazin-1-ylmethyl]-phenoxy}-piperidine-1-carboxylic acid tert-butyl ester (D7) using the method described in Description 4 (D4). MS (ES+) m/e 380 [M+H]+.
    • EXAMPLE 33 1-{4-[4-(1-Isopropyl-piperidin-4-yloxy)-benzyl]-piperazin-1-yl}-1-phenyl-methanone (E33)
  • Figure US20100075953A1-20100325-C00031
  • The title compound (E33) was prepared from 1-phenyl-1-{4-[4-(piperidin-4-yloxy)-benzyl]-piperazin-1-yl}-methanone (E32) and acetone using the method described in Description 1 (D1). MS (ES+) m/e 422 [M+H]+.
    • EXAMPLE 34 1-(4-{4-[1-(2-Methoxy-ethyl)-piperidin-4-yloxy]-benzyl}-piperazin-1-yl)-1-phenyl-methanone (E34)
  • Figure US20100075953A1-20100325-C00032
  • 1-Phenyl-1-{4-[4-(piperidin-4-yloxy)-benzyl]-piperazin-1-yl}-methanone (E32) (150 mg, 0.40 mmol) was dissolved in 2-butanone and treated with 1-chloro-2-methoxy-ethane (0.08 ml, 0.80 mmol), potassium carbonate (132 mg, 0.96 mmol) and potassium iodide (159 mg, 0.96 mmol). The reaction mixture was heated under reflux for 24 hours. The mixture was allowed to cool to room temperature, acidified by the addition of glacial acetic acid and passed down an SCX ion exchange column (2 g) eluting with methanol followed by ammonia/methanol (1:9). The basic fractions were combined and concentrated in vacuo to afford the title compound (76 mg). MS (ES+) m/e 438 [M+H]+.
    • EXAMPLES 35-37
  • Examples 35-37 (E35-E37) were prepared in accordance with the following general synthesis:
  • The appropriate acid chloride (1.1 eq) was added to a mixture of 1-[4-(3-piperidin-1-yl-propoxy)-phenyl]-piperazine (D11) (100 mg; 0.33 mM) and potassium carbonate (55 mg; 1.5 eq) in butan-2-one (2 ml). The resulting mixtures were stirred at room temperature for 3 hours and then purified on SCX ion exchange cartridges to afford the title compounds.
  • Example Acid Chloride Mass Spectrum
    1-Cyclopropyl-1-{4-[4-(3-piperidin- Cyclopropane MS (ES+) m/e
    1-yl-propoxy)-phenyl]-piperazin-1- carbonyl chloride 372 [M + H]+.
    yl}-methanone (E35)
    1-Phenyl-1-{4-[4-(3-piperidin-1-yl- Benzoyl chloride MS (ES+) m/e
    propoxy)-phenyl]-piperazin-1-yl}- 408 [M + H]+.
    methanone (E36)
    1-(3,4-Dichloro-phenyl)-1-{4-[4-(3- 3,4- MS (ES+) m/e
    piperidin-1-yl-propoxy)-phenyl]- Dichlorobenzoyl 477 [M + H]+.
    piperazin-1-yl}-methanone (E37) chloride
    • EXAMPLES 38-39
  • Examples 38-39 (E38-E39) were prepared from 1-[3-(3-piperidin-1-yl-propoxy)-phenyl]-piperazine (D15) using the same procedure as described in Examples 36 and 37, respectively.
  • Example Mass Spectrum
    1-Phenyl-1-{4-[3-(3-piperidin-1-yl-propoxy)- MS (ES+)m/e
    phenyl]-piperazin-1-yl}-methanone (E38) 408 [M + H]+.
    1-(3,4-Dichloro-phenyl)-1-{4-[3-(3-piperidin-1-yl- MS (ES+) m/e
    propoxy)-phenyl]-piperazin-1-yl}-methanone 477 [M + H]+.
    (E39)
    • EXAMPLES 40-42
  • Examples 40-42 (E40-E42) were prepared in accordance with the following general synthesis:
  • The appropriate sulphonyl chloride (1.1 eq) was added to a mixture of 1-[4-(3-piperidin-1-yl-propoxy)-phenyl]-piperazine (D11) (100 mg; 0.33 mM) and potassium carbonate (55 mg; 1.5 eq) in butan-2-one (2 ml). The resulting mixtures were stirred at room temperature for 3 hours and then purified on SCX ion exchange cartridges to afford the title compounds.
  • Example Sulfonyl Chloride Mass Spectrum
    1-Methanesulphonyl-4-[4-(3-piperidin-1-yl- Methane sulfonyl MS (ES+) m/e
    propoxy)-phenyl]-piperazine (E40) chloride 382 [M + H]+.
    1-Benzenesulphonyl-4-[4-(3-piperidin-1-yl- Benzene sulfonyl MS (ES+) m/e
    propoxy)-phenyl]-piperazine (E41) chloride 444 [M + H]+.
    1-(3,4-Dichloro benzenesulphonyl)-4-[4-(3- 3,4- MS (ES+) m/e
    piperidin-1-yl-propoxy)-phenyl]-piperazine Dichlorobenzene 513 [M + H]+.
    (E42) sulfonyl chloride
    • EXAMPLES 43-45
  • Examples 43-45 (E43-E45) were prepared from 1-[3-(3-piperidin-1-yl-propoxy)-phenyl]-piperazine (D15) using the same procedure as described in Examples 40, 41 and 42, respectively.
  • Example Mass Spectrum
    1-Methanesulphonyl-4-[3-(3-piperidin-1-yl- MS (ES+) m/e
    propoxy)-phenyl]-piperazine (E43) 382 [M + H]+.
    1-Benzenesulphonyl-4-[3-(3-piperidin-1-yl- MS (ES+) m/e
    propoxy)-phenyl]-piperazine (E44) 444 [M + H]+.
    1-(3,4-Dichloro benzenesulphonyl)-4-[3-(3- MS (ES+) m/e
    piperidin-1-yl-propoxy)-phenyl]-piperazine (E45) 513 [M + H]+.
    • EXAMPLES 46-47
  • Examples 46-47 (E46-E47) were prepared in accordance with the following general synthesis:
  • The appropriate isocyanate (1.1 eq) was added to 1-[4-(3-piperidin-1-yl-propoxy)-phenyl]-piperazine (D11) (100 mg; 0.33 mM) in butan-2-one (2 ml). The resulting mixtures were stirred at room temperature for 3 hours and then purified on SCX ion exchange cartridges to afford the title compounds.
  • Example Isocyanate Mass Spectrum
    4-[4-(3-Piperidin-1-yl-propoxy)- Isocyanatobenzene MS (ES+) m/e
    phenyl] piperazine-1-carboxylic acid 423 [M + H]+.
    phenylamide (E46)
    4-[4-(3-Piperidin-1-yl-propoxy)- 3,4-Dichloro MS (ES+) m/e
    phenyl] piperazine-1-carboxylic acid isocyanato benzene 492 [M + H]+.
    (3,4-dichloro-phenyl)-amide (E47)
    • EXAMPLE 48 4-[4-(3-Piperidin-1-yl-propoxy)-phenyl]piperazine-1-carboxylic acid cyclopropylamide (E48)
  • Figure US20100075953A1-20100325-C00033
  • To a solution of 1-[4-(3-piperidin-1-yl-propoxy)-phenyl]-piperazine (D11) (150 mg; 0.49 mM) in dry dichloromethane (3 ml) was added drop wise a 20% solution of phosgene in toluene (0.5 ml; ˜2 eq) and the resulting mixture stirred for 1 hour. The solvent was removed by evaporation and the resulting white powder dissolved in dry dichloromethane (4 ml). Triethylamine (0.14 ml: 2 eq) was added followed by cyclopropylamine (0.1 ml; 3 eq) and the mixture stirred for 18 hours. The solvent was removed by evaporation in vacuo and the residue purified on a silica column eluting with 3% methanol in dichloromethane to afford the title compound as a white solid (155 mg)
  • MS (ES+) m/e 387 [M+H]+.
    • EXAMPLES 49-50
  • Examples 49-50 (E49-E50) were prepared from 1-[3-(3-piperidin-1-yl-propoxy)-phenyl]-piperazine (D15) using the same procedure as described in Examples 46 and 47, respectively.
  • Example Mass Spectrum
    4-[3-(3-Piperidin-1-yl-propoxy)-phenyl] MS (ES+) m/e
    piperazine-1-carboxylic acid phenylamide (E49) 423 [M + H]+.
    4-[3-(3-Piperidin-1-yl-propoxy)-phenyl] MS (ES+) m/e
    piperazine-1-carboxylic acid (3,4-dichloro- 492 [M + H]+.
    phenyl)-amide (E50)
    • EXAMPLE 51 1-(3,4-Dichloro-phenyl)-4-[4-(3-Piperidin-1-yl-propoxy)-phenyl]piperazine (E51)
  • Figure US20100075953A1-20100325-C00034
  • Tris(dibenzylidineacetone) di palladium (0) (5 mol %; 23 mg) was added to a mixture of 1-[4-(3-piperidin-1-yl-propoxy)-phenyl]-piperazine (D11) (150 mg; 0.49 mmol), 3,4-dichloro bromo benzene (160 mg; 1.2 eq), sodium tert-butoxide (71 mg; 1.1 eq) and racemic 2,2′-bis(diphenylphosphino)-1,1′-binaphthyl (7.5 mol %; 24 mg) in dry toluene (3 ml). The resulting mixture was heated at reflux under argon for 18 hours. The reaction was allowed to cool to room temperature and diluted with ethyl acetate (10 ml). The resulting solids were removed by filtration and the filtrate evaporated in vacuo. The residue was purified by column chromatography on silica eluting with 3% methanol in dichloromethane to afford the title compound as a buff solid (45 mg)
  • MS (ES+) m/e 448 [M+H]+.
    • EXAMPLE 52 1-(3,4-Dichloro-phenyl)-4-[3-(3-Piperidin-1-yl-propoxy)-phenyl]piperazine (E52)
  • Figure US20100075953A1-20100325-C00035
  • The title compound (E52) was prepared from 1-[3-(3-piperidin-1-yl-propoxy)-phenyl]-piperazine (D15) using the same method as described in Example 51 (E51).
  • MS (ES+) m/e 448 [M+H]+.
    • EXAMPLE 53 5-Fluoro-1-methyl-3-{[4-(4-{[3-(1-piperidinyl)propyl]oxy}phenyl)-1-piperazinyl]carbonyl}-1H-indole (E53)
  • Figure US20100075953A1-20100325-C00036
  • A solution of 5-fluoro-1-methyl-1H-indole-3-carboxylic acid [WO 0071537 A1] (35 mg) and 1-(4-{[3-(1-piperidinyl)propyl]oxy}phenyl)piperazine (D11) (50 mg) in dichloromethane (1 ml) was treated with benzotriazol-1-yloxytripyrrolidinophosphonium hexafluorophosphate (94.4 mg) and heated in a microwave (CEM™ Discover microwave) at 120° C. for 5 min. The reaction mixture was concentrated in vacuo and purified on a SCX cartridge (2 g) eluting with methanol-aqueous ammonia (10:1) followed by mass directed auto preparative HPLC to give the title compound (12 mg). LCMS RT=2.49 min, 478 (M+H)+
    • EXAMPLES 54-61
  • The following compounds were prepared in an analogous manner to the process described for E53 from D11 and a known appropriate acid, with the exception of Example 57 which was prepared from D11 and D17.
  • Mass ion
    Example Structure RT (min) (M + H)+
    54
    Figure US20100075953A1-20100325-C00037
         		2.37 448 450
    55
    Figure US20100075953A1-20100325-C00038
         		2.26 464
    56
    Figure US20100075953A1-20100325-C00039
         		2.41 478
    57
    Figure US20100075953A1-20100325-C00040
         		2.40 539 541
    58
    Figure US20100075953A1-20100325-C00041
         		2.32 474
    59
    Figure US20100075953A1-20100325-C00042
         		2.56 539 541
    60
    Figure US20100075953A1-20100325-C00043
         		2.54 546
    61
    Figure US20100075953A1-20100325-C00044
         		2.80 536
    • EXAMPLE 62 (1-Methyl-3-{[4-(4-{[3-(1-piperidinyl)propyl]oxy}phenyl)-1-piperazinyl]carbonyl}-1H-indol-2-yl)acetic acid (E62)
  • Figure US20100075953A1-20100325-C00045
  • A solution of ethyl (1-methyl-3-{[4-(4-{[3-(1-piperidinyl)propyl]oxy}phenyl)-1-piperazinyl]carbonyl}-1H-indol-2-yl)acetate (E60) [54 mg] in methanol [6 ml] and water [0.8 ml] was treated with 2N sodium hydroxide [0.46 ml] and was heated under reflux for 2 h. The reaction mixture was quenched with hydrochloric acid [10 ml] at room temperature. The reaction mixture was concentrated in vacuo and partitioned between ethyl acetate and water. The organic phase was dried and concentrated in vacuo to give the title compound (20 mg). LCMS RT=2.35 min, 518 (M+H)+
    • EXAMPLE 63 1-(1-Naphthoyl)-4-[4-(3-piperidin-1-ylpropoxy)phenyl]piperazine trifluoroacetate (E63)
  • Figure US20100075953A1-20100325-C00046
    • E63a: 4-[4-(1-Naphthoyl)piperazin-1-yl]phenol
  • Figure US20100075953A1-20100325-C00047
  • To a stirring mixture of 4-(1-piperazinyl)phenol (5.54 g) and triethylamine (10.83 ml) in dichloromethane (140 ml) was added dropwise, 1-naphthalenecarbonyl chloride (9.83 ml). The resulting reaction mixture was stirred under a nitrogen atmosphere for 3 h. The mixture was partitioned between dichloromethane and water and the organic phase was washed with saturated brine, dried (MgSO4) and evaporated to dryness. The residue was suspended in 6:4 tetrahydrofuran-methanol (370 ml) and treated with a saturated solution of potassium carbonate in methanol (45 ml). The mixture was stirred at room temperature under a nitrogen atmosphere for 20 h. The solvent was evaporated and the residue was partitioned between dichloromethane and water. The organic phase was washed with saturated brine, dried (MgSO4) and evaporated to give an oil (15.5 g), part of which (14.5 g) was purified by chromatography on a silica SPE bond elut cartridge eluting with 10%-80% ethyl acetate-cyclohexane gradient to give the title compound (8.9 g). LCMS RT=2.97 min.
    • E63b: 1-[4-(3-Chloropropoxy)phenyl]-4-(1-naphthoyl)piperazine
  • Was prepared from 4-[4-(1-naphthoyl)piperazin-1-yl]phenol (E63a) and 1-bromo-3-chloropropane using the same method described in Description 9 LCMS RT=3.59 min
    • E63c: 1-(1-Naphthoyl)-4-[4-(3-piperidin-1-ylpropoxy)phenyl]piperazine trifluoroacetate
  • 1-[4-(3-Chloropropoxy)phenyl]-4-(1-naphthoyl)piperazine (E63b) (27 mg) piperidine (0.033 ml), potassium carbonate (46 mg), potassium iodide (56 mg) in 2-butanone (2 ml) was heated to reflux for 36 h. The solvent was removed at room temperature by a stream of nitrogen gas. The residue was dissolved in water and dichloromethane. The organic layer was separated, concentrated and purified by mass directed preparative HPLC to give the title compound (23 mg). LCMS RT=2.15 min, ES+ve m/z 458 (M+H)+.
    • EXAMPLES 64-75
  • Examples 64-75 were prepared in an array format using the same method described in Example 63c from 1-[4-(3-chloropropoxy)phenyl]-4-(1-naphthoyl)piperazine (0.067 mmol), the appropriate secondary amine (5.0 eq), potassium carbonate (5.0 eq), and potassium iodide (5.0 eq) in 2-butanone (2 ml). The products were purified by mass directed auto-preparative HPLC to provide the compounds as TFA salts.
  • Mass Ion
    Example Structure RT (min) (M + H)+
    64
    Figure US20100075953A1-20100325-C00048
         		2.76 500
    65
    Figure US20100075953A1-20100325-C00049
         		2.63 472
    66
    Figure US20100075953A1-20100325-C00050
         		2.55 476
    67
    Figure US20100075953A1-20100325-C00051
         		2.27 486
    68
    Figure US20100075953A1-20100325-C00052
         		2.66 472
    69
    Figure US20100075953A1-20100325-C00053
         		2.58 458
    70
    Figure US20100075953A1-20100325-C00054
         		2.71 485.73
    71
    Figure US20100075953A1-20100325-C00055
         		2.22 472
    72
    Figure US20100075953A1-20100325-C00056
         		2.22 472
    73
    Figure US20100075953A1-20100325-C00057
         		2.26 514
    74
    Figure US20100075953A1-20100325-C00058
         		2.35 500
    75
    Figure US20100075953A1-20100325-C00059
         		2.24 486
    • EXAMPLE 76 5-Fluoro-1-methyl-3-[(4-{4-[3-(2-methylpiperidin-1-yl)propoxy]phenyl}piperazin-1-yl)carbonyl]-1H-indole (E76)
  • Figure US20100075953A1-20100325-C00060
    • E76a: 1,1-Dimethylethyl 4-(4-{[3-(2-methyl-1-piperidinyl)propyl]oxy}phenyl)-1-piperazinecarboxylate
  • Figure US20100075953A1-20100325-C00061
  • 1,1-Dimethylethyl 4-{4-[(3-chloropropyl)oxy]phenyl}-1-piperazinecarboxylate (D9) (1.6 g), was dissolved in 2-butanone (10 ml). Potassium carbonate (1.38 g) and a catalytic amount of potassium iodide were added, followed by 2-methylpiperidine (0.99 g). The mixture was heated at reflux for 72 h under nitrogen. The reaction mixture was diluted with water and extracted with dichloromethane. The organic phases were separated using a hydrophobic frit, combined and evaporated in vacuo. The residue was purified on a 100 g silica SPE bond elut cartridge, eluting with a gradient of 0% to 20% [0.880 ammonia-methanol (1:9)]-dichloromethane mixtures, to give the title compound (1.66 g). LCMS RT=2.48 min.
    • E76b: 1-(4-{[3-(2-Methyl-1-piperidinyl)propyl]oxy}phenyl)piperazine
  • Figure US20100075953A1-20100325-C00062
  • 1,1-Dimethylethyl 4-(4-{[3-(2-methyl-1-piperidinyl) propyl]oxy}phenyl)-1-piperazinecarboxylate (E76a) (1.66 g) was dissolved in dry dichloromethane (25 ml) and stirred under nitrogen. 50% Trifluoroacetic acid in dichloromethane (5 ml) was added, and the mixture was stirred at room temperature for 4 h. Saturated sodium bicarbonate solution was then added and the mixture was extracted with dichloromethane. The organic phase was separated using a hydrophobic frit, and evaporated in vacuo, however, most of the product was in the aqueous phase. The product was removed from the aqueous phase using an OASIS cartridge, washing with water and eluting with methanol, and further purified using an aminopropyl bond elut cartridge, eluting with dichloromethane and then SCX cartridge, eluting with 50% [0.880 ammonia-methanol (1:9)]-dichloromethane to give the title compound (0.94 g). LCMS RT=1.01 min, ES+ve m/z=318 (M+H)+
    • E76c: 5-Fluoro-1-methyl-3-[(4-{4-[3-(2-methylpiperidin-1-yl)propoxy]phenyl}piperazin-1-yl)carbonyl]-1H-indole
  • A solution of 5-fluoro-1-methyl-1H-indole-3-carboxylic acid (19.3 mg) and O-(1H-benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium tetrafluoroborate (TBTU) (56 mg) in DMF (1 ml) and diisopropylethylamine (0.035 ml) was stirred for 10 min before 1-{4-[3-(2-methylpiperidin-1-yl)propoxy]phenyl}piperazine (E76b) (21.3 mg) in DMF (0.5 ml) was added. The mixture was stirred for 18 h and then concentrated under reduced pressure. The residue was purified by SPE ion exchange chromatography on an SCX-2 cartridge (1 g). The cartridge was washed with methanol (3 ml) and the product eluted with 2M ammonia in methanol (2.5 ml), to give the title compound (15 mg) LCMS RT=2.42 min, ES+ve m/z 493 (M+H)+.
    • EXAMPLES 77-224
  • Examples 77 to 224 were prepared in an array format in vials using a solution of the appropriate carboxylic acid (0.1 mmol) in DMF (0.5 ml) and a solution of O-(1H-benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium tetrafluoroborate (TBTU) (0.15 mmol) in DMF (0.5 ml) and diisopropylethylamine (0.2 mmol). Each vial was shaken manually and stood for 10 min, before a solution of the appropriate piperazine (selected from D18-D23 or D46 in the case of Example 99) (0.067 mmol) in DMF (0.5 ml) was added to each reaction mixture. The vials were left to stand overnight for approximately 18 h at room temperature. Each solution was then added to the top of a preconditioned SCX-2 SPE cartridge (1 g). The cartridge was washed with methanol (3 ml) and the product eluted with 2M ammonia in methanol (2.5 ml), into pre-weighed vials. The solutions were evaporated to dryness on the genevac to provide the products (Examples 77-222). Examples 151, 154, 162-171 and 206-222 were further purified by mass directed auto-preparative HPLC to provide the products as trifluoroacetate salts.
  • Mass ion
    Example Structure RT (min) (M + H)+
    77
    Figure US20100075953A1-20100325-C00063
         		2.36 438
    78
    Figure US20100075953A1-20100325-C00064
         		2.52 464
    79
    Figure US20100075953A1-20100325-C00065
         		2.55 466
    80
    Figure US20100075953A1-20100325-C00066
         		2.44 452
    81
    Figure US20100075953A1-20100325-C00067
         		2.74 484
    82
    Figure US20100075953A1-20100325-C00068
         		2.52 436
    83
    Figure US20100075953A1-20100325-C00069
         		2.74 480
    84
    Figure US20100075953A1-20100325-C00070
         		2.58 476
    85
    Figure US20100075953A1-20100325-C00071
         		2.50 442 444
    86
    Figure US20100075953A1-20100325-C00072
         		2.39 444
    87
    Figure US20100075953A1-20100325-C00073
         		2.50 434
    88
    Figure US20100075953A1-20100325-C00074
         		2.36 485
    89
    Figure US20100075953A1-20100325-C00075
         		2.58 480
    90
    Figure US20100075953A1-20100325-C00076
         		2.34 480
    91
    Figure US20100075953A1-20100325-C00077
         		2.66 480
    92
    Figure US20100075953A1-20100325-C00078
         		2.23 456
    93
    Figure US20100075953A1-20100325-C00079
         		2.76 464
    94
    Figure US20100075953A1-20100325-C00080
         		2.24 424
    95
    Figure US20100075953A1-20100325-C00081
         		2.16 468
    96
    Figure US20100075953A1-20100325-C00082
         		1.87 463
    97
    Figure US20100075953A1-20100325-C00083
         		1.96 463
    98
    Figure US20100075953A1-20100325-C00084
         		1.85 467
    99
    Figure US20100075953A1-20100325-C00085
         		2.11 461
    100
    Figure US20100075953A1-20100325-C00086
         		2.37 484
    101
    Figure US20100075953A1-20100325-C00087
         		2.11 485
    102
    Figure US20100075953A1-20100325-C00088
         		2.05 473 475
    103
    Figure US20100075953A1-20100325-C00089
         		2.07 460 462
    104
    Figure US20100075953A1-20100325-C00090
         		2.07 478
    105
    Figure US20100075953A1-20100325-C00091
         		2.18 476 478
    106
    Figure US20100075953A1-20100325-C00092
         		2.13 466
    107
    Figure US20100075953A1-20100325-C00093
         		2.05 440
    108
    Figure US20100075953A1-20100325-C00094
         		2.20 450
    109
    Figure US20100075953A1-20100325-C00095
         		2.31 464
    110
    Figure US20100075953A1-20100325-C00096
         		2.31 464
    111
    Figure US20100075953A1-20100325-C00097
         		2.29 464
    112
    Figure US20100075953A1-20100325-C00098
         		2.22 462
    113
    Figure US20100075953A1-20100325-C00099
         		2.07 436
    114
    Figure US20100075953A1-20100325-C00100
         		2.07 436
    115
    Figure US20100075953A1-20100325-C00101
         		2.12 476 478
    116
    Figure US20100075953A1-20100325-C00102
         		2.13 448
    117
    Figure US20100075953A1-20100325-C00103
         		2.26 480
    118
    Figure US20100075953A1-20100325-C00104
         		2.29 478
    119
    Figure US20100075953A1-20100325-C00105
         		2.15 485
    120
    Figure US20100075953A1-20100325-C00106
         		2.52 472
    121
    Figure US20100075953A1-20100325-C00107
         		2.52 452
    122
    Figure US20100075953A1-20100325-C00108
         		2.63 475
    123
    Figure US20100075953A1-20100325-C00109
         		2.53 464
    124
    Figure US20100075953A1-20100325-C00110
         		2.53 480
    125
    Figure US20100075953A1-20100325-C00111
         		2.60 464
    126
    Figure US20100075953A1-20100325-C00112
         		2.47 468
    127
    Figure US20100075953A1-20100325-C00113
         		2.59 464
    128
    Figure US20100075953A1-20100325-C00114
         		2.61 537
    129
    Figure US20100075953A1-20100325-C00115
         		2.37 475
    130
    Figure US20100075953A1-20100325-C00116
         		2.58 534
    131
    Figure US20100075953A1-20100325-C00117
         		2.66 518 520
    132
    Figure US20100075953A1-20100325-C00118
         		2.54 494
    133
    Figure US20100075953A1-20100325-C00119
         		2.76 504
    134
    Figure US20100075953A1-20100325-C00120
         		2.60 478
    135
    Figure US20100075953A1-20100325-C00121
         		2.60 517
    136
    Figure US20100075953A1-20100325-C00122
         		2.65 588
    137
    Figure US20100075953A1-20100325-C00123
         		2.83 579
    138
    Figure US20100075953A1-20100325-C00124
         		2.60 476
    139
    Figure US20100075953A1-20100325-C00125
         		2.63 536
    140
    Figure US20100075953A1-20100325-C00126
         		2.69 542 544
    141
    Figure US20100075953A1-20100325-C00127
         		2.62 528 530
    142
    Figure US20100075953A1-20100325-C00128
         		2.68 589
    143
    Figure US20100075953A1-20100325-C00129
         		2.61 521
    144
    Figure US20100075953A1-20100325-C00130
         		2.58 478
    145
    Figure US20100075953A1-20100325-C00131
         		2.70 492
    146
    Figure US20100075953A1-20100325-C00132
         		2.81 506
    147
    Figure US20100075953A1-20100325-C00133
         		2.77 522
    148
    Figure US20100075953A1-20100325-C00134
         		2.77 506
    149
    Figure US20100075953A1-20100325-C00135
         		2.59 464
    150
    Figure US20100075953A1-20100325-C00136
         		2.57 464
    151
    Figure US20100075953A1-20100325-C00137
         		2.27 486
    152
    Figure US20100075953A1-20100325-C00138
         		2.60 478
    153
    Figure US20100075953A1-20100325-C00139
         		2.63 494
    154
    Figure US20100075953A1-20100325-C00140
         		2.36 466
    155
    Figure US20100075953A1-20100325-C00141
         		2.36 466
    156
    Figure US20100075953A1-20100325-C00142
         		2.65 478
    157
    Figure US20100075953A1-20100325-C00143
         		2.54 464
    158
    Figure US20100075953A1-20100325-C00144
         		2.40 450
    159
    Figure US20100075953A1-20100325-C00145
         		2.42 493
    160
    Figure US20100075953A1-20100325-C00146
         		2.42 561
    161
    Figure US20100075953A1-20100325-C00147
         		2.51 500 502
    162
    Figure US20100075953A1-20100325-C00148
         		2.66 492
    163
    Figure US20100075953A1-20100325-C00149
         		2.60 528 530
    164
    Figure US20100075953A1-20100325-C00150
         		2.54 522
    165
    Figure US20100075953A1-20100325-C00151
         		2.51 462
    166
    Figure US20100075953A1-20100325-C00152
         		2.76 565
    167
    Figure US20100075953A1-20100325-C00153
         		2.55 504
    168
    Figure US20100075953A1-20100325-C00154
         		2.51 464
    169
    Figure US20100075953A1-20100325-C00155
         		2.67 490
    170
    Figure US20100075953A1-20100325-C00156
         		2.45 480
    171
    Figure US20100075953A1-20100325-C00157
         		2.57 504 506
    172
    Figure US20100075953A1-20100325-C00158
         		2.63 478
    173
    Figure US20100075953A1-20100325-C00159
         		2.65 494
    174
    Figure US20100075953A1-20100325-C00160
         		2.69 478
    175
    Figure US20100075953A1-20100325-C00161
         		2.56 482
    176
    Figure US20100075953A1-20100325-C00162
         		2.49 500 502
    177
    Figure US20100075953A1-20100325-C00163
         		2.66 478
    178
    Figure US20100075953A1-20100325-C00164
         		2.55 514 516
    179
    Figure US20100075953A1-20100325-C00165
         		2.47 448
    180
    Figure US20100075953A1-20100325-C00166
         		2.72 551
    181
    Figure US20100075953A1-20100325-C00167
         		2.52 560
    182
    Figure US20100075953A1-20100325-C00168
         		2.47 489
    183
    Figure US20100075953A1-20100325-C00169
         		2.54 490
    184
    Figure US20100075953A1-20100325-C00170
         		2.47 450
    185
    Figure US20100075953A1-20100325-C00171
         		2.60 476
    186
    Figure US20100075953A1-20100325-C00172
         		2.39 466
    187
    Figure US20100075953A1-20100325-C00173
         		2.53 491
    188
    Figure US20100075953A1-20100325-C00174
         		2.63 478
    189
    Figure US20100075953A1-20100325-C00175
         		2.64 494
    190
    Figure US20100075953A1-20100325-C00176
         		2.68 478
    191
    Figure US20100075953A1-20100325-C00177
         		2.58 482
    192
    Figure US20100075953A1-20100325-C00178
         		2.55 464
    193
    Figure US20100075953A1-20100325-C00179
         		2.44 450
    194
    Figure US20100075953A1-20100325-C00180
         		2.47 500 502
    195
    Figure US20100075953A1-20100325-C00181
         		2.66 478
    196
    Figure US20100075953A1-20100325-C00182
         		2.44 508
    197
    Figure US20100075953A1-20100325-C00183
         		2.44 448
    198
    Figure US20100075953A1-20100325-C00184
         		2.71 551
    199
    Figure US20100075953A1-20100325-C00185
         		2.52 560
    200
    Figure US20100075953A1-20100325-C00186
         		2.46 489
    201
    Figure US20100075953A1-20100325-C00187
         		2.50 490
    202
    Figure US20100075953A1-20100325-C00188
         		2.46 450
    203
    Figure US20100075953A1-20100325-C00189
         		2.62 476
    204
    Figure US20100075953A1-20100325-C00190
         		2.39 466
    205
    Figure US20100075953A1-20100325-C00191
         		2.52 490 492
    206
    Figure US20100075953A1-20100325-C00192
         		2.40 508
    207
    Figure US20100075953A1-20100325-C00193
         		2.37 496
    208
    Figure US20100075953A1-20100325-C00194
         		2.35 478
    209
    Figure US20100075953A1-20100325-C00195
         		2.27 464
    210
    Figure US20100075953A1-20100325-C00196
         		2.37 504 506
    211
    Figure US20100075953A1-20100325-C00197
         		2.26 514 516
    212
    Figure US20100075953A1-20100325-C00198
         		2.34 528 530
    213
    Figure US20100075953A1-20100325-C00199
         		2.00 514
    214
    Figure US20100075953A1-20100325-C00200
         		2.28 522
    215
    Figure US20100075953A1-20100325-C00201
         		2.26 462
    216
    Figure US20100075953A1-20100325-C00202
         		2.57 574
    217
    Figure US20100075953A1-20100325-C00203
         		2.30 503
    218
    Figure US20100075953A1-20100325-C00204
         		2.30 504
    219
    Figure US20100075953A1-20100325-C00205
         		2.29 464
    220
    Figure US20100075953A1-20100325-C00206
         		2.31 504 506
    221
    Figure US20100075953A1-20100325-C00207
         		2.09 524
    222
    Figure US20100075953A1-20100325-C00208
         		2.26 520
    223
    Figure US20100075953A1-20100325-C00209
         		2.77 506
    224
    Figure US20100075953A1-20100325-C00210
         		2.49 492
    • EXAMPLE 225 1-[3-Chloro-4-(3-piperidin-1-ylpropoxy)phenyl]-4-(1-naphthoyl)piperazine formate (E225)
  • Figure US20100075953A1-20100325-C00211
    • E225a: tert-Butyl 4-(1-naphthoyl)piperazine-1-carboxylate
  • 1-Naphthoyl chloride (2.15 ml) was added to a solution of tert-butyl piperazine-1-carboxylate (3.28 g) and diisopropylethylamine (3.44 ml) in dichloromethane (100 ml) at 0° C. After 2 h stirring the mixture was partitioned between dichloromethane and 2M hydrochloric acid. The organic phase was washed with sat. aq. sodium bicarbonate solution, dried (MgSO4) and evaporated to dryness to give the title compound (4.9 g) LCMS RT=3.16 min.
    • E225b: 1-(1-Naphthoyl)piperazine
  • tert-Butyl 4-(1-naphthoyl)piperazine-1-carboxylate (E225a) (4.2 g) was dissolved in dichloromethane (80 ml) and treated with trifluoroacetic acid (10 ml) for 4.5 h at 20° C. The solvent was removed under reduced pressure and the residue was partitioned between dichloromethane and 2M sodium hydroxide. The organic phase was dried (MgSO4) and evaporated to dryness to give the title compound (3.19 g) LCMS RT=1.50 min.
    • E225c: 2-Chloro-4-[4-(1-naphthoyl)piperazin-1-yl]phenol
  • A mixture of 1-(1-naphthoyl)piperazine (E225b) (143.7 mg), 4-bromo-2-chlorophenol (207 mg), tris(dibenzylideneacetone) dipalladium (4.75 mg), 2-dicyclohexylphosphino-2′-(N,N-dimethylamino)biphenyl (4.91 mg) was dissolved in tetrahydrofuran (3 ml) and then treated at 0° C. with 1M solution of lithium bis(trimethylsilyl)amide (1.1 ml) under nitrogen. The mixture was heated to 70° C. for 18 h and then partitioned between water and dichloromethane. The organic phase was separated using hydrophobic frit, and purified on a silica SPE bond elut cartridge eluting with aq. ammonia-methanol-dichloromethane (1:2:98) to give the title compound (81 mg) LCMS RT=3.16 min.
    • E225d: 1-[3-Chloro-4-(3-piperidin-1-ylpropoxy)phenyl]-4-(1-naphthoyl)piperazine formate
  • 2-Chloro-4-[4-(1-naphthoyl)piperazin-1-yl]phenol (E225c) (37 mg), caesium carbonate (81 mg), sodium iodide (2.3 mg), 1-(3-chloropropyl)piperidine (22 mg) in DMF (2.5 ml) were heated in a microwave oven at 160° C. for 10 min and at 170° C. for 20 min. The reaction mixture was poured into water and extracted with ethyl acetate. The organic phase was washed with brine, dried (MgSO4), and purified by mass directed auto-preparative HPLC to give the title compound (30 mg) LCMS RT=2.60 min, ES+ve m/z 492 and 494.
    • EXAMPLE 226 1-(2-Bromo-4-{[3-(1-piperidinyl)propyl]oxy}phenyl)-4-(1-naphthalenylcarbonyl)piperazine (E226)
  • Figure US20100075953A1-20100325-C00212
    • E226a: 4-(4-Acetylpiperazin-1-yl)-3-bromophenyl acetate
  • 4-(4-Acetylpiperazin-1-yl)phenol (38.5 g) in dichloromethane (875 ml) was treated with triethylamine (35 ml) and the solution was cooled in ice. Acetyl chloride (15.05 ml) in dichloromethane (87 ml) was added dropwise with stirring, keeping the temperature between 18 and 20°. After 30 min, the solution was washed with water, dried and evaporated to give 4-(4-acetylpiperazin-1-yl)phenyl acetate (44.2 g). A portion of this (31.4 g) was dissolved in acetic acid (720 ml) and sodium acetate (19.7 g) was added. The solution was cooled to 15°, and bromine (6.2 ml) in acetic acid (72 ml) was added dropwise with stirring over 15 min, keeping the temp. at 15° C. After 30 min, aqueous sodium metabisulphite solution (4.6 g in 60 ml water) was added and the mixture was concentrated by evaporation to ca. 200 ml. Dichloromethane (500 ml) was added, followed by sodium bicarbonate solution until the pH of the aqueous layer was 5. The dichloromethane layer was diluted (1 L) and separated, washed with an equal volume of water, dried, evaporated and purified by chromatography on Biotage (800 g cartridge) eluting with ethyl acetate-hexane (3:1) to give the title compound. (34.8 g) mp 75° C.
    • E226b: 4-(4-Acetylpiperazin-1-yl)-3-bromophenol
  • A solution of 4-(4-acetylpiperazin-1-yl)-3-bromophenyl acetate (E226a) (29.5 g) in methanol (300 ml) was cooled in an ice bath to 15° C. and treated dropwise with 2N NaOH aqueous solution (87 ml). After 30 min, the solution was poured into ice-water (1.7 L) and the mixture acidified to pH 6. The white precipitate was collected by filtration and washed with water (0.5 L). Drying under vacuum gave the title compound (22.8 g), mp 212-4° C.
    • E226c: 1-(2-Bromo-4-{[3-(1-piperidinyl)propyl]oxy}phenyl)piperazine
  • A mixture of 4-(4-acetyl-1-piperazinyl)-3-bromophenol (E226b) (1 g) in DMF (10 ml) and chloropropyl piperidine hydrochloride (0.72 g), Cs2CO3 (2.99 g), and NaI (75 mg) was heated at 80° C. for 24 h. The mixture was cooled to room temperature and quenched with water (10 ml), then extracted with ethyl acetate and evaporated. The residue was treated with 5 ml of conc. HCl and 5 ml of water and heated to reflux. The reaction mixture was cooled to 20° C. and diluted with water (10 ml), basified with solid potassium carbonate and extracted with DCM. The residue was purified by chromatography on biotage (40 g cartridge) eluting with DCM-EtOH—NH3 (45:5:1) to give the title compound (0.86 g) LCMS RT=1.68 min, ES+ve m/z 382, 384 (M+H)+.
    • E226d: 1-(2-Bromo-4-{[3-(1-piperidinyl)propyl]oxy}phenyl)-4-(1-naphthalenylcarbonyl)piperazine
  • A solution of 1-(2-bromo-4-{[3-(1-piperidinyl)propyl]oxy}phenyl)piperazine (E226c) (0.86 g) in anhydrous DCM (10 ml) and triethylamine (0.34 ml) was cooled to 0° C. and naphthoyl chloride (0.37 ml) was added. The mixture was stirred under nitrogen for 48 h, evaporated to dryness and partitioned between saturated sodium bicarbonate solution and DCM. The organic phase was separated, concentrated and the residue was purified by chromatography on biotage (40 g cartridge) eluting with DCM-MeOH-aqueous NH3 (200:8:1) to afford the title compound (1.2 g). LCMS RT=2.71 min, ES+ve m/z 536, 538 (M+H)+.
    • EXAMPLE 227 1-(2-Methyl-4-{[3-(1-piperidinyl)propyl]oxy}phenyl)-4-(1-naphthalenylcarbonyl)piperazine (E227)
  • Figure US20100075953A1-20100325-C00213
  • A solution of 1-(2-bromo-4-{[3-(1-piperidinyl)propyl]oxy}phenyl)-4-(1-naphthalenylcarbonyl)piperazine (E226) (50 mg), tetrakis(triphenylphosphine) palladium (0) (10 mg), potassium carbonate (38 mg) and trimethylboroxine (23 mg) in of DMF (1 ml) was heated at 150° C. in a microwave oven for 10 min, cooled, evaporated to dryness and purified by chromatography on a biotage cartridge eluting with DCM-MeOH— aqueous NH3 (200:8:1) to afford the title compound (21 mg). LCMS RT=2.63 min, 472 (M+H)+.
    • EXAMPLE 228 1-{[5-Methyl-2-(methyloxy)phenyl]methyl}-4-(4-{[3-(1-piperidinyl)propyl]oxy}phenyl)piperazine formate (E228)
  • Figure US20100075953A1-20100325-C00214
  • A solution of 5-methyl-2-(methyloxy)benzaldehyde (40 mg) and 1-(4-{[3-(1-piperidinyl)propyl]oxy}phenyl)piperazine [D11] (40 mg) in dichloromethane (2 ml) was treated with acetic acid (7.9 μl) and sodium triacetoxyborohydride (56 mg). The resulting suspension was stirred at 22° C. for 24 h. The reaction mixture was concentrated and purified by mass directed auto preparative HPLC to give the title compound (4.8 mg). LCMS RT=1.99 min, 438 (MH+).
    • EXAMPLE 229 8-{4-[(3-{[3-(1-Piperidinyl)propyl]oxy}phenyl)methyl]-1-piperazinyl}quinoline trifluoroacetate (E229)
  • Figure US20100075953A1-20100325-C00215
    • E229a: 1,1-Dimethylethyl 4-(8-quinolinyl)-1-piperazinecarboxylate
  • Figure US20100075953A1-20100325-C00216
  • A solution of 8-bromoquinoline (28.6 mg) in dry THF (1 mL) was treated with 1,1-dimethylethyl 1-piperazinecarboxylate (30.7 mg), tris(dibenzylidineacetone) dipalladium (0) (1.5 mg) and 2-dicyclohexylphosphino-2′-(N,N-dimethylamino)biphenyl (1.6 mg). The reaction mixture was treated with lithium bis(trimethylsilyl)amide (1M in THF, 0.27 mL) and then heated at 75° C. for 4 h. The reaction mixture was cooled to room temperature and concentrated in vacuo. The residue was purified by chromatography (silica SPE bond elut cartridge), eluting with a gradient between cyclohexane and EtOAc to give the title compound (29 mg). LCMS RT=2.86 min.
    • E229b: 8-(1-piperazinyl)quinoline
  • Figure US20100075953A1-20100325-C00217
  • A solution of 1,1-dimethylethyl 4-(8-quinolinyl)-1-piperazinecarboxylate (E229c) (2.5 g) in DCM (60 mL) was treated with TFA (20 mL) and stirred at room temperature for 4 h prior to pouring into DCM and washing with saturated NaHCO3 (Aq). The organic phase was washed with water, dried (MgSO4) and concentrated in vacuo. The residue was purified by chromatography (silica SPE cartridge), eluting with gradient between DCM and 100:10:1 DCM-MeOH— aqueous NH3) to give the title compound (643 mg). LCMS RT=0.68 min.
    • E229c: 3-{[4-(8-Quinolinyl)-1-piperazinyl]methyl}phenol
  • Figure US20100075953A1-20100325-C00218
  • A solution of 8-(1-piperazinyl)quinoline (E229b) (126 mg) in dry DCM (2 mL) was treated with AcOH (500 μL). A solution of 3-hydroxybenzaldehyde (88 mg) in dry DCM (3 mL) was added followed by sodium borohydride (191 mg). The reaction mixture was stirred for 16 h prior to the addition of water. The aqueous phase was neutralised with 2N NaOH. The organic phase was extracted twice with DCM and the combined organic phase concentrated in vacuo. The residue was purified by chromatography (silica SPE) eluting with a gradient between DCM and 100:10:1 DCM-MeOH-aqueous NH3) to give the title compound (133 mg). LCMS RT=1.96 min.
    • E229d: 8-{4-[(3-{[3-(1-Piperidinyl)propyl]oxy}phenyl)methyl]-1-piperazinyl}quinoline trifluoroacetate
  • A solution of 1-(3-chloropropyl)piperidine hydrochloride (46 mg) in dry DMF was treated with a solution of 3-{[4-(8-quinolinyl)-1-piperazinyl]methyl}phenol (E229c) (43 mg). The resultant solution was treated with sodium hydride (60% oil dispersion, 11 mg) and stirred at room temperature for 16 h. The reaction mixture was quenched with water (1 drop) and partitioned between water and DCM. The organic phase was concentrated in vacuo. The residue was purified by mass directed auto-preparative HPLC to give the title compound (5.7 mg). LCMS RT=1.83 min, ES+ve m/z 445 (MH)+
    • EXAMPLES 230-236
  • Examples 230-236 were prepared in an analogous manner to that described for E229d from known starting materials and those indicated in the table below:
  • Starting RT Mass ion
    Example Structure Materials (min) (M + H)+
    230
    Figure US20100075953A1-20100325-C00219
         		D30 1.86 458
    231
    Figure US20100075953A1-20100325-C00220
         		D30 1.78 444
    232
    Figure US20100075953A1-20100325-C00221
         		D30 1.82 458
    233
    Figure US20100075953A1-20100325-C00222
         		D28 3.59 457
    234
    Figure US20100075953A1-20100325-C00223
         		D29 2.18 457
    235
    Figure US20100075953A1-20100325-C00224
         		D32 2.14 457
    236
    Figure US20100075953A1-20100325-C00225
         		D31 1.67 & 1.89 459 & 459
    • EXAMPLE 237 8-{4-[2-(4-{[3-(1-Piperidinyl)propyl]oxy}phenyl)ethyl]-1-piperazinyl}quinoline trifluoroacetate (E237)
  • Figure US20100075953A1-20100325-C00226
    • E237a: 8-[4-(2-{4-[(Phenylmethyl)oxy]phenyl}ethyl)-1-piperazinyl]quinoline
  • Figure US20100075953A1-20100325-C00227
  • A solution of 8-(1-piperazinyl)quinoline (E229b) (126 mg) in dry DMF (2 mL) was treated with diisopropylethylamine (176 μL) followed by a solution of 1-(2-bromoethyl)-4-[(phenylmethyl)oxy]benzene (277 mg) in dry DMF (1 mL). The resultant reaction mixture was stirred under nitrogen for 18 h prior to quenching with water. The reaction mixture was partitioned between water and DCM and the organic phase dried (MgSO4) and concentrated in vacuo. The residue was purified by chromatography on silica SPE, eluting with a gradient between DCM and 100:10:1 DCM-MeOH-aqueous NH3 to give the title compound (51 mg).
  • LCMS RT=2.54 min.
    • E237b: 4-{2-[4-(8-Quinolinyl)-1-piperazinyl]ethyl}phenol
  • Figure US20100075953A1-20100325-C00228
  • A solution of 8-[4-(2-{4-[(phenylmethyl)oxy]phenyl}ethyl)-1-piperazinyl]quinoline (E237a) (107 mg) in dry DCM (5 mL) was cooled to −20° C. and treated with a solution of boron tribromide (1M in DCM, 2504). The reaction mixture was stirred at −20° C. for 30 min and at room temp. for 12 h. The reaction mixture was concentrated in vacuo. The residue was purified by chromatography on silica SPE eluting with a gradient between DCM and 100:10:1 DCM-MeOH-aqueous NH3) to give the title compound (51 mg). LCMS RT=1.73 min.
    • E237c: 8-{4-[2-(4-{[3-(1-Piperidinyl)propyl]oxy}phenyl)ethyl]-1-piperazinyl}quinoline trifluoroacetate
  • Was prepared using the method described in E228d LCMS RT=2.32 min, ES+ve m/z 460 (M+H)±.
    • EXAMPLES 238-244
  • Examples 238-244 were prepared in an analogous manner to that described for E229d from known starting materials and those indicated in the table below:
  • Starting RT Mass ion
    Example Structure Materials (min) (M + H)+
    238
    Figure US20100075953A1-20100325-C00229
         		 E237b 2.19 474
    239
    Figure US20100075953A1-20100325-C00230
         		D38 1.68 474
    240
    Figure US20100075953A1-20100325-C00231
         		D39 1.73 486
    241
    Figure US20100075953A1-20100325-C00232
         		D39 1.75 473
    242
    Figure US20100075953A1-20100325-C00233
         		D40 1.82 459
    243
    Figure US20100075953A1-20100325-C00234
         		D41 3.01 459
    244
    Figure US20100075953A1-20100325-C00235
         		D42 2.15 408
    • EXAMPLE 245 1-Diphenylacetyl-4-[4-(3-piperidin-1-ylpropoxy)phenyl]piperazine (E245)
  • Figure US20100075953A1-20100325-C00236
  • A solution of diphenylacetic acid (11 mg, 50 mmol) in DMF (1 ml) was treated with a solution of 1-[4-(3-piperidin-1-ylpropoxy)phenyl]piperazine (D11) (15 mg) in DMF (1 ml), followed by triethylamine (20 μl) and HBTU (19 mg). The mixture was shaken for 5 min then left to stand at room temperature overnight. Polystyryl-trisamine (100 mmol) and polystyryl-isocyanate (50 μmol) were added and the mixture shaken for a further 20 h. The mixture was then filtered and the filtrate loaded onto a solid phase cation exchange (SCX) cartridge.
  • After washing with 80% MeOH-DCM, the product was eluted with a solution of NH3 in MeOH (0.5 M). The eluted fraction was concentrated to dryness under vacuum giving the title compound (17.5 mg). LCMS RT=3.36 min, ES+ve m/z 498 (M+H)+.
    • EXAMPLE 246 1-(Naphthalen-1-ylsulfonyl)-4-[4-(3-piperidin-1-ylpropoxy)phenyl]piperazine (E246)
  • Figure US20100075953A1-20100325-C00237
  • A solution of 1-[4-(3-piperidin-1-ylpropoxy)phenyl]piperazine (D11) (30 mg) in DCM (3 ml) was treated with a solution of naphthalene-1-sulfonyl chloride (27 mg) in DCM (1 ml). Polystyryl-methylmorpholine (200 mmol) was added and the mixture shaken at room temperature for 24 h. The mixture was loaded onto a SCX cartridge and after washing with 50% MeOH-DCM, the crude product was eluted with a solution of NH3 in MeOH (0.5 M). The eluted fraction was concentrated to dryness under vacuum and purified by flash silica chromatography, eluting with 5% MeOH-DCM, to give the title compound (22 mg). LCMS RT=3.30 min, ES+ve m/z 394 (M+H)+.
    • EXAMPLE 247 1-(9H-Xanthen-9-ylcarbonyl)-4-[4-(3-piperidin-1-ylpropoxy)phenyl]piperazine (E247)
  • Figure US20100075953A1-20100325-C00238
  • Polystyryl-carbodiimide (450 mmol) was treated with a solution of 9H-xanthene-9-carboxylic acid (34 mg) in DMF (2 ml) and shaken for 5 min then treated with a solution of 1-[4-(3-piperidin-1-ylpropoxy)phenyl]piperazine (D11) (30 mg) in DMF (1 ml) and shaken at room temperature for 20 h. Polystyryl-isocyanate (100 mmol) was added and the mixture shaken for a further 24 h. The mixture was then filtered and the filtrate loaded onto a SCX cartridge. After washing with 80% MeOH-DCM, the crude product was eluted with a solution of NH3 in MeOH (0.5 M). The eluted fraction was concentrated to dryness under vacuum and purified by flash silica chromatography, eluting with 5-10% MeOH-DCM gradient, to give the title compound (5.7 mg). LCMS RT=3.16 min, ES+ve m/z 512 [M+H]+.
    • EXAMPLES 248-251
  • Examples 248-251 were prepared according to the procedure for Example 247.
  • RT Mass ion
    Example Structure (min) (M + H)+
    248
    Figure US20100075953A1-20100325-C00239
         		3.08 496
    249
    Figure US20100075953A1-20100325-C00240
         		1.98 459
    250
    Figure US20100075953A1-20100325-C00241
         		2.24 501
    251
    Figure US20100075953A1-20100325-C00242
         		2.14 465
    • EXAMPLE 252 1-(4-Carboxy-1-naphthoyl)-4-[4-(3-piperidin-1-ylpropoxy)phenyl]piperazine di(trifluoroacetate) (E252)
  • Figure US20100075953A1-20100325-C00243
  • A solution of 1,4-dinaphthoic acid (50 mg) in DMF (2 ml) was treated with a solution of 1-[4-(3-piperidin-1-ylpropoxy)phenyl]piperazine (D11) (70 mg) in DMF (1.5 ml) followed by HBTU (88 mg). The mixture was shaken for 5 min then left to stand at room temperature overnight. Water (100 μl) was added, then the mixture was concentrated to dryness under vacuum and purified using reverse phase HPLC, affording the title compound (80 mg).
  • LCMS RT=2.36 min. ES+ve m/z 502 [M+H]+.
    • EXAMPLE 253
  • 1-[4-(Methoxycarbonylmethoxy)naphth-1-oyl]-4-[4-(3-piperidin-1-ylpropoxy)phenyl]piperazine (E253)
  • Figure US20100075953A1-20100325-C00244
    • E253a: 4-(Methoxycarbonylmethoxy)naphthalene-1-carboxylic acid
  • Figure US20100075953A1-20100325-C00245
  • To a solution of methyl (4-formylnaphthalen-1-yloxy)acetate (J. Med. Chem. 2002, 45, 5755) (2.35 g) in t-BuOH (10 ml), acetone (10 ml), and H2O (5 ml) at 0° C. were added solid NaClO2 (1.30 g) and NaH2PO4.H2O (1.99 g) and the mixture was stirred at room temperature under nitrogen overnight. Further NaClO2 (1.73 g) and Na3PO4 (2.66 g) dissolved in H2O (3 ml) were added and the reaction continued for 24 h. The mixture was then concentrated under vacuum and treated with H2O. The resultant precipitate was collected by filtration, washed with H2O, and dried under vacuum to give the title compound (2.2 g). 1H-NMR δ (DMSO-d6, 400 MHz) 12.74 (br. s, 1H), 8.97 (d, 1H), 8.27 (d, 1H), 8.13 (d, 1H), 7.63 (m, 1H), 7.58 (m, 1H), 6.95 (d, 1H), 5.07 (s, 2H), 3.70 (s, 3H).
    • E253b: 1-[4-(Methoxycarbonylmethoxy)naphth-1-oyl]-4-[4-(3-piperidin-1-ylpropoxy)phenyl]piperazine
  • The title compound was prepared from 4-(methoxycarbonylmethoxy) naphthalene-1-carboxylic acid (E253a) (50 mg) and 1-[4-(3-piperidin-1-ylpropoxy)phenyl]piperazine (D11) (58 mg) according to the procedure for Example 252 (76 mg). LCMS RT=2.79 min, ES+ve m/z 545 [M+H]+.
    • EXAMPLE 254 1-[4-(Carboxymethoxy)naphth-1-oyl]-4-[4[(3-piperidin-1-ylpropoxy)phenyl]piperazine (E254)
  • Figure US20100075953A1-20100325-C00246
  • A stirred solution of 1-[4-(methoxycarbonylmethoxy)naphth-1-oyl]-4-[4-(3-piperidin-1-ylpropoxy)phenyl]piperazine (E253b) (38 mg) in THF (2 ml) was treated with a solution of KOH (6 mg) in H2O (1 ml). After 1.5 h the mixture was treated with a solution of 2M HCl in Et2O (50 μl) and concentrated to dryness under vacuum. The residue was treated with EtOH, then filtered and the filtrate concentrated to dryness under vacuum to give the title compound (29 mg). LCMS RT=2.42 min, ES+ve m/z 532 [M+H]+.
    • EXAMPLE 255 1-[(4-Fluorophenyl)carbonyl]-4-(4-{[1-(1-methylethyl)-4-piperidinyl]oxy}phenyl)piperazine (E255)
  • Figure US20100075953A1-20100325-C00247
    • Step 1: 4-{4[(4-Fluorophenyl)carbonyl]-1-piperazinyl}phenol
  • 4-Fluorobenzoylchloride (1.59 ml, 18.5 mmol) in dichloromethane (15 ml) was added to an ice cooled mixture of 4-(1-piperazinyl)phenol (3 g, 16.8 ml) and triethylamine (2.8 ml, 20.2 mmol). The resulting mixture was stirred at room temperature for 18 hours. The solvent was removed by evaporation and the residue dissolved in methanol (30 ml). This was treated with potassium carbonate (5 g) for 30 minutes and filtered. The filtrate was evaporated and dissolved in ethyl acetate. This solution was washed with saturated sodium hydrogen carbonate solution, dried (sodium sulphate) and evaporated to give a pink solid (2.58 g, 51%) MS (ES+) m/e 301 [M+H]+.
    • Step 2: 1,1-Dimethylethyl 4-[(4-{4-[(4-fluorophenyl)carbonyl]-1-piperazinyl}phenyl)oxy]-1-piperidinecarboxylate
  • Di-tert-butyl azodicarboxylate (2.4 g, 10.3 mmol) was added to a mixture of 4-{4-[(4-fluorophenyl)carbonyl]-1-piperazinyl}phenol (2.57 g, 8.6 mmol), triphenyl phospine (2.7 g, 10.3 mmol) and 1,1-dimethylethyl 4-hydroxy-1-piperidinecarboxylate (2 g, 10.3 mmol) in tetrahydrofuran (30 ml). The mixture was stirred at room temperature for 18 hours. The reaction was diluted with ethyl acetate and washed with 2 molar sodium hydroxide solution. The organic portion was dried (sodium sulphate) and evaporated. The residue was purified on a silica gel column eluting with a mixture of hexane:ethyl acetate (1:1) to afford the title compound (2.75 g, 67%) MS (ES+) m/e 484 [M+H]+.
    • Step 3: 1-[(4-Fluorophenyl)carbonyl]-4-[4-(4-piperidinyloxy)phenyl]piperazine
  • A solution of 1,1-dimethylethyl 4-[(4-{4-[(4-fluorophenyl)carbonyl]-1-piperazinyl}phenyl)oxy]-1-piperidinecarboxylate (2.75 g, 5.7 mmol) in trifluoroacetic acid (10 ml) was stirred at room temperature for 30 minutes. The solvent was removed by evaporation and the residue purified on SCX ion exchange resin eluting with methanol and then a mixture of 0.88 ammonia:methanol (1:9) to afford the title compound (2.1 g, 95%) MS (ES+) m/e 384 [M+H]+.
    • Step 4: 1-[(4-Fluorophenyl)carbonyl]-4-(4-{[1-(1-methylethyl)-4-piperidinyl]oxy}phenyl)piperazine
  • Sodium triacetoxyborohydride (360 mg, 1.72 mmol) was added to a solution of 1-[(4-fluorophenyl)carbonyl]-4-[4-(4-piperidinyloxy)phenyl]piperazine (330 mg, 0.86 mmol) and acetone (126 μl, 1.72 mmol) in dichloromethane (5 ml). After stirring at room temperature for 18 hours, with 2 molar sodium hydroxide solution was added and the mixture extracted with ethyl acetate. The extracts were dried (sodium sulphate) and evaporated. The residue was purified on a silica gel column eluting with a mixture of methanol: 0.88 ammonia:methanol:dichloromethane (0.5:4.5:95) to afford the title compound (191 mg, 52%)
  • MS (ES+) m/e 426 [M+H]+.
    • EXAMPLES 256-259
  • Examples 256-259 were prepared in the same manner as Example 255 using the appropriate ketone or aldehyde as indicated in the table:
  • MS (ES+) m/e
    Compound Ketone/Aldehyde [M + H]+.
    1-(4-{[1-(Cyclopropylmethyl)-4- cyclopropane 475
    piperidinyl]oxy}phenyl)-4-[(4- carbaldehyde
    fluorophenyl)carbonyl]piperazine (E256)
    1-[(4-Fluorophenyl)carbonyl]-4-(4-{[1-(2- 2-methylpropanal 440
    methylpropyl)-4-piperidinyl]oxy}phenyl)piperazine
    (E257)
    1-{4-[(1-Cyclopentyl-4-piperidinyl)oxy]phenyl}-4- cyclopentanone 452
    [(4-fluorophenyl)carbonyl]piperazine (E258)
    1-{4-[(1-Cyclobutyl-4-piperidinyl)oxy]phenyl}-4- cyclobutanone 438
    [(4-fluorophenyl)carbonyl]piperazine (E259)
    • EXAMPLE 260 1-{4-[(1-Cyclopropyl-4-piperidinyl)oxy]phenyl}-4-[(4-fluorophenyl)carbonyl]piperazine (E260)
  • Figure US20100075953A1-20100325-C00248
  • {[1-(ethyloxy)cyclopropyl]oxy}(trimethyl)silane 524 μl, 2.6 mmol) was added to a stirring mixture of the product of Example 255, step 3 (1-[(4-fluorophenyl)carbonyl]-4-[4-(4-piperidinyloxy)phenyl]piperazine) (250 mg, 0.65 mmol) and polymer bound cyanoborohydride (650 mg of 4 mmol/g resin) in methanol (10 ml) and acetic acid (250 μl). This mixture was heated at 50° C. for 18 hours. The mixture was filtered and the filtrate evaporated. The residue was purified on a silica cartridge eluting with a mixture of: 0.88 ammonia:methanol:dichloromethane (0.5:4.5:95) to afford the title compound (155 mg, 56%)
  • MS (ES+) m/e 424 [M+H]+.
    • EXAMPLES 261-262
  • Examples 261-262 may be prepared in an analogous manner to that described in Example 255, step 4 from pentan-3-one and the product of Example 255, step 3.
  • Compound Structure
    1-(4-{4-[1-(1-Ethyl-propyl)-piperidin-4- yloxy]-phenyl}-piperazin-1-yl)-1-(4-fluoro- phenyl)-methanone (E261)
    Figure US20100075953A1-20100325-C00249
    1-{4-[4-(1-sec-Butyl-piperidin-4-yloxy)- phenyl]-piperazin-1-yl}-1-(4-fluoro- phenyl)-methanone (E262)
    Figure US20100075953A1-20100325-C00250
    • EXAMPLE 263 1-(4-{[1-(1-Methylethyl)-4-piperidinyl]oxy}phenyl)-4-(tetrahydro-2H-pyran-4-ylcarbonyl)piperazine (E263)
  • Figure US20100075953A1-20100325-C00251
    • Step 1: 1,1-Dimethylethyl 4-[(4-iodophenyl)oxy]-1-piperidinecarboxylate
  • Di-tert-butyl azodicarboxylate (5.9 g, 25.8 mmol) was added to a mixture of 4-iodophenol (4.72 g, 21.5 mmol), triphenyl phospine (6.8 g, 25.8 mmol) and 1,1-dimethylethyl 4-hydroxy-1-piperidinecarboxylate (5.18 g, 25.8 mmol) in tetrahydrofuran (100 ml). The mixture was stirred at room temperature for 18 hours. The reaction was diluted with ethyl acetate and washed with 2 molar sodium hydroxide solution. The organic portion was dried (sodium sulphate) and evaporated. The residue was purified on a silica column eluting with 9-1 hexane-ethyl acetate to afford the title compound (5.5 g, 64%) MS (ES+) m/e 304 [M+H]+-BOC.
    • Step 2: 4-[(4-Iodophenyl)oxy]piperidine
  • Product of Step 1 (1,1-dimethylethyl 4-[(4-iodophenyl)oxy]-1-piperidinecarboxylate) (5.5 g, 13.6 mmol) in trifluoroacetic acid (10 ml) was stirred at room temperature for 30 minutes. The solvent was removed by evaporation and the residue basified using 2M sodium hydroxide solution. This was extracted into dichloromethane, the extracts were dried (sodium sulphate) and evaporated to afford the title compound (3.4 g, 82%) MS (ES+) m/e 304 [M+H]+.
    • Step 3: 4-[(4-Iodophenyl)oxy]-1-(1-methylethyl)piperidine
  • Sodium triacetoxyborohydride (4.75 mg, 22.4 mmol) was added to a solution of the product of Step 2 (4-[(4-iodophenyl)oxy]piperidine) (3.4 g, 11.2 mmol) and acetone (1.65 ml, 22.4 mmol) in dichloromethane (70 ml). After stirring at room temperature for 18 hours, 2 molar sodium hydroxide solution was added and the mixture extracted with ethyl acetate. The extracts were dried (sodium sulphate) and evaporated to afford the title compound (3.63 mg, 94%) MS (ES+) m/e 346 [M+H]+.
    • Step 4: 1,1-Dimethylethyl 4-(4-{[1-(1-methylethyl)-4-piperidinyl]oxy}phenyl)-1-piperazinecarboxylate
  • A mixture of palladium acetate (32 mg, 5 mol %) and 2,2′-bis(diphenylphosphino)-1,1′-binaphthyl (135 mg, 7.5 mol %) in toluene was heated at 100° C. for 10 minutes. A solution of the product of Step 3 (4-[(4-iodophenyl)oxy]-1-(1-methylethyl)piperidine) (1 g, 2.9 mmol) and 1,1-dimethylethyl 1-piperazinecarboxylate (647 mg, 3.5 mmol) in toluene (10 ml) was added followed by sodium tert-butoxide (390 mg, 4.4 mmol). This mixture was heated at 100° C. for 3 hours and filtered through kieselghur. The filtrate was evaporated and purified on a silica gel eluting with a mixture of 0.88 ammonia solution:methanol:dichloromethane (0.3:2.7:97) to furnish the title compound (770 mg, 66%) MS (ES+) m/e 404 [M+H]+.
    • Step 5: 1-(4-{[1-(1-Methylethyl)-4-piperidinyl]oxy}phenyl)piperazine
  • A solution of the product of Step 5 (1,1-dimethylethyl 4-(4-{[1-(1-methylethyl)-4-piperidinyl]oxy}phenyl)-1-piperazinecarboxylate) (750 mg, 1.86 mmol) in trifluoroacetic acid (4 ml) was stirred at room temperature for 30 minutes. The solvent was removed by evaporation and the residue purified on SCX ion exchange resin eluting with methanol and then 10% of 0.88 ammonia solution in methanol to furnish the title compound (514 mg, 91%)
  • MS (ES+) m/e 304 [M+H]+.
    • Step 6: 1-(4-{[1-(1-Methylethyl)-4-piperidinyl]oxy}phenyl)-4-(tetrahydro-2H-pyran-4-ylcarbonyl)piperazine
  • A mixture of polymer bound cyclohexyl carbodiimide (460 mg of 1.9 mmol/g resin), tetrahydro-2H-pyran-4-carboxylic acid (111 mg, 0.86 mmol) and 1H-1,2,3-benzotriazol-1-ol (116 mg, 0.86 mmol) in dichloromethane (10 ml). After 20 minutes the product of Step 5 (1-(4-{[1-(1-methylethyl)-4-piperidinyl]oxy}phenyl)piperazine) (128 mg, 0.46 mmol) was added and the mixture stirred for 60 minutes. The mixture was evaporated and the residue was purified on silica gel eluting with a mixture of 0.88 ammonia solution:methanol:dichloromethane (0.3:2.7:97) to furnish the title compound (134 mg, 75%)
  • MS (ES+) m/e 416 [M+H]+.
    • EXAMPLES 264-268
  • Examples 264 to 268 were prepared in the same manner as Example 263 using the appropriate acid highlighted in the table below:
  • MS (ES+) m/e
    Compound Acid [M + H]+.
    4-{[4-(4-{[1-(1-Methylethyl}4- 4-cyanobenzoic acid 433
    piperidinyl]oxy}phenyl)-1-
    piperazinyl]carbonyl}benzonitrile (E264)
    1-(4-{[1-(1-Methylethyl)-4- Pyridine-4-carboxylic 409
    piperidinyl]oxy}phenyl)-4-(4- acid
    pyridinylcarbonyl)piperazine (E265)
    1-(4-{[1-(1-Methylethyl)-4- 4-(methylsulfonyl) 486
    piperidinyl]oxy}phenyl)-4-{[4- benzoic acid
    (methylsulfonyl)phenyl]carbonyl}piperazine
    (E266)
    1-[(1,1-Dioxidotetrahydro-2H-thiopyran-4- tetrahydro-2H- 464
    yl)carbonyl]-4-(4-{[1-(1-methylethyl)-4- thiopyran-4-carboxylic
    piperidinyl]oxy}phenyl)piperazine (E267) acid 1,1-dioxide
    1-(4-{[1-(1-Methylethyl)-4- 4-(1-pyrrolidinyl 505
    piperidinyl]oxy}phenyl)-4-{[4-(1- carbonyl)benzoic acid
    pyrrolidinylcarbonyl)phenyl]carbonyl} (J.Med. Chem., 46(10),
    piperazine (E268) 1845-1857, 2003)
    • EXAMPLE 269 4-{[4-(4-{[3-(1-Piperidinyl)propyl]oxy}phenyl)-1-piperazinyl]carbonyl}morpholine (E269)
  • Figure US20100075953A1-20100325-C00252
    • Step 1: 4-(4-{[3-(1-Piperidinyl)propyl]oxy}phenyl)-1-piperazinecarbonyl chloride hydrochloride salt
  • A solution of 1-(4-{[3-(1-piperidinyl)propyl]oxy}phenyl)piperazine (D11) (524 mg, 1.73 mmol) in dichloromethane (10 ml) was added drop-wise to 2M solution of phosgene in toluene (1.8 ml). The mixture was stirred at room temperature for 60 minutes and the solvent was removed by evaporation to give a white powder (680 mg) NMR (DMSO) δ 1.4 (2H, m), 1.75 (4H, m), 2.2 (2H, m), 2.88 (2H, m), 3.1-3.9 (12H, m), 4.06 (2H, m), 6.89 (2H, m), 7.01 (2H, m), 9.97 (H, m)
    • Step 2: 4-{[4-(4-{[3-(1-Piperidinyl)propyl]oxy}phenyl)-1-piperazinyl]carbonyl}morpholine
  • Morpholine (75 μl, 1.1 mmol) was added to a mixture of the product of Step 1 (4-(4-{[3-(1-piperidinyl)propyl]oxy}phenyl)-1-piperazinecarbonyl chloride hydrochloride salt) (170 mg, 0.42 mmol) and triethylamine (126 μl, 0.88 mmol) in dichloromethane (5 ml). After 60 minutes the mixture was evaporated and purified on a silica gel eluting with mixture of methanol: 0.88 ammonia: methanol: dichloromethane 0.2:2.8:98) solution to give a white solid (141 mg, 81%) MS (ES+) m/e 417 [M+H]+.
    • EXAMPLES 270-282
  • Examples 270 to 282 were prepared in the same manner as Example 269 using the appropriate amine highlighted in the table below.
  • MS (ES+) m/e
    Compound Amine [M + H]+.
    1-(4-{[3-(1-Piperidinyl)propyl]oxy}phenyl)-4-(1- Pyrrolidine 401
    pyrrolidinylcarbonyl)piperazine (E270)
    1-(1-Piperidinylcarbonyl)-4-(4-{[3-(1- Piperidine 415
    piperidinyl)propyl]oxy}phenyl)piperazine (E271)
    4-(4-{[3-(1-Piperidinyl)propyl]oxy}phenyl)-1- Ammonia 347
    piperazinecarboxamide (E272)
    4-{[4-(4-{[3-(1-Piperidinyl)propyl]oxy}phenyl)-1- Thiomorpholine 433
    piperazinyl]carbonyl}thiomorpholine (E273)
    4-{[4-(4-{[3-(1-Piperidinyl)propyl]oxy}phenyl)-1- thiomorpholine 465
    piperazinyl]carbonyl}thiomorpholine 1,1-dioxide (E274) 1,1-dioxide
    4-(4-{[3-(1-Piperidinyl)propyl]oxy}phenyl)-N- tetrahydro-2H- 431
    (tetrahydro-2H-pyran-4-yl)-1-piperazinecarboxamide pyran-4-amine
    (E275)
    1-{[(2R,6S)-2,6-Dimethyl-1-piperidinyl]carbonyl}-4-(4- (2R,6S)-2,6- 443
    {[3-(1-piperidinyl)propyl]oxy}phenyl)piperazine (E276) dimethylpiperidine
    1-{[4-(4-{[3-(1-Piperidinyl)propyl]oxy}phenyl)-1- 4-piperidine 458
    piperazinyl]carbonyl}-4-piperidinecarboxamide (E277) carboxamide
    1-{[(2R,5S)-2,5-Dimethyl-1-pyrrolidinyl]carbonyl}-4-(4- (2R,5S)-2,5- 429
    {[3-(1-piperidinyl)propyl]oxy}phenyl)piperazine (E278) dimethyl
    pyrrolidine
    1-[(2-Phenyl-1-pyrrolidinyl)carbonyl]-4-(4-{[3-(1- 2-phenyl 477
    piperidinyl)propyl]oxy}phenyl)piperazine (E279) pyrrolidine
    1-[(3-Phenyl-1-pyrrolidinyl)carbonyl]-4-(4-{[3-(1- 3-phenyl 477
    piperidinyl)propyl]oxy}phenyl)piperazine (E280) pyrrolidine
    4-(4-{[3-(1-Piperidinyl)propyl]oxy}phenyl)-N-6- 6-quinolinamine 474
    quinolinyl-1-piperazinecarboxamide (E281)
    N-(4-Cyanophenyl)-4-(4-{[3-(1- 4-amino 448
    piperidinyl)propyl]oxy}phenyl)-1- benzonitrile
    piperazinecarboxamide (E282)
    • EXAMPLE 283 1,1-Dimethylethyl 4-{[4-(4-{[3-(1-piperidinyl)propyl]oxy}phenyl)-1-piperazinyl]carbonyl}-1-piperazinecarboxylate (E283)
  • Figure US20100075953A1-20100325-C00253
  • A solution of 1-(4-{[3-(1-piperidinyl)propyl]oxy}phenyl)piperazine (D11) (1.8 g, 5.94 mmol) in dichloromethane 15 ml) was added to a 2M solution of phosgene in toluene (6 ml) and stirrer for 60 minutes. The solvent was removed by evaporation and the residue dissolved in dichloromethane (30 ml). Triethylamine (1.7 ml, 11.9 mmol) was added followed by 1,1-dimethylethyl 1-piperazinecarboxylate (1.2 g, 6.5 mmol) and the mixture stirred for 90 minutes. The solvent was removed by evaporation and the residue purified on silica gel eluting with a mixture of 0.88 ammonia solution:methanol:dichloromethane (0.5:4.5:95) to furnish the title compound (1.13 g, 37%) MS (ES+) m/e 516 [M+H]+.
    • EXAMPLE 284 1-(1-piperazinylcarbonyl)-4-(4-{[3-(1-piperidinyl)propyl]oxy}phenyl)piperazine (E284)
  • Figure US20100075953A1-20100325-C00254
  • A solution of 1,1-dimethylethyl 4-{[4-(4-{[3-(1-piperidinyl)propyl]oxy}phenyl)-1-piperazinyl]carbonyl}-1-piperazinecarboxylate (E283) (1.13 g, 2.19 mmol) in trifluoroacetic acid (5 ml) and dichloromethane (5 ml) was stirred at room temperature for 90 minutes. The solvent was removed by evaporation and the residue purified an SCX ion exchange resin eluting with methanol and then a mixture of 0.88 ammonia solution:methanol (1:9) to furnish the title compound (854 mg, 94%) MS (ES+) m/e 416 [M+H]+.
    • EXAMPLE 285 1-(2-Methylpropanoyl)-4-{[4-(4-{[3-(1-piperidinyl)propyl]oxy}phenyl)-1-piperazinyl]carbonyl}piperazine (E285)
  • Figure US20100075953A1-20100325-C00255
  • 2-methylpropanoyl chloride (30 μl, 1.2 mmol) was added to a stirring mixture of 1-(1-piperazinylcarbonyl)-4-(4-{[3-(1-piperidinyl)propyl]oxy}phenyl)piperazine (E284) (100 mg, 0.24 mmol) and triethylamine (37 μl, 0.26 mmol) in dichloromethane (2 ml). The resulting mixture was stirred at room temperature for 60 minutes. This was evaporated and passed through an SCX ion exchange resin eluting with methanol and then a mixture of 0.88 ammonia solution:methanol (1:9). The basic fractions were evaporated and the residue purified on silica gel eluting with a mixture of 0.88 ammonia solution:methanol:dichloromethane (0.5:4.5:95) to furnish the title compound (50 mg, 43%)
  • MS (ES+) m/e 486 [M+H]+.
    • EXAMPLES 286-291
  • Examples 286 to 291 were prepared in the same manner as Example 285 using the appropriate acid chloride:
  • MS (ES+) m/e
    Compound Acid Chloride [M + H]+.
    1-(Cyclopropylcarbonyl)-4-{[4-(4-{[3-(1- cyclopropanecarbonyl 484
    piperidinyl)propyl]oxy}phenyl)-1- chloride
    piperazinyl]carbonyl}piperazine (E286)
    1-(Cyclobutylcarbonyl)-4-{[4-(4-{[3-(1- cyclobutanecarbonyl 497
    piperidinyl)propyl]oxy}phenyl)-1- chloride
    piperazinyl]carbonyl}piperazine (E287)
    1-(Cyclopentylcarbonyl)-4-{[4-(4-{[3-(1- cyclopentanecarbonyl 512
    piperidinyl)propyl]oxy}phenyl)-1- chloride
    piperazinyl]carbonyl}piperazine (E288)
    1-(Cyclohexylcarbonyl)-4-{[4-(4-{[3-(1- cyclohexanecarbonyl 526
    piperidinyl)propyl]oxy}phenyl)-1- chloride
    piperazinyl]carbonyl}piperazine (E289)
    1-(4-{[3-(1-Piperidinyl)propyl]oxy}phenyl)-4-{[4- tetrahydro-2H-pyran- 528
    (tetrahydro-2H-pyran-4-ylcarbonyl)-1- 4-carbonyl chloride
    piperazinyl]carbonyl}piperazine (E290)
    1-[(4-Chlorophenyl)carbonyl]-4-{[4-(4-{[3-(1- 4-chlorobenzoyl 555
    piperidinyl)propyl]oxy}phenyl)-1- chloride
    piperazinyl]carbonyl}piperazine (E291 )
    • EXAMPLE 292 4-[(4-{4-[(1-Cyclobutyl-4-piperidinyl)oxy]phenyl}-1-piperazinyl)carbonyl]morpholine (E292)
  • Figure US20100075953A1-20100325-C00256
    • Step 1: Phenylmethyl 4-{4-[(1-{[(1,1-dimethylethyl)oxy]carbonyl}-4-piperidinyl)oxy]phenyl}-1-piperazinecarboxylate
  • A mixture of palladium acetate (300 mg, 5 mol %) and 2,2′-bis(diphenylphosphino)-1,1′-binaphthyl (1.3 g, 7.5 mol %) in toluene was heated at 100° C. for 10 minutes. A solution of the product of Example 263, step 1 (1,1-dimethylethyl 4-[(4-iodophenyl)oxy]-1-piperidinecarboxylate) (13 g, 59.5 mmol) and phenylmethyl 1-piperazinecarboxylate (20 g, 49.6 mmol) in toluene (120 ml) was added followed by sodium tert-butoxide (7.1 g, 64.5 mmol). This mixture was heated at 100° C. for 15 minutes and filtered through kieselghur. The filtrate was evaporated and purified on silica gel eluting with a mixture of hexane:ethyl:acetate (2:1) to furnish the title compound (6.4 g, 26%) MS (ES+) m/e 496 [M+H]+.
    • Step 2: Phenylmethyl 4-[4-(4-piperidinyloxy)phenyl]-1-piperazinecarboxylate
  • A solution of the product from step 1 (phenylmethyl 4-{4-[(1-{[(1,1-dimethylethyl)oxy]carbonyl}-4-piperidinyl)oxy]phenyl}-1-piperazinecarboxylate) (2 g, 4 mmol) in trifluoroacetic acid (5 ml) and dichloromethane (5 ml) was stirred at room temperature for 45 minutes. The solvent was removed by evaporation and the residue purified an SCX ion exchange resin eluting with methanol and then a mixture of 0.88 ammonia solution:methanol (1:9). methanol. The basic fractions were then reduced in vacuo to furnish the title compound (1.53 mg, 97%) MS (ES+) m/e 396 [M+H]+.
    • Step 3: Phenylmethyl 4-{4-[(1-cyclobutyl-4-piperidinyl)oxy]phenyl}-1-piperazinecarboxylate
  • Sodium triacetoxyborohydride (1.64 g, 7.74 mmol) was added to a solution of the product of step 2 (phenylmethyl 4-[4-(4-piperidinyloxy)phenyl]-1-piperazinecarboxylate) (1.53 g, 3.87 mmol) and cyclobutanone (578 μl, 7.74 mmol) in dichloromethane (15 ml). After 2 hours, methanol was added and the mixture evaporated. The residue was passed through an SCX ion exchange resin eluting with methanol and then a mixture of 0.88 ammonia solution:methanol (1:9). The basic fractions were evaporated and the residue purified on silica gel eluting with a mixture of 0.88 ammonia solution:methanol:dichloromethane (0.5:4.5:95) to furnish the title compound (1.35 g, 78%) MS (ES+) m/e 450 [M+H]+.
    • Step 4: 1-{4-[(1-Cyclobutyl-4-piperidinyl)oxy]phenyl}piperazine
  • A solution of phenylmethyl 4-{4-[(1-cyclobutyl-4-piperidinyl)oxy]phenyl}-1-piperazinecarboxylate (1.35 g, 3 mmol) in absolute ethanol 20 ml was hydrogenated at room temperature and pressure over a 50% wet paste of 10% palladium on carbon (500 mg). After 18 hours the catalyst was removed by filtration and the filtrate evaporated to give the title compound (889 mg, 94%) MS (ES+) m/e 316 [M+H]+.
    • Step 5: 4-[(4-{4-[(1-Cyclobutyl-4-piperidinyl)oxy]phenyl}-1-piperazinyl)carbonyl]morpholine
  • 4-morpholinecarbonyl chloride (78 mg, 0.53 mmol) was added to a mixture of the product from step 4 (1-{4-[(1-cyclobutyl-4-piperidinyl)oxy]phenyl}piperazine) (150 mg, 0.48 mmol) and polymer bound diethylamine resin (300 mg of 3.2 mmol/g) in dichloromethane (5 ml). After 2 hours the mixture was filtered and the filtrate evaporated. The residue was residue purified on a silica on silica gel eluting with a mixture of 0.88 ammonia solution:methanol:dichloromethane (0.5:4.5:95) to furnish the title compound (121 mg, 58%)
  • MS (ES+) m/e 429 [M+H]+.
    • EXAMPLE 293 4-{[4-(4-{[1-(1-Methylethyl)-4-piperidinyl]oxy}phenyl)-1-piperazinyl]carbonyl}morpholine (E293)
  • Figure US20100075953A1-20100325-C00257
  • A solution of the product of Example 263, step 5 (1-(4-{[1-(1-methylethyl)-4-piperidinyl]oxy}phenyl)piperazine) (200 mg, 0.66 mmol) was added to a 2M solution of phosgene in toluene (1.3 ml) and the mixture stirred for 30 minutes. The solvent was removed by evaporation and the residue dissolved in dichloromethane (5 ml). Morpholine (75 μl, 1.1 mmol) followed by triethylamine (126 μl, 0.88 mmol) were then added. After 60 minutes the mixture was evaporated and purified on a silica gel eluting with a mixture of 0.88 ammonia solution:methanol:dichloromethane (0.3:2.7:97) to furnish the title compound (177 mg, 65%) MS (ES+) m/e 417 [M+H]+.
    • EXAMPLE 294 1-(4-{[1-(1-Methylethyl)-4-piperidinyl]oxy}phenyl)-4-(1-piperidinylcarbonyl)piperazine (E294)
  • Example 294 was Prepared in the Same Manner as Example 293 from Piperidine.
  • MS (ES+) m/e 415 [M+H]+.
    • EXAMPLE 295 1-[4-({[1-(1-Methylethyl)-4-piperidinyl]methyl}oxy)phenyl]-4-(phenylcarbonyl)piperazine (E295)
  • Figure US20100075953A1-20100325-C00258
    • Step 1: 1,1-Dimethylethyl 4-(hydroxymethyl)-1-piperidinecarboxylate
  • 1-{[(1,1-dimethylethyl)oxy]carbonyl}-4-piperidinecarboxylic acid (2.0 g, 8.73 mmol) was dissolved in dry tetrahydrofuran (20 ml), cooled in an ice bath and treated with 1M borane-tetrahydrofuran solution (17.46 ml, 17.46 mmol) under argon. The mixture was allowed to warm to ambient temperature and stirred under argon for 4 hours. A solution of methanol (5 ml) in tetrahydrofuran (10 ml) was added followed by methanol (4 ml) and water (2 ml). The solvent was removed in vacuo and the residue dissolved in ethyl acetate and washed with saturated sodium bicarbonate solution (×2). The organic layer was separated, dried under magnesium sulphate and evaporated in vacuo to give the title compound (1.83 g). 1H NMR (CDCl3) δ 4.18-4.10 (2H, m), 3.51-3.50 (2H, m), 2.72-2.68 (2H, m), 1.75-1.69 (2H, m), 1.62 (1H, m), 1.46 (9H, s), 1.20-1.10 (2H, m).
    • Step 2: 1,1-Dimethylethyl 4-(iodomethyl)-1-piperidinecarboxylate
  • Triphenylphosphine (2.79 g, 10.6 mmol) was added to a mixture of iodine (2.59 g, 10.2 mmol) in toluene (90 ml). After 5 minutes, pyridine (1.65 ml, 20.4 mmol) followed by the product from Step 1 was added. The resulting mixture was heated under reflux for 3 hours. The cooled reaction mixture was filtered and the filtrate was washed with saturated sodium thiosulfate and brine, dried under magnesium sulphate, filtered and concentrated in vacuo. The residue was purified by silica gel chromatography eluting with a mixture of ethyl acetate:hexane (1:9) to give the title compound (1.83 g). 1H NMR (CDCl3) δ 4.18-4.10 (2H, m), 3.11-3.09 (2H, d), 2.72-2.65 (2H, m), 1.88-1.82 (2H, m), 1.62 (1H, m), 1.46 (9H, s), 1.20-1.11 (2H, m).
    • Step 3: 4[4-(Phenylcarbonyl)-1-piperazinyl]phenol
  • 4-(1-piperazinyl)phenol (4.0 g, 22.5 mmol) was dissolved in dry dichloromethane (50 ml), treated with triethylamine (3.4 ml, 24.8 mmol) and benzoyl chloride (2.6 ml, 22.5 mmol) and stirred at ambient temperature under argon for 2 hours. The solvent was removed in vacuo and the residue dissolved in ethyl acetate. The ethyl acetate layer was washed with saturated sodium bicarbonate solution, dried under magnesium sulphate and evaporated in vacuo. The crude product was dissolved in methanol, treated with potassium carbonate (2 equivalents) and stirred at ambient temperature for 30 minutes. The potassium carbonate was filtered and the filtrate evaporated in vacuo. The residue was dissolved in ethyl acetate, washed with saturated sodium bicarbonate solution, dried under magnesium sulphate and evaporated in vacuo to give the title compound (5.27 g). MS (ES+) m/e 283 [M+H]+.
    • Step 4: 1,1-Dimethylethyl 4[({4-[4-(phenylcarbonyl)-1-piperazinyl]phenyl}oxy)methyl]-1-piperidine carboxylate
  • The product from step 2 (1.83 g, 5.63 mmol), the product from step 3 (1.59 g, 5.63 mmol), potassium carbonate (1.86 g, 13.5 mmol) and potassium iodide (2.24 g, 13.5 mmol) were added together in 2-butanone (70 ml) and the mixture heated under reflux for 24 hours. The mixture was allowed to cool to room temperature, treated with sodium thiosulfate (1M, 15 ml) and extracted with ethyl acetate. The organic layer was separated, washed with water and brine, dried under magnesium sulphate and evaporated in vacuo. The title compound (0.30 g) was obtained by silica gel chromatography eluting with a mixture of ethyl acetate:hexane (1:1). MS (ES+) m/e 480 [M+H]+.
    • Step 5: 1-(Phenylcarbonyl)-4-{4[(4-piperidinylmethyl)oxy]phenyl}piperazine
  • The product from step 4 (0.30 g, 0.63 mmol) was dissolved in dichloromethane (3 ml), treated with trifluoroacetic acid (2 ml) and stirred at room temperature under argon for 2 hours. The solvent was removed in vacuo and the residue dissolved in methanol and passed down an SCX ion exchange column (5 g) eluting with methanol followed by a mixture of 0.880 ammonia:methanol (1:9). The basic fractions were combined and concentrated in vacuo to afford the title compound (0.1 g); MS (ES+) m/e 380 [M+H]+.
    • Step 6: 1-[4-({[1-(1-Methylethyl)-4-piperidinyl]methyl}oxy)phenyl]-4-(phenylcarbonyl)piperazine
  • The product of step 5 (90 mg, 0.24 mmol) in dry dichloromethane (4 ml) was treated with acetone (0.06 ml, 0.72 mmol) and glacial acetic acid (1 drop) and stirred at ambient temperature for 15 minutes. Sodium triacetoxyborohydride (152 mg, 0.72 mmol) was added and the reaction mixture stirred at ambient temperature under argon for 36 hours. The reaction mixture was diluted with methanol and passed down an SCX ion exchange column (5 g) eluting with methanol followed by a mixture of 0.880 ammonia:methanol (1:9). The basic fractions were combined and concentrated in vacuo to afford the title compound (98 mg); MS (ES+) m/e 422 [M+H]+.
    • EXAMPLE 296 1-[4-({[(35)-1-(1-Methylethyl)-3-piperidinyl]methyl}oxy)phenyl]-4-(phenylcarbonyl)piperazine (E296)
  • Figure US20100075953A1-20100325-C00259
    • Step 1: 1,1-Dimethylethyl (3S)-3-(hydroxymethyl)-1-piperidinecarboxylate
  • The title compound was prepared from (3S)-1-{[(1,1-dimethylethyl)oxy]carbonyl}-3-piperidinecarboxylic acid using the method of Example 295 step 1. 1H NMR (CDCl3) δ 3.99-3.58 (3H, m), 3.50 (1H, m), 3.22-2.95 (1H, m), 2.80-2.52 (1H, m), 1.87-1.52 (3H, m), 1.46 (9H, s), 1.32-1.12 (1H, m), 0.95-0.92 (1H, q).
    • Step 2: 1,1-Dimethylethyl (3S)-3-(iodomethyl)-1-piperidinecarboxylate
  • The title compound was prepared from the product of step 1 using the method of Example 295 step 2. 1H NMR (CDCl3) δ 4.11-3.98 (1H, m), 3.87-3.82 (1H, m), 3.09-2.08 (2H, d), 2.85-2.78 (2H, m), 1.93-1.91 (1H, m), 1.66-1.62 (2H, m), 1.47 (10H, s), 1.30-1.22 (1H, m).
    • Step 3: 1,1-Dimethylethyl (3S)-3-[({4-[4-(phenylcarbonyl)-1-piperazinyl]phenyl}oxy)methyl]-1-piperidinecarboxylate
  • The title compound was prepared from the product of step 2 and the product of Example 295 Step 3 using the method of Example 295 Step 4. MS (ES+) m/e 480 [M+H]+
    • Step 4: 1-(Phenylcarbonyl)-4-(4-{[(3S)-3-piperidinylmethyl]oxy}phenyl)piperazine
  • The title compound was prepared from the product of step 3 using the method of Example 295 Step 5. MS (ES+) m/e 380 [M+H]+
    • Step 5: 1-[4-({[(3S)-1-(1-Methylethyl)-3-piperidinyl]methyl}oxy)phenyl]-4-(phenylcarbonyl)piperazine
  • The title compound was prepared from the product of step 4 and acetone using the method of Example 295 Step 6. MS (ES+) m/e 422 [M+H]+
    • EXAMPLES 297-299
  • The following examples were prepared from the product of Example 296 Step 4 using the method of Example 295 Step 6 with the appropriate ketone or aldehyde as indicated in the table below.
  • MS (ES+)
    Ketone or m/e
    Example Aldehyde [M + H]+
    1-[4-({[(3S)-1-Cyclopentyl-3- Cyclopentanone 448
    piperidinyl]methyl}oxy)phenyl]-4-
    (phenylcarbonyl)piperazine (E297)
    1-[4-({[(3S)-1-(Cyclopropylmethyl)-3- Cyclopropane 434
    piperidinyl]methyl}oxy)phenyl]-4- carboxaldehyde
    (phenylcarbonyl)piperazine (E298)
    1-[4-({[(3S)-1-Ethyl-3- Acetaldehyde 408
    piperidinyl]methyl}oxy)phenyl]-
    4-(phenylcarbonyl)piperazine (E299)
    • EXAMPLE 300 1-[4-({[(3R)-1-(1-Methylethyl)-3-piperidinyl]methyl}oxy)phenyl]-4-(phenylcarbonyl)piperazine (E300)
  • Figure US20100075953A1-20100325-C00260
    • Step 1: 1,1-Dimethylethyl (3R)-3-(hydroxymethyl)-1-piperidinecarboxylate
  • The title compound was prepared from (3R)-1-{[(1,1-dimethylethyl)oxy]carbonyl}-3-piperidinecarboxylic acid using the method of Example 295 step 1. 1H NMR (CDCl3) δ 3.99-3.58 (3H, m), 3.50 (1H, m), 3.22-2.95 (1H, m), 2.80-2.52 (1H, m), 1.87-1.52 (3H, m), 1.46 (9H, s), 1.32-1.12 (1H, m), 0.95-0.92 (1H, q).
    • Step 2: 1,1-Dimethylethyl (3R)-3-(iodomethyl)-1-piperidinecarboxylate
  • The title compound was prepared from the product of step 1 using the method of Example 295 step 2. 1H NMR (CDCl3) δ 4.11-3.98 (1H, m), 3.87-3.82 (1H, m), 3.09-2.08 (2H, d), 2.85-2.78 (2H, m), 1.93-1.91 (1H, m), 1.66-1.62 (2H, m), 1.47 (10H, s), 1.30-1.22 (1H, m).
    • Step 3: 1,1-Dimethylethyl (3R)-3-[({4-[4-(phenylcarbonyl)-1-piperazinyl]phenyl}oxy)methyl]-1-piperidinecarboxylate
  • The title compound was prepared from the product of step 2 and the product of Example 295 Step 3 using the method of Example 295 Step 4. MS (ES+) m/e 480 [M+H]+
    • Step 4: 1-(Phenylcarbonyl)-4-(4-{[(3R)-3-piperidinylmethyl]oxy}phenyl)piperazine
  • The title compound was prepared from the product of step 3 using the method of Example 295 Step 5. MS (ES+) m/e 380 [M+H]+
    • Step 5: 1-[4-({[(3R)-1-(1-Methylethyl)-3-piperidinyl]methyl}oxy)phenyl]-4-(phenylcarbonyl)piperazine
  • The title compound was prepared from the product of step 4 and acetone using the method of Example 295 Step 6. MS (ES+) m/e 422 [M+H]+
    • EXAMPLES 301-302
  • The following examples were prepared from the product of Example 300 Step 4 using the method of Example 295 Step 6 using the appropriate aldehyde or ketone as indicated.
  • MS (ES+)
    Ketone or m/e
    Example Aldehyde [M + H]+
    1-[4-({[(3R)-1-Cyclopentyl-3- Cyclopentanone 448
    piperidinyl]methyl}oxy)phenyl]-4-
    (phenylcarbonyl)piperazine (E301)
    1-[4-({[(3R)-1-(Cyclopropylmethyl)-3- Cyclopropane 434
    piperidinyl]methyl}oxy)phenyl]-4- carboxaldehyde
    (phenylcarbonyl)piperazine (E302)
    • EXAMPLE 303 4-({4-[4-({[(3S)-1-Cyclopentyl-3-piperidinyl]methyl}oxy)phenyl]-1-piperazinyl}carbonyl)benzonitrile (E303)
  • Figure US20100075953A1-20100325-C00261
    • Step 1: 4-{[4-(4-Hydroxyphenyl)-1-piperazinyl]carbonyl}benzonitrile
  • 4-Cyanobenzoic acid (6.2 g, 42.2 mmol), 1,3-dicyclohexylcarbodiimide (8.7 g, 42.2 mmol) and 1-hydroxybenzotriazole hydrate (5.7 g, 42.2 mmol) were added to a suspension of 4-(1-piperazinyl)phenol (5.0 g, 28.1 mmol) in dry dichloromethane (50 ml). The mixture was stirred at ambient temperature for 2 hours, diluted with dichloromethane and washed with saturated sodium bicarbonate solution. The organic layer was separated, dried under magnesium sulphate and evaporated in vacuo. The residue was purified by column chromatography eluting with a mixture of ethyl acetate:hexane (1:1) to give the title compound (2.2 g).
  • MS (ES+) m/e 308 [M+H]+.
    • Step 2: 1,1-Dimethylethyl (3S)-3-{[(4-{4-[(4-cyanophenyl)carbonyl]-1-piperazinyl}phenyl)oxy]methyl}-1-piperidinecarboxylate
  • The title compound was prepared from the product of step 1 and the product of Example 296 Step 2 using the method of Example 295 Step 4. MS (ES+) m/e 505 [M+H]+
    • Step 3: 4-{[4-(4-{[(3S)-3-Piperidinylmethyl]oxy}phenyl)-1-piperazinyl]carbonyl}benzonitrile
  • The title compound was prepared from the product of step 2 using the method of Example 295 Step 5. MS (ES+) m/e 405 [M+H]+
    • Step 4: 4-({4-[4-({[(3S)-1-Cyclopentyl-3-piperidinyl]methyl}oxy)phenyl]-1-piperazinyl}carbonyl)benzonitrile
  • The title compound were prepared from the product of step 3 and cyclopentanone using the method of Example 295 step 6. MS (ES+) m/e 473 [M+H]+
    • EXAMPLE 304 1-(Phenylcarbonyl)-4-(4-{[2-(1-piperidinyl)ethyl]oxy}phenyl)piperazine (E304)
  • Figure US20100075953A1-20100325-C00262
    • Step 1: 1-{4-[(2-Bromoethyl)oxy]phenyl}-4-(phenylcarbonyl)piperazine
  • The product from Example 295 Step 3 (1.0 g, 3.55 mmol) was dissolved in 2-butanone (20 ml), treated with 1,2-dibromoethane (0.46 ml, 5.32 mmol) and potassium carbonate (0.73 g, 5.32 mmol) and the resulting mixture was heated under reflux for 18 hours. The reaction mixture was allowed to cool to ambient temperature, diluted with water, made basic by addition of aqueous sodium hydroxide solution (2M) and extracted with ethyl acetate. The ethyl acetate layer was separated, dried under magnesium sulphate and evaporated in vacuo. The residue was purified by silica gel chromatography eluting with a mixture of ethyl acetate:hexane (1:1) to give the title compound (0.40 g). MS (ES+) m/e 390 [M+H]+
    • Step 2: 1-(Phenylcarbonyl)-4-(4-{[2-(1-piperidinyl)ethyl]oxy}phenyl)piperazine
  • The title compound was prepared from the product of step 1 and piperidine using the method of Example 295 Step 4. MS (ES+) m/e 394 [M+H]+
    • EXAMPLE 305 4-({4-[4-{[3-(1-Piperidinyl)propyl]oxy}-2-(trifluoromethyl)phenyl]-1-piperazinyl}carbonyl)benzonitrile (E305)
  • Figure US20100075953A1-20100325-C00263
    • Step 1: 4-Bromo-3-(trifluoromethyl)phenol
  • 3-(Trifluoromethyl)phenol (1.88 ml, 15.4 mmol) was dissolved in acetic acid (4 ml) and treated with bromine (2.7 g, 16.9 mmol) dropwise. The resulting mixture was stirred at ambient temperature for 2 hours, poured into water (15 ml) and extracted with dichloromethane (×3). The dichloromethane layers were combined, washed with saturated sodium bicarbonate solution, dried under magnesium sulphate and evaporated in vacuo. The residue was purified by silica gel chromatography eluting with a mixture of hexane:dichloromethane (1:4) to give the title compound (0.73 g). 1H NMR (CDCl3) δ 7.55-7.53 (1H, d), 7.19-7.18 (1H, d), 6.89-6.86 (1H, dd), 5.51 (1H, s).
    • Step 2: 1-(3-{[4-Bromo-3-(trifluoromethyl)phenyl]oxy}propyl)piperidine
  • The product from step 1 was dissolved in 2-butanone (30 ml), treated with 1-(3-chloropropyl)piperidine hydrochloride (0.72 g, 3.63 mmol), potassium carbonate (1.17 g, 8.48 mmol) and sodium iodide (0.15 g, 0.91 mmol) and heated under reflux for 18 hours. The mixture was allowed to cool to ambient temperature, diluted with ethyl acetate and washed with water. The organic layer was separated, dried under magnesium sulphate and evaporated in vacuo. The residue was purified by silica gel chromatography eluting with a mixture of 0.880 ammonia:methanol:dichloromethane (0.5:4.5:95) to give the title compound (0.76 g). MS (ES+) m/e 367 [M+H]+
    • Step 3: 1,1-Dimethylethyl 4-[4-{[3-(1-piperidinyl)propyl]oxy}-2-(trifluoromethyl)phenyl]-1-piperazinecarboxylate
  • An oven dried 50 ml round bottomed flask was charged with palladium acetate (23 mg, 0.10 mmol), rac-2,2′-bis(diphenylphosphino)-1,1′-binaphthyl (97 mg, 0.16 mmol) and dry toluene (4 ml). The mixture was heated under argon at 100° C. for 3 minutes after which a dark purple solution was obtained. The product from step 2 (0.76 g, 2.08 mmol) in toluene (2 ml), 1,1-dimethylethyl 1-piperazinecarboxylate (0.46 g, 2.49 mmol) in toluene (2 ml) and potassium tert-butoxide (0.30 g, 3.12 mmol) were added and the mixture heated at 100° C. for 5 hours. The reaction mixture was allowed to cool, acidified with acetic acid and passed down an SCX ion exchange column (10 g) eluting with methanol followed by a mixture of 0.880 ammonia:methanol (1:9). The basic fractions were combined and evaporated in vacuo. The residue was purified by silica gel chromatography eluting with a mixture of 0.880 ammonia/methanol/dichloromethane (0.7:6.3:93) to give the title compound (0.49 g).
  • MS (ES+) m/e 472 [M+H]+
    • Step 4: 1-[4-{[3-(1-Piperidinyl)propyl]oxy}-2-(trifluoromethyl)phenyl]piperazine
  • The title compound was prepared from the product of step 3 using the procedure of Example 295 Step 5. MS (ES+) m/e 372 [M+H]+
    • Step 5: 4-({4-[4-{[3-(1-Piperidinyl)propyl]oxy}-2-(trifluoromethyl)phenyl]-1-piperazinyl}carbonyl)benzonitrile
  • 4-Cyanobenzoic acid (123 mg, 0.84 mmol), polymer bound 1,3-dicyclohexylcarbodiimide (1.9 mmol/g, 442 mg, 0.84 mmol) and 1-hydroxybenzotriazole hydrate (113 mg, 0.84 mmol) were stirred in dry dichloromethane (5 ml) for 30 minutes. The product from step 4 (154 mg, 0.42 mmol) was added and the mixture stirred at ambient temperature for 2 hours. The reaction mixture was diluted with methanol and passed down an SCX ion exchange column (5 g) eluting with methanol followed by a mixture of 0.880 ammonia:methanol (1:9). The basic fractions were combined and evaporated in vacuo to give the title compound (0.199 g).
  • MS (ES+) m/e 501 [M+H]+.
    • EXAMPLE 306 2-[4-(Phenylcarbonyl)-1-piperazinyl]-5-{[3-(1-piperidinyl)propyl]oxy}benzonitrile (E306)
  • Figure US20100075953A1-20100325-C00264
    • Step 1: 2-Bromo-5-hydroxybenzonitrile
  • 3-Hydroxybenzonitrile (2.0 g, 16.8 mmol) was dissolved in acetonitrile (20 ml) and cooled to 20° C. Tetrafluoroboric acid diethyl ether complex (2.3 ml, 16.8 mmol) followed by N-bromosuccinimide (3.0 g, 16.8 mmol) were added and the mixture allowed to warm to ambient temperature. The resulting mixture was stirred for 5 hours, treated with aqueous sodium hydrogen sulfate solution (38%, 10 ml) and extracted with methyl 2-methylpropyl ether (×2). The organic extracts were combined, washed with water (×2) and brine, dried under magnesium sulphate and evaporated in vacuo. The residue was purified by silica gel chromatography eluting with a mixture of methyl 2-methylpropyl ether/dichloromethane (2:98) to give the title compound (1.58 g). MS (ES+) m/e 197 [M−H]+
    • Step 2: 2-Bromo-5-{[3-(1-piperidinyl)propyl]oxy}benzonitrile
  • The title compound was prepared from the product of step 1 and 1-(3-chloropropyl)piperidine hydrochloride using the method of Example 305 Step 2. MS (ES+) m/e 324 [M+H]+
    • Step 3: 1,1-Dimethylethyl 4-(2-cyano-4-{[3-(1-piperidinyl)propyl]oxy}phenyl)-1-piperazinecarboxylate
  • The title compound was prepared from the product of step 2 and 1,1-dimethylethyl 1-piperazinecarboxylate using the method of Example 305 Step 3. MS (ES+) m/e 429 [M+H]+
    • Step 4: 2-(1-piperazinyl)-5-{[3-(1-piperidinyl)propyl]oxy}benzonitrile
  • The title compound was prepared from the product of step 3 using the procedure of Example 295 Step 5. MS (ES+) m/e 329 [M+H]+
    • Step 5: 2-[4-(Phenylcarbonyl)-1-piperazinyl]-5-{[3-(1-piperidinyl)propyl]oxy}benzonitrile
  • The title compound was prepared from the product of step 4 and benzoic acid using the procedure of Example 305 Step 5. MS (ES+) m/e 433 [M+H]+
    • EXAMPLES 307-309
  • The following examples were prepared from the product of Example 306 Step 4 and the appropriate carboxylic acid indicated in table below using the method of Example 305 Step 5.
  • MS (ES+)
    m/e
    Example Carboxylic Acid [M + H]+
    2-{4-[(4-Cyanophenyl)carbonyl]-1-piperazinyl}-5- 4-cyano benzoic acid 458
    {[3-(1-piperidinyl)propyl]oxy}benzonitrile (E307)
    2-{4-[(4-Fluorophenyl)carbonyl]-1-piperazinyl}-5- 4-fluoro benzoic 451
    {[3-(1-piperidinyl)propyl]oxy}benzonitrile (E308) acid
    5-{[3-(1-Piperidinyl)propyl]oxy}-2-(4-{[4-(1- 4-(1-pyrrolidinyl 530
    pyrrolidinylcarbonyl)phenyl]carbonyl}-1- carbonyl) benzoic
    piperazinyl)benzonitrile (E309) acid (J. Med.
    Chem., 46(10),
    1845-1857, 2003)
    • EXAMPLE 310 1-(2-Fluoro-4-{[3-(1-piperidinyl)propyl]oxy}phenyl)-4-(phenylcarbonyl)piperazine (E310)
  • Figure US20100075953A1-20100325-C00265
    • Step 1: 1-{3-[(4-Bromo-3-fluorophenyl)oxy]propyl}piperidine
  • The title compound was prepared from 4-bromo-3-fluorophenol and 1-(3-chloropropyl)piperidine hydrochloride using the method of Example 305 Step 2. MS (ES+) m/e 317 [M+H]+
    • Step 2: 1,1-Dimethylethyl 4-(2-fluoro-4-{[3-(1-piperidinyl)propyl]oxy}phenyl)-1-piperazinecarboxylate
  • The title compound was prepared from the product of step 1 and 1,1-dimethylethyl 1-piperazinecarboxylate using the method of Example 305 Step 3. MS (ES+) m/e 422 [M+H]+
    • Step 3: 1-(2-Fluoro-4-{[3-(1-piperidinyl)propyl]oxy}phenyl)piperazine
  • The title compound was prepared from the product of step 2 using the procedure of Example 295 Step 5. MS (ES+) m/e 322 [M+H]+
    • Step 4: 1-(2-Fluoro-4-{[3-(1-piperidinyl)propyl]oxy}phenyl)-4-(phenylcarbonyl)piperazine
  • The title compound was prepared from the product of step 3 and benzoic acid using the procedure of Example 305 Step 5. MS (ES+) m/e 426 [M+H]+
    • EXAMPLES 311-313
  • The following examples were prepared from the product of Example 310 Step 3 and the appropriate carboxylic acid indicated in the table below using the method of Example 305 Step 5.
  • MS (ES+) m/e
    Example Carboxylic Acid [M + H]+
    4-{[4-(2-Fluoro-4-{[3-(1-piperidinyl)propyl]oxy}phenyl)-1- 4-cyanobenzoic 451
    piperazinyl]carbonyl}benzonitrile (E311) acid
    1-[(4-Fluorophenyl)carbonyl]-4-(2-fluoro-4-{[3-(1- 4-fluorobenzoic 444
    piperidinyl)propyl]oxy}phenyl)piperazine (E312) acid
    1-(2-Fluoro-4-{[3-(1-piperidinyl)propyl]oxy}phenyl)-4-{[4- 4-(1-pyrrolidinyl 523
    (1-pyrrolidinylcarbonyl)phenyl]carbonyl}piperazine (E313) carbonyl) benzoic
    acid (J. Med.
    Chem., 46(10),
    1845-1857, 2003)
    • EXAMPLE 314 4-{[4-(2-Fluoro-4-{[3-(1-piperidinyl)propyl]oxy}phenyl)-1-piperazinyl]carbonyl}morpholine (E314)
  • Figure US20100075953A1-20100325-C00266
  • The product from Example 310 step 3 (150 mg, 0.47 mmol) was dissolved in dry dichloromethane (5 ml), treated with diethylaminomethyl polystyrene (3.2 mmol/g, 294 mg, 0.94 mmol) and morpholine carbonyl chloride (0.11 ml, 0.94 mmol) and stirred at ambient temperature under argon for 1 hour. The reaction mixture was diluted with methanol and passed down an SCX ion exchange column (5 g) eluting with methanol followed by a mixture of 0.880 ammonia:methanol (1:9). The basic fractions were combined and evaporated in vacuo. The residue was purified by column chromatography eluting with a mixture of 0.880 ammonia:methanol:dichloromethane (0.5:4.5:95) to give the title compound (84 mg).
  • MS (ES+) m/e 435 [M+H]+
    • EXAMPLE 315 4-{[4-(2-Fluoro-4-{[1-(1-methylethyl)-4-piperidinyl]oxy}phenyl)-1-piperazinyl]carbonyl}morpholine (E315)
  • Figure US20100075953A1-20100325-C00267
    • Step 1: 1,1-Dimethylethyl 4-[(4-bromo-3-fluorophenyl)oxy]-1-piperidinecarboxylate
  • 4-Bromo-3-fluorophenol (5.0 g, 26.2 mmol) was dissolved in dry tetrahydrofuran (100 ml) and treated with 1,1-dimethylethyl 4-hydroxy-1-piperidinecarboxylate (6.3 g, 31.4 mmol), triphenylphosphine (8.2 g, 31.4 mmol) and di-t-butylazodicarboxylate (7.2 g, 31.4 mmol). The resulting mixture was stirred at ambient temperature under argon for 18 hours and the solvent removed in vacuo. The residue was triturated with a mixture of ethyl acetate/hexane (1:9), the white solid filtered and the filtrate purified by silica gel chromatography eluting with ethyl acetate:hexane (1:9) to give the title compound (4.67 g). MS (ES+) m/e 375 [M+H]+
    • Step 2: 4-[(4-Bromo-3-fluorophenyl)oxy]piperidine
  • The product from step 1 (4.67 g, 12.5 mmol) was dissolved in dry dichloromethane (30 ml), treated with trifluoroacetic acid (20 ml) and stirred at ambient temperature for 2 hours. The solvent was removed in vacuo and the residue made basic by addition of aqueous sodium hydroxide solution (2M). The resulting mixture was extracted with dichloromethane (×2). The organic layers were combined, washed with brine, dried under magnesium sulphate and concentrated in vacuo. The residue was purified by column chromatography eluting with a mixture of 0.880 ammonia:methanol:dichloromethane (1:9:90) to give the title compound (2.13 g). MS (ES+) m/e 275 [M+H]+
    • Step 3: 4-[(4-Bromo-3-fluorophenyl)oxy]-1-(1-methylethyl)piperidine
  • The product from step 2 (2.13 g, 7.77 mmol) was dissolved in dry dichloromethane (20 ml), treated with acetone (0.86 ml, 11.7 mmol) and acetic acid (2 drops) and stirred for 15 minutes at ambient temperature. Sodium triacetoxyborohydride (2.48 g, 11.7 mmol) was added and the mixture stirred at ambient temperature under argon for 18 hours. The resulting mixture was diluted with dichloromethane and washed with saturated sodium bicarbonate solution and brine. The organic layer was dried under magnesium sulphate and evaporated in vacuo to give the title compound. MS (ES+) m/e 317 [M+H]+
    • Step 4: 1,1-Dimethylethyl 4-(2-fluoro-4-{[1-(1-methylethyl)-4-piperidinyl]oxy}phenyl)-1-piperazinecarboxylate
  • The title compound was prepared from the product of step 3 and 1,1-dimethylethyl 1-piperazinecarboxylate using the method of Example 305 Step 3. MS (ES+) m/e 422 [M+H]+
    • Step 5: 1-(2-Fluoro-4-{[1-(1-methylethyl)-4-piperidinyl]oxy}phenyl)piperazine
  • The title compound was prepared from the product of step 4 using the procedure of Example 295 Step 5. MS (ES+) m/e 322 [M+H]+
    • Step 6: 4-{[4-(2-Fluoro-4-{[1-(1-methylethyl)-4-piperidinyl]oxy}phenyl)-1-piperazinyl]carbonyl}morpholine
  • The title compound was prepared from the product step 5 and morpholine carbonyl chloride using the procedure of Example 314. MS (ES+) m/e 435 [M+H]+
    • EXAMPLE 316 4-{[(2R,6S)-2,6-Dimethyl-4-(4-{[3-(1-piperidinyl)propyl]oxy}phenyl)-1-piperazinyl]carbonyl}benzonitrile (E316)
  • Figure US20100075953A1-20100325-C00268
    • Step 1: 1-{3-[(4-Iodophenyl)oxy]propyl}piperidine
  • 1-(3-Chloropropyl)piperidine hydrochloride (9.9 g, 50.0 mmol), potassium carbonate (17.6 g, 127.4 mmol) and potassium iodide (1.1 g, 6.8 mmol) were added to a solution of 4-iodophenol (10 g, 45.5 mmol) in dimethylformamide (150 ml) and the resulting mixture was heated at 90° C. for 18 hours. The mixture was allowed to cool to ambient temperature, poured onto water/ice (500 ml) and stirred for 10 minutes. The solid was filtered and washed with ice water to give the title compound (13.5 g). MS (ES+) m/e 346 [M+H]+
    • Step 2: (3R,5S)-3,5-Dimethyl-1-(4-{[3-(1-piperidinyl)propyl]oxy}phenyl)piperazine
  • The title compound was prepared from the product of step 1 and (2R,6S)-2,6-dimethylpiperazine using the procedure of Example 305 Step 3. MS (ES+) m/e 332 [M+H]+
    • Step 3: 4-{[(2R,6S)-2,6-Dimethyl-4-(4-{[3-(1-piperidinyl)propyl]oxy}phenyl)-1-piperazinyl]carbonyl}benzonitrile
  • The product from step 2 (249 mg, 0.75 mmol) was dissolved in dry dichloromethane (5 ml), treated with triethylamine (0.21 ml, 1.50 mmol) and 4-cyanobenzoyl chloride (248 mg, 1.50 mmol) and the resulting mixture was stirred at ambient temperature under argon for 2 hours. Methanol was added and the mixture passed down an SCX ion exchange column (5 g) eluting with methanol followed by a mixture of 0.880 ammonia:methanol (1:9). The basic fractions were combined and evaporated in vacuo. The residue was purified by silica gel chromatography eluting with ammonia:methanol:dichloromethane (0.5:4.5:95) to give the title compound (158 mg). MS (ES+) m/e 461 [M+H]+
    • EXAMPLE 317 (2R,6S)-2,6-Dimethyl-4-(4-{[3-(1-piperidinyl)propyl]oxy}phenyl)-1-(4-pyridinylcarbonyl)piperazine (E317)
  • Figure US20100075953A1-20100325-C00269
  • 4-Pyridinecarboxylic acid (116 mg, 0.94 mmol) was dissolved in dry dichloromethane (5 ml), treated with oxalyl chloride (0.08 ml, 0.96 mmol) and dimethylformamide (1 drop) and stirred under argon at ambient temperature for 2 hours. The solvent was removed in vacuo and the residue azeotroped with toluene. The residue was redissolved in dry dichloromethane (5 ml) and treated with the product from Example 316 Step 2 (156 mg, 0.47 mmol) and triethylamine (0.13 ml, 0.94 mmol). The resulting mixture was stirred under argon at ambient temperature for 1.5 hours, diluted with methanol and passed down an SCX ion exchange column (5 g) eluting with methanol followed by a mixture of 0.880 ammonia:methanol (1:9). The basic fractions were combined and evaporated in vacuo. The residue was purified by silica gel chromatography eluting with ammonia:methanol:dichloromethane (0.7:6.3:93) to give the title compound (110 mg). MS (ES+) m/e 437 [M+H]+
    • EXAMPLE 318 4-{[(2S)-2-Methyl-4-(4-{[3-(1-piperidinyl)propyl]oxy}phenyl)-1-piperazinyl]carbonyl}benzonitrile (E318)
  • Figure US20100075953A1-20100325-C00270
    • Step 1: (3S)-3-Methyl-1-(4-{[3-(1-piperidinyl)propyl]oxy}phenyl)piperazine
  • The title compound was prepared from the product of Example 316 Step 1 and (2S)-2-methylpiperazine using the procedure of Example 305 Step 3. MS (ES+) m/e 318 [M+H]+
    • Step 2: 4-{[(2S)-2-Methyl-4-(4-{[3-(1-piperidinyl)propyl]oxy}phenyl)-1-piperazinyl]carbonyl}benzonitrile
  • The title compound was prepared from the product of step 1 and 4-cyanobenzoic acid using the procedure of Example 305 Step 5. MS (ES+) m/e 447 [M+H]+
    • EXAMPLES 319-324
  • The following compounds were prepared from the product of Example 318 Step 1 with the appropriate carboxylic acid indicated in the table below using the procedure of Example 305 Step 5.
  • MS (ES+) m/e
    Example Carboxylic Acid [M + H]+
    (2S)-2-Methyl-4-(4-{[3-(1-piperidinyl)propyl]oxy}phenyl)- 4-(1- 519
    1-{[4-(1-pyrrolidinylcarbonyl)phenyl]carbonyl}piperazine pyrrolidinylcarbonyl)benzoic
    (E319) acid (J. Med.
    Chem., 46(10),
    1845-1857, 2003)
    (2S)-2-Methyl-4-(4-{[3-(1-piperidinyl)propyl]oxy}phenyl)- 4-pyridinecarboxylic 423
    1-(4-pyridinylcarbonyl)piperazine acid
    (E320)
    (2S)-1-[(4-Fluorophenyl)carbonyl]-2-methyl-4- 4-fluorobenzoic acid 440
    (4-{[3-(1-piperidinyl)propyl]oxy}phenyl)piperazine
    (E321)
    (2S)-2-Methyl-4-(4-{[3-(1- tetrahydro-2H- 430
    piperidinyl)propyl]oxy}phenyl)-1-(tetrahydro- pyran-4-carboxylic
    2H-pyran-4-ylcarbonyl)piperazine (E322) acid
    (2S)-2-Methyl-1-{[4-(methylsulfonyl)phenyl]carbonyl}- 4-(methylsulfonyl)benzoic 500
    4-(4-{[3-(1-piperidinyl)propyl]oxy}phenyl)piperazine acid
    (E323)
    1-(4-{[(2S)-2-Methyl-4-(4-{[3-(1- 4-acetylbenzoic acid 464
    piperidinyl)propyl]oxy}phenyl)-1-
    piperazinyl]carbonyl}phenyl)ethanone (E324)
    • EXAMPLE 325 4-{[(3R)-3-Methyl-4-(4-{[3-(1-piperidinyl)propyl]oxy}phenyl)-1-piperazinyl]carbonyl}benzonitrile (E325)
  • Figure US20100075953A1-20100325-C00271
    • Step 1: 1,1-Dimethylethyl (3R)-3-methyl-4-(4-{[3-(1-piperidinyl)propyl]oxy}phenyl)-1-piperazinecarboxylate
  • The title compound was prepared from the product of Example 316 Step 1 and 1,1-dimethylethyl (3R)-3-methyl-1-piperazinecarboxylate using the method of Example 305 Step 3. MS (ES+) m/e 418 [M+H]+
    • Step 2: (2R)-2-Methyl-1-(4-{[3-(1-piperidinyl)propyl]oxy}phenyl)piperazine
  • The title compound was prepared from the product of step 1 using the method of Example 295 Step 5. MS (ES+) m/e 318 [M+H]+
    • Step 3: 4-{[(3R)-3-Methyl-4-(4-{[3-(1-piperidinyl)propyl]oxy}phenyl)-1-piperazinyl]carbonyl}benzonitrile
  • The title compound was prepared from the product of step 2 and 4-cyanobenzoic acid using the procedure of Example 305 Step 5. MS (ES+) m/e 447 [M+H]+
    • EXAMPLES 326-329
  • The following compounds were prepared from the product of Example 325 Step 2 with the appropriate carboxylic acid indicated in the table below using the procedure of Example 305 Step 5.
  • MS (ES+) m/e
    Example Carboxylic Acid [M + H]+
    (2R)-2-Methyl-1-(4-{[3-(1- 4-(1-pyrrolidinyl 519
    piperidinyl)propyl]oxy}phenyl)-4-{[4-(1- carbonyl)benzoic
    pyrrolidinylcarbonyl)phenyl]carbonyl}piperazine acid
    (E326) (J. Med. Chem.,
    46(10), 1845-1857,
    2003)
    (2R)-2-Methyl-1-(4-{[3-(1- 4-pyridine 423
    piperidinyl)propyl]oxy}phenyl)-4-(4- carboxylic acid
    pyridinylcarbonyl)piperazine (E327)
    (2R)-4-[(4-Fluorophenyl)carbonyl]-2-methyl-1-(4-{[3- 4-fluorobenzoic 440
    (1-piperidinyl)propyl]oxy}phenyl)piperazine (E328) acid
    (2R)-2-Methyl-1-(4-{[3-(1- tetrahydro-2H- 430
    piperidinyl)propyl]oxy}phenyl)-4-(tetrahydro-2H- pyran-4-
    pyran-4-ylcarbonyl)piperazine (E329) carboxylic acid
    • EXAMPLE 330 1-(4-{[3-(1-Piperidinyl)propyl]oxy}phenyl)-4-{[4-(trifluoromethyl)phenyl]carbonyl}piperazine (E330)
  • Figure US20100075953A1-20100325-C00272
  • 4-(Trifluoromethyl)phenyl [4-(trifluoromethyl)phenyl]carbonyl carbonate (358 mg, 1 mmol) was added to a stirring solution of 1-(4-{[3-(1-piperidinyl)propyl]oxy}phenyl)piperazine (D11) (150 mg, 0.5 mmol) in dichloromethane (20 ml). After 3 hours the mixture was passed through an SCX ion exchange cartridge eluting with methanol and then a mixture of 0.880 ammonia:methanol (1:9). The basic fractions were evaporated and the residue purified on silica gel eluting with a mixture of 0.88 ammonia solution:methanol:dichloromethane (0.5:4.5:95) to furnish the title compound (204 mg, 87%) MS (ES+) m/e 476 [M+H]+.
    • EXAMPLE 331 1-(Cyclohexylcarbonyl)-4-(4-{[3-(1-piperidinyl)propyl]oxy}phenyl)piperazine (E331)
  • Figure US20100075953A1-20100325-C00273
  • Cyclohexanecarbonyl chloride (79 mg, 0.55 mmol) was added to a mixture of 1-(4-{[3-(1-piperidinyl)propyl]oxy}phenyl)piperazine (D11) (150 mg, 0.5 mmol) and triethylamine (100 μl, 0.75 mmol) in dichloromethane (5 ml). After 5 hours the solvent was removed by evaporation and the residue purified on silica gel eluting with a mixture of 0.88 ammonia solution:methanol:dichloromethane (0.5:4.5:95) to furnish the title compound (150 mg, 89%)
  • MS (ES+) m/e 414 [M+H]+.
    • EXAMPLES 332-342
  • E332 to E342 were prepared from 1-(4-{[3-(1-piperidinyl)propyl]oxy}phenyl)piperazine (D11) with the appropriate acid chloride indicated in the table below using the procedure of Example 331
  • MS (ES+) m/e
    Compound Acid Chloride [M + H]+.
    1-(4-{[3-(1-Piperidinyl)propyl]oxy}phenyl)-4-(2- 2-thiophene 414
    thienylcarbonyl)piperazine (E332) carbonyl chloride
    3-{[4-(4-{[3-(1-Piperidinyl)propyl]oxy}phenyl)-1- 4-cyanobenzoyl 433
    piperazinyl]carbonyl}benzonitrile (E333) chloride
    1-{[4-(Methyloxy)phenyl]carbonyl}-4-(4-{[3-(1- 4-(methyloxy)benzoyl 438
    piperidinyl)propyl]oxy}phenyl)piperazine (E334) chloride
    1-(1,3-Benzodioxol-5-ylcarbonyl)-4-(4-{[3-(1- 1,3- 452
    piperidinyl)propyl]oxy}phenyl)piperazine (E335) benzodioxole-5-
    carbonyl chloride
    1-{[3,5-bis(Trifluoromethyl)phenyl]carbonyl}-4-(4- 3,5-bis(trifluoromethyl)benzoyl 544
    {[3-(1-piperidinyl)propyl]oxy}phenyl)piperazine chloride
    (E336)
    1-[(3,5-Dichlorophenyl)carbonyl]-4-(4-{[3-(1- 3,5- 477
    piperidinyl)propyl]oxy}phenyl)piperazine (E337) dichlorobenzoyl
    chloride
    1-[(4-Bromophenyl)carbonyl]-4-(4-{[3-(1- 4-bromobenzoyl 486
    piperidinyl)propyl]oxy}phenyl)piperazine (E338) chloride
    1-[(3-Bromophenyl)carbonyl]-4-(4-{[3-(1- 3-bromobenzoyl 486
    piperidinyl)propyl]oxy}phenyl)piperazine (E339) chloride
    1-[(2,6-Dichlorophenyl)carbonyl]-4-(4-{[3-(1- 2,6- 477
    piperidinyl)propyl]oxy}phenyl)piperazine (E340) dichlorobenzoyl
    chloride
    1-(2-Naphthalenylcarbonyl)-4-(4-{[3-(1- 2-naphthalene 458
    piperidinyl)propyl]oxy}phenyl)piperazine (E341) carbonyl chloride
    1-(4-{[3-(1-Piperidinyl)propyl]oxy}phenyl)-4-(3- 3-pyridine 409
    pyridinylcarbonyl)piperazine (E342) carbonyl chloride
    • EXAMPLE 343 1-[(4-Chlorophenyl)carbonyl]-4-(4-{[3-(1-piperidinyl)propyl]oxy}phenyl)piperazine (E343)
  • Figure US20100075953A1-20100325-C00274
  • 4-Chlorobenzoic acid (192 mg, 1.23 mmol) was treated with N,N′-dicyclohexylcarbodiimide (0.25 g, 1.23 mmol) and 1-hydroxybenzotriazole hydrate (165 mg, 1.23 mmol) in dichloromethane (5 ml) after 2 hours 1-(4-{[3-(1-piperidinyl)propyl]oxy}phenyl)piperazine (D11) (150 mg, 0.5 mmol) was added and stirring continued for 18 hours. The solvent was removed by evaporation and the residue purified on silica gel eluting with a mixture of 0.88 ammonia solution:methanol:dichloromethane (0.5:4.5:95) to furnish the title compound (198 mg, 91%) MS (ES+) m/e 442 [M+H]+.
    • EXAMPLES 344-374
  • E344 to E374 were prepared from 1-(4-{[3-(1-piperidinyl)propyl]oxy}phenyl)piperazine (D11) with the appropriate carboxylic acid indicated in the table below using the procedure of Example 343.
  • MS (ES+) m/e
    Compound Acid [M + H]+.
    1-[(4-Fluorophenyl)carbonyl]-4-(4-{[3-(1- 4-Fluorobenzoic 426
    piperidinyl)propyl]oxy}phenyl)piperazine (E344) acid
    1-(4-Biphenylylcarbonyl)-4-(4-{[3-(1- 4-biphenyl 484
    piperidinyl)propyl]oxy}phenyl)piperazine (E345) carboxylic acid
    1-(4-{[3-(1-Piperidinyl)propyl]oxy}phenyl)-4- tetrahydro-2H- 416
    (tetrahydro-2H-pyran-4-ylcarbonyl)piperazine pyran-4-
    (E346) carboxylic acid
    1-(4-{[3-(1-Piperidinyl)propyl]oxy}phenyl)-4-(2- 2-pyridine 409
    pyridinylcarbonyl)piperazine (E347) carboxylic acid
    1-{[4-(4-{[3-(1-Piperidinyl)propyl]oxy}phenyl)-1- 1-isoquinoline 459
    piperazinyl]carbonyl}isoquinoline (E348) carboxylic acid
    2-{[4-(4-{[3-(1-Piperidinyl)propyl]oxy}phenyl)-1- 2-quinoline 459
    piperazinyl]carbonyl}quinoline (E349) carboxylic acid
    6-{[4-(4-{[3-(1-Piperidinyl)propyl]oxy}phenyl)-1- 6-quinoline 459
    piperazinyl]carbonyl}quinoline (E350) carboxylic acid
    1-(4-{[3-(1-Piperidinyl)propyl]oxy}phenyl)-4-(4- 4-pyridine 409
    pyridinylcarbonyl)piperazine (E351) carboxylic acid
    5-{[4-(4-{[3-(1-Piperidinyl)propyl]oxy}phenyl)-1- 5-pyrimidine 410
    piperazinyl]carbonyl}pyrimidine (E352) carboxylic acid
    1-(4-{[3-(1-Piperidinyl)propyl]oxy}phenyl)-4-(3- 3-thiophene 414
    thienylcarbonyl)piperazine (E353) carboxylic acid
    Methyl 4-{[4-(4-{[3-(1- 4-[(methyloxy)carbonyl] 466
    piperidinyl)propyl]oxy}phenyl)-1- benzoic
    piperazinyl]carbonyl}benzoate (E354) acid
    Methyl 3-{[4-(4-{[3-(1- 3-[(methyloxy)carbonyl] 466
    piperidinyl)propyl]oxy}phenyl)-1- benzoic
    piperazinyl]carbonyl}benzoate (E355) acid
    1-(Cyclopropylacetyl)-4-(4-{[3-(1- cyclopropyl acetic 386
    piperidinyl)propyl]oxy}phenyl)piperazine (E356) acid
    1-{[4-Fluoro-2-(trifluoromethyl)phenyl]carbonyl}-4- 4-fluoro-2- 494
    (4-{[3-(1-piperidinyl)propyl]oxy}phenyl)piperazine (trifluoromethyl)benzoic
    (E357) acid
    1-[(4-Bromo-2-methylphenyl)carbonyl]-4-(4-{[3-(1- 4-bromo-2- 501
    piperidinyl)propyl]oxy}phenyl)piperazine (E358) methylbenzoic
    acid
    1-[(4-Chloro-3-fluorophenyl)carbonyl]-4-(4-{[3-(1- 4-chloro-3- 460
    piperidinyl)propyl]oxy}phenyl)piperazine (E359) fluorobenzoic
    acid
    1-{[4-(Methylsulfonyl)phenyl]carbonyl}-4-(4-{[3-(1- 4-(methylsulfonyl)benzoic 486
    piperidinyl)propyl]oxy}phenyl)piperazine (E360) acid
    1-{[2-Chloro-4-(methylsulfonyl)phenyl]carbonyl}-4- 2-chloro-4- 521
    (4-{[3-(1-piperidinyl)propyl]oxy}phenyl)piperazine (methylsulfonyl)benzoic
    (E361) acid
    1-[(2,4-Difluorophenyl)carbonyl]-4-(4-{[3-(1- 2,4-difluoro 444
    piperidinyl)propyl]oxy}phenyl)piperazine (E362) benzoic acid
    1-(3-Methylbutanoyl)-4-(4-{[3-(1- 3-methyl butanoic 388
    piperidinyl)propyl]oxy}phenyl)piperazine (E363) acid
    1-[(2,4-Dichlorophenyl)carbonyl]-4-(4-{[3-(1- 2,4-dichloro 477
    piperidinyl)propyl]oxy}phenyl)piperazine (E364) benzoic acid
    1-[(4-Chloro-2-fluorophenyl)carbonyl]-4-(4-{[3-(1- 4-chloro-2- 461
    piperidinyl)propyl]oxy}phenyl)piperazine (E365) fluorobenzoic
    acid
    1-[(4-Fluoro-3-methylphenyl)carbonyl]-4-(4-{[3-(1- 4-fluoro-3- 440
    piperidinyl)propyl]oxy}phenyl)piperazine (E366) methylbenzoic
    acid
    1-[(4-Bromo-2-fluorophenyl)carbonyl]-4-(4-{[3-(1- 4-bromo-2- 505
    piperidinyl)propyl]oxy}phenyl)piperazine (E367) fluorobenzoic
    acid
    1-[(3,4-Difluorophenyl)carbonyl]-4-(4-{[3-(1- 3,4-difluoro 444
    piperidinyl)propyl]oxy}phenyl)piperazine (E368) benzoic acid
    1-[(4-Chloro-3-methylphenyl)carbonyl]-4-(4-{[3-(1- 4-chloro-3- 457
    piperidinyl)propyl]oxy}phenyl)piperazine (E369) methylbenzoic
    acid
    1-[(4-Bromo-3-methylphenyl)carbonyl]-4-(4-{[3-(1- 4-bromo-3- 501
    piperidinyl)propyl]oxy}phenyl)piperazine (E370) methylbenzoic
    acid
    1-[(2-Bromo-4-fluorophenyl)carbonyl]-4-(4-{[3-(1- 2-bromo-4- 505
    piperidinyl)propyl]oxy}phenyl)piperazine (E371) fluorobenzoic
    acid
    N,N-Dimethyl-3-{[4-(4-{[3-(1- 3-(dimethyl 451
    piperidinyl)propyl]oxy}phenyl)-1- amino)benzoic
    piperazinyl]carbonyl}aniline (E372) acid
    N,N-Dimethyl-4-{[4-(4-{[3-(1- 4-(dimethyl 451
    piperidinyl)propyl]oxy}phenyl)-1- amino)benzoic
    piperazinyl]carbonyl}aniline (E373) acid
    1-(4-{[3-(1-Piperidinyl)propyl]oxy}phenyl)-4-{[4-(1- 4-(1-pyrrolidinyl 505
    pyrrolidinylcarbonyl)phenyl]carbonyl}piperazine carbonyl)benzoic
    (E374) acid
    (Journal of
    Medicinal
    Chemistry (2003),
    46(10), 1845-1857)
    • EXAMPLE 375 8-{[4-(4-{[3-(1-Piperidinyl)propyl]oxy}phenyl)-1-piperazinyl]carbonyl}quinoline (E375)
  • Figure US20100075953A1-20100325-C00275
  • A mixture of 8-quinolinecarboxylic acid (U.S. Pat. Appl. Publ., 20020045225, 18 Apr. 2002) (173 mg, 1 mmol), polymer bound N-cyclohexylcarbodiimide, N-methyl polystyrene HL (200-400 mesh) (526 mg of 1.9 mmol/g resin) and 1-hydroxybenzotriazole hydrate (135 mg, 1 mmol) in dichloromethane (5 ml) was stirred at room temperature for 30 minutes. 1-(4-{[3-(1-Piperidinyl)propyl]oxy}phenyl)piperazine (D11) (150 mg, 0.5 mmol) was added and stirring continued for 18 hours. The solvent was removed by evaporation and the residue purified on silica gel eluting with a mixture of 0.88 ammonia solution:methanol:dichloromethane (0.5:4.5:95) to furnish the title compound (93 mg, 41%) MS (ES+) m/e 459 [M+H]+.
    • EXAMPLES 376-431
  • E376 to E431 were prepared from 1-(4-{[3-(1-piperidinyl)propyl]oxy}phenyl)piperazine (D11) with the appropriate carboxylic acid indicated in the table below using the procedure of Example 375.
  • MS (ES+) m/e
    Compound Acid [M + H]+.
    1-(4-{[3-(1-Piperidinyl)propyl]oxy}phenyl)- 3-pyridinylacetic acid 423
    4-(3-pyridinylacetyl)piperazine
    (E377)
    6-Methyl-4-{[4-(4-{[3-(1-piperidinyl)propyl]oxy}phenyl)- 6-methyl-2-oxo-1,2-dihydro-4- 439
    1-piperazinyl]carbonyl}- pyridinecarboxylic acid
    2(1H)-pyridinone (E378)
    1-(4-{[3-(1-Piperidinyl)propyl]oxy}phenyl)- 2H-tetrazol-2-ylacetic acid 414
    4-(1H-tetrazol-1-
    ylacetyl)piperazine (E379)
    1-(4-{[3-(1-Piperidinyl)propyl]oxy}phenyl)- 4-(1H-pyrrol-1-yl)benzoic acid 473
    4-{[4-(1H-pyrrol-1-
    yl)phenyl]carbonyl}piperazine (E380)
    1-Acetyl-4-(4-{[3-(1-piperidinyl)propyl]oxy}phenyl)piperazine Acetic acid 346
    (E381)
    1-(4-{[3-(1-Piperidinyl)propyl]oxy}phenyl)- 4-(1H-1,2,3-triazol-1- 413
    4-(1H-1,2,3-triazol-1- yl)benzoic acid
    ylacetyl)piperazine (E382)
    1-{2-Oxo-2-[4-(4-{[3-(1-piperidinyl)propyl]oxy}phenyl)- (2-oxo-1(2H)-pyridinyl)acetic 439
    1-piperazinyl]ethyl}- acid (Tetrahedron Letters
    2(1H)-pyridinone (E383) (1998), 39(34), 6167-6170)
    6-{[4-(4-{[3-(1-Piperidinyl)propyl]oxy}phenyl)- 6-quinoxalinecarboxylic acid 460
    1-piperazinyl]carbonyl}quinoxaline
    (E384)
    5-{[4-(4-{[3-(1-Piperidinyl)propyl]oxy}phenyl)- 5-quinoxalinecarboxylic acid 460
    1-piperazinyl]carbonyl}quinoxaline
    (E385)
    1-(4-{[4-(4-{[3-(1-Piperidinyl)propyl]oxy}phenyl)- 4-acetylbenzoic acid 450
    1-piperazinyl]carbonyl}phenyl)ethanone
    (E386)
    1-[(Methylsulfonyl)acetyl]-4-(4-{[3-(1- (methylsulfonyl)acetic acid 424
    piperidinyl)propyl]oxy}phenyl)piperazine
    (E387)
    1-(4-{[3-(1-Piperidinyl)propyl]oxy}phenyl)- 1,3-thiazole-5-carboxylic acid 415
    4-(1,3-thiazol-5- (Izvestiya Akademii Nauk
    ylcarbonyl)piperazine (E388) SSSR, Seriya
    Khimicheskaya, (1), 132-6;
    1976)
    1-(5-Isothiazolylacetyl)-4-(4-{[3-(1- 5-isothiazolylacetic acid 429
    piperidinyl)propyl]oxy}phenyl)piperazine (Journal of Medicinal
    (E389) Chemistry (1967), 11(1), 70-3.)
    3-{[4-(4-{[3-(1-Piperidinyl)propyl]oxy}phenyl)- 1,2-benzisoxazole-3- 449
    1-piperazinyl]carbonyl}-1,2- carboxylic acid
    benzisoxazole (E390)
    1-(4-{[3-(1-Piperidinyl)propyl]oxy}phenyl)- 3-(1-pyrrolidinylcarbonyl)benzoic 505
    4-{[3-(1-pyrrolidinylcarbonyl)phenyl]carbonyl}piperazine acid (WO 0304468)
    (E391)
    2-{[4-(4-{[3-(1-Piperidinyl)propyl]oxy}phenyl)- 2-quinoxalinecarboxylic acid 460
    1-piperazinyl]carbonyl}quinoxaline (Organic Process Research &
    (E392) Development, 6(4), 477-481;
    2002)
    4-{[4-(4-{[3-(1-Piperidinyl)propyl]oxy}phenyl)- 4-quinolinecarboxylic acid 459
    1-piperazinyl]carbonyl}quinoline
    (E393)
    4-{[4-(4-{[3-(1-Piperidinyl)propyl]oxy}phenyl)- 6-cyano-3-pyridinecarboxylic 434
    1-piperazinyl]carbonyl}cinnoline acid (J. Am. Chem. Soc., 68,
    (E394) 1310-13; 1946)
    3-{[4-(4-{[3-(1- pyrazolo[1,5-a]pyrazine-3- 449
    Piperidinyl)propyl]oxy}phenyl)-1- carboxylic acid
    piperazinyl]carbonyl}pyrazolo[1,5-
    a]pyrimidine (E395)
    1-[(2-Chloro-6-methyl-4-pyridinyl)carbonyl]- 2-chloro-6-methyl-4- 458
    4-(4-{[3-(1-piperidinyl)propyl]oxy}phenyl)piperazine pyridinecarboxylic acid
    (E396)
    1-[(1-Methyl-1H-1,2,3-triazol-4- 1-methyl-1H-1,2,3-triazole-4- 413
    yl)carbonyl]-4-(4-{[3-(1-piperidinyl)propyl]oxy}phenyl)piperazine carboxylic acid
    (E397) (Journal of Organic Chemistry
    (1976), 41(6), 1041-51)
    2-{[4-(4-{[3-(1-Piperidinyl)propyl]oxy}phenyl)- 1,8-naphthyridine-2- 460
    1-piperazinyl]carbonyl}- carboxylic acid
    1,8-naphthyridine (E398)
    5-{[4-(4-{[3-(1-Piperidinyl)propyl]oxy}phenyl)- 1H-indole-5-carboxylic acid 447
    1-piperazinyl]carbonyl}-1H-
    indole (E399)
    2-{[4-(4-{[3-(1-Piperidinyl)propyl]oxy}phenyl)- 4-pyrimidinecarboxylic acid 410
    1-piperazinyl]carbonyl}pyrazine
    (E400)
    3-{[4-(4-{[3-(1-Piperidinyl)propyl]oxy}phenyl)- pyrazolo[1,5-a]pyridine-3- 448
    1-piperazinyl]carbonyl}pyrazolo[1, carboxylic acid
    5-a]pyridine (E401)
    1-(4-{[3-(1-Piperidinyl)propyl]oxy}phenyl)- 4-(1H-tetrazol-1-yl)benzoic 476
    4-{[4-(1H-tetrazol-1- acid
    yl)phenyl]carbonyl}piperazine (E402)
    1-(1-Benzofuran-2-ylcarbonyl)-4-(4-{[3- Benzofuran-2-carboxylic acid 448
    (1-piperidinyl)propyl]oxy}phenyl)piperazine
    (E403)
    1-(3-Isoxazolylcarbonyl)-4-(4-{[3-(1- 3-Isoxazolecarboxylic acid 399
    piperidinyl)propyl]oxy}phenyl)piperazine
    (E404)
    5-{[4-(4-{[3-(1-Piperidinyl)propyl]oxy}phenyl)- 2,1,3-Benzoxo-diazole-5- 450
    1-piperazinyl]carbonyl}-2,1,3- carboxylic acid
    benzoxadiazole (E405)
    1-(4-{[3-(1-Piperidinyl)propyl]oxy}phenyl)- 3-Thiopheneacetic acid 428
    4-(3-thienylacetyl)piperazine
    (E406)
    1-(4-{[3-(1-Piperidinyl)propyl]oxy}phenyl)- 1,2,3-Thiadiazole-4- 416
    4-(1,2,3-thiadiazol-4- carboxylic acid
    ylcarbonyl)piperazine (E407)
    4-{2-Oxo-2-[4-(4-{[3-(1- 4-Cyanobenzeneacetic acid 447
    piperidinyl)propyl]oxy}phenyl)-1- (WO 0247762)
    piperazinyl]ethyl}benzonitrile (E408)
    1-(2,3-Dihydro-1-benzofuran-7- 2,3-Dihydrobenzofuran-7- 450
    ylcarbonyl)-4-(4-{[3-(1-piperidinyl)propyl]oxy}phenyl)piperazine carboxylic acid
    (E409)
    1-[(1,1-Dioxidotetrahydro-2H-thiopyran- 1,1-dioxohexahydro-1lambda 464
    4-yl)carbonyl]-4-(4-{[3-(1-piperidinyl)propyl]oxy}phenyl)piperazine 6-thiopyran-4-carboxylic acid
    (E410)
    1-(4-{2-Oxo-2-[4-(4-{[3-(1-piperidinyl)propyl]oxy}phenyl)- 4-Acetylphenylacetic acid 464
    1-piperazinyl]ethyl}phenyl)ethanone (Chemical Communications,
    (E411) 2001, (20), 2147-2148)
    1-{[3,5-bis(Methyloxy)phenyl]carbonyl}- 3,5-Dimethoxybenzoic acid 468
    4-(4-{[3-(1-piperidinyl)propyl]oxy}phenyl)piperazine
    (E412)
    1-(2-Methyl-2-phenylpropanoyl)-4-(4- 2-Methyl-2-phenylpropionic 450
    {[3-(1-piperidinyl)propyl]oxy}phenyl)piperazine acid
    (E413)
    1-[(4-Methyl-1,2,3-thiadiazol-5- 4-Methyl-1,2,3-thiadiazole-5- 430
    yl)carbonyl]-4-(4-{[3-(1-piperidinyl)propyl]oxy}phenyl)piperazine carboxylic acid
    (E414)
    1-(5-{[4-(4-{[3-(1-Piperidinyl)propyl]oxy}phenyl)- 5-Acetylthiophene-2- 456
    1-piperazinyl]carbonyl}-2- carboxylic acid
    thienyl)ethanone (E415)
    4-{3-Oxo-3-[4-(4-{[3-(1- 4-Cyanobenzenepropionic 461
    piperidinyl)propyl]oxy}phenyl)-1- acid
    piperazinyl]propyl}benzonitrile (E416) (U.S. Pat. No. 5,726,159)
    3-{[4-(4-{[3-(1-Piperidinyl)propyl]oxy}phenyl)- 1,2-Benzisothiazole-3- 465
    1-piperazinyl]carbonyl}- carboxylic acid
    1,2-benzisothiazole (E417)
    (4-{[4-(4-{[3-(1-Piperidinyl)propyl]oxy}phenyl)- 2-cyanomethyl-thiazole-4- 454
    1-piperazinyl]carbonyl}- carboxylic acid (Bioorganic
    1,3-thiazol-2-yl)acetonitrile (E418) and Medicinal Chemistry
    Letters, 12; 4; 2002; 561-566)
    3-{2-Oxo-2-[4-(4-{[3-(1- 3-Cyanophenylacetic acid 447
    piperidinyl)propyl]oxy}phenyl)-1- (WO 0351797)
    piperazinyl]ethyl}benzonitrile (E419)
    (4-{[4-(4-{[3-(1-Piperidinyl)propyl]oxy}phenyl)- 4-(Cyanomethyl)benzoic acid 447
    1-piperazinyl]carbonyl}phenyl)acetonitrile
    (E420)
    1-(3,4-Dihydro-2H-chromen-6- 2H-1-Benzopyran-6- 464
    ylcarbonyl)-4-(4-{[3-(1-piperidinyl)propyl]oxy}phenyl)piperazine carboxylic acid, 3,4-dihydro-
    (E421) (Journal of Heterocyclic
    Chemistry 1994 31 (2) 457-79)
    6-{[4-(4-{[3-(1-Piperidinyl)propyl]oxy}phenyl)- Benzothiazole-6-carboxylic 465
    1-piperazinyl]carbonyl}- acid
    1,3-benzothiazole (E422)
    3,5-Difluoro-4-{[4-(4-{[3-(1-piperidinyl)propyl]oxy}phenyl)- 4-cyano-2,6-difluoro-benzoic 469
    1-piperazinyl]carbonyl}benzonitrile acid
    (E423) (U.S. Pat. No. 5,914,319)
    1-(4-{[3-(1-Piperidinyl)propyl]oxy}phenyl)- 2,4,6-Trifluorobenzoic acid 462
    4-[(2,4,6-trifluorophenyl)carbonyl]piperazine
    (E424)
    1-[3-(Methyloxy)propanoyl]-4-(4-{[3-(1- 3-Methoxypropionic acid 390
    piperidinyl)propyl]oxy}phenyl)piperazine
    (E425)
    1-[3-(2-Furanyl)propanoyl]-4-(4-{[3-(1- 3-(2-Furyl)propionic acid 426
    piperidinyl)propyl]oxy}phenyl)piperazine
    (E426)
    1-[(Methyloxy)acetyl]-4-(4-{[3-(1- Methoxyacetic acid 376
    piperidinyl)propyl]oxy}phenyl)piperazine
    (E427)
    1-[(3,5-Dimethyl-1H-1,2,4-triazol-1- (3,5-dimethyl-1H-1,2,4-triazol- 441
    yl)acetyl]-4-(4-{[3-(1-piperidinyl)propyl]oxy}phenyl)piperazine 1-yl)acetic acid
    (E428)
    1-[(3,5-Dimethyl-4-isoxazolyl)carbonyl]- 3,5-Dimethylisoxazole-4- 427
    4-(4-{[3-(1-piperidinyl)propyl]oxy}phenyl)piperazine carboxylic acid
    (E429)
    1-(4-{[3-(1-Piperidinyl)propyl]oxy}phenyl)- Tetrahydrothiopyran-4- 432
    4-(tetrahydro-2H-thiopyran-4- carboxylic acid
    ylcarbonyl)piperazine (E430) (Helvetica. Chimica. Acta.
    1997 80 (5) 1528-1554)
    1-[(1-Oxidotetrahydro-2H-thiopyran-4- 2H-Thiopyran-4-carboxylic 448
    yl)carbonyl]-4-(4-{[3-(1-piperidinyl)propyl]oxy}phenyl)piperazine acid, tetrahydro-, 1-oxide
    (E431) (Arkiv foer Kemi (1966),
    26(6), 73-7)
    • EXAMPLE 432 Methyl 4-{[4-(4-{[3-(1-piperidinyl)propyl]oxy}phenyl)-1-piperazinyl]carbonyl}benzoate (E432)
  • Figure US20100075953A1-20100325-C00276
  • Methyl 4-chlorocarbonylbenzoate (3.6 g, 18.12 mM) was added to a solution of 1-[4-(3-Piperidin-1-yl-propoxy)-phenyl]-piperazine (D11) (5 g, 16.48 mM) and triethylamine (2.53 ml, 18.12 mM) in dichloromethane (25 ml), and the resulting solution stirred at room temperature for 16 hours. A saturated aqueous solution of sodium bicarbonate (25 ml) was added to the reaction and stirred for 1 hour. The organic phase was separated, washed with water, dried over anhydrous sodium sulfate and evaporated in vacuo to afford the title compound (7.46 g); MS (ES+) m/e 466 [M+H]+.
    • EXAMPLE 433 4-{[4-(4-{[3-(1-Piperidinyl)propyl]oxy}phenyl)-1-piperazinyl]carbonyl}benzoic acid (E433)
  • Figure US20100075953A1-20100325-C00277
  • To a solution of methyl 4-{[4-(4-{[3-(1-piperidinyl)propyl]oxy}phenyl)-1-piperazinyl]carbonyl}benzoate (E432) (6.45 g, 13.86 mM) in a mixture of methanol:water (5:1) (90 ml) was added lithium hydroxide (365 mg, 15.24 mM) and the reaction stirred at room temperature for 3 days. Acetic acid (3.17 ml, 55.44 mM) was added and the reaction stirred for an additional 10 minutes. The solvent was evaporated in vacuo and the resulting residue dissolved in a mixture of methanol/dichloromethane (1:10) (20 ml), and purified using silica gel chromatography eluting with a mixture of 0.880 ammonia:methanol:dichloromethane (2:18:80) to afford the title compound (6.21 g); MS (ES+), m/e 452 [M+H]+.
    • EXAMPLE 434 1-{[4-(1-piperazinylcarbonyl)phenyl]carbonyl}-4-(4-{[3-(1-piperidinyl)propyl]oxy}phenyl)piperazine (E434)
  • Figure US20100075953A1-20100325-C00278
    • Step 1: 1,1-Dimethylethyl 4-[(4-{[4-(4-{[3-(1-piperidinyl)propyl]oxy}phenyl)-1-piperazinyl]carbonyl}phenyl)carbonyl]-1-piperazinecarboxylate
  • N-Cyclohexylcarbodiimide, N-methyl polystyrene HL (200-400 mesh) 1.9 mMol/g (530 mg, 1 mM) was suspended in dichloromethane (10 ml) and treated sequentially with 4-{[4-(4-{[3-(1-piperidinyl)propyl]oxy}phenyl)-1-piperazinyl]carbonyl}benzoic acid (E433) (225 mg, 1 mM), 1-hydroxybenzotriazole hydrate (135 mg, 1 mM) and tert-butyl 1-piperazinecarboxylate (93 mg, 0.5 mM) and stirred at room temperature for 16 hours. After filtration, the filtrate was applied to a Mega Bond elute SCX ion exchange column washing sequentially with water and methanol, followed by 0.880 ammonia:methanol (1:10) to elute the crude reaction mixture. Purification by silica gel chromatography eluting with a mixture of 0.880 ammonia:methanol:dichloromethane (0.5:4.5:95) to afford the title product (162 mg); MS (ES+), m/e 620 [M+H]+.
    • Step 2: 1-{[4-(1-piperazinylcarbonyl)phenyl]carbonyl}-4-(4-{[3-(1-piperidinyl)propyl]oxy}phenyl)piperazine
  • The title compound was prepared from the product of step 1 (162 mg, 0.26 mM) using the procedure detailed in description D11; MS (ES+), m/e 520 [M+H]+
    • EXAMPLES 435-445
  • E435 to E445 were prepared from 4-{[4-(4-{[3-(1-piperidinyl)propyl]oxy}phenyl)-1-piperazinyl]carbonyl}benzoic acid (E433) with the appropriate amine indicated in the table below using the procedure of Example 434 step 1.
  • MS (ES+) m/e
    Compound Amine [M + H]+.
    1-{[4-(1-Piperidinylcarbonyl)phenyl]carbonyl}-4-(4- Piperidine 519
    {[3-(1-piperidinyl)propyl]oxy}phenyl)piperazine
    (E435)
    4-[(4-{[4-(4-{[3-(1-Piperidinyl)propyl]oxy}phenyl)-1- Morpholine 521
    piperazinyl]carbonyl}phenyl)carbonyl]morpholine
    (E436)
    4-[(4-{[4-(4-{[3-(1-Piperidinyl)propyl]oxy}phenyl)-1- Thiomorpholine 537
    piperazinyl]carbonyl}phenyl)carbonyl]thiomorpholine
    (E437)
    1-({4-[(4-Methyl-1-piperidinyl)carbonyl]phenyl}carbonyl)- 4-Methyl 533
    4-(4-{[3-(1-piperidinyl)propyl]oxy}phenyl)piperazine piperidine
    (E438)
    N,N-Diethyl-4-{[4-(4-{[3-(1-piperidinyl)propyl]oxy}phenyl)- Diethylamine 507
    1-piperazinyl]carbonyl}benzamide (E439)
    N,N-Dimethyl-4-{[4-(4-{[3-(1-piperidinyl)propyl]oxy}phenyl)- Dimethylamine 479
    1-piperazinyl]carbonyl}benzamide (E440) 2M Solution in
    Tetrahydrofuran
    N-Cyclopentyl-4-{[4-(4-{[3-(1-piperidinyl)propyl]oxy}phenyl)- Cyclopentyl 519
    1-piperazinyl]carbonyl}benzamide (E441) amine
    1-{[4-(1-Azetidinylcarbonyl)phenyl]carbonyl}-4-(4- Azetidine 491
    {[3-(1-piperidinyl)propyl]oxy}phenyl)piperazine
    (E442)
    1-[(4-{[(3S)-3-Fluoro-1-pyrrolidinyl]carbonyl}phenyl)carbonyl]- (S)-3-Fluoro 523
    4-(4-{[3-(1-piperidinyl)propyl]oxy}phenyl)piperazine pyrrolidine
    (E443) WO 9108206
    1-{[4-({(2R)-2-[(Methyloxy)methyl]-1- (R)-2-(Methoxy 549
    pyrrolidinyl}carbonyl)phenyl]carbonyl}-4-(4-{[3-(1- methyl)pyrrolidine
    piperidinyl)propyl]oxy}phenyl)piperazine (E444)
    (3R)-1-[(4-{[4-(4-{[3-(1-Piperidinyl)propyl]oxy}phenyl)- (R)-(+)-3- 521
    1-piperazinyl]carbonyl}phenyl)carbonyl]-3- Pyrrolidinol
    pyrrolidinol (E445)
    • EXAMPLE 446 1-(3-Fluoro-4-{[3-(1-piperidinyl)propyl]oxy}phenyl)-4-(phenylcarbonyl)piperazine (E446)
  • Figure US20100075953A1-20100325-C00279
    • Step 1: 1-{3-[(4-Bromo-2-fluorophenyl)oxy]propyl}piperidine
  • 2-Fluoro-4-bromophenol (4.20 g, 22 mmol), 1-(3-chloropropyl)piperidine (3.96 g, 20 mmol), potassium carbonate (8.26 g, 60 mmol) and catalytic potassium iodide were heated at reflux for 24 hours in 2-butanone (100 ml). The solids were filtered, washed with acetone and concentrated in vacuo to a crude oil. The residue was purified on silica gel eluting with a mixture of ethyl acetate:hexane (0.7:0.3) and then ethyl acetate, to afford the title compound (5.71 g, 90%); MS (ES+) m/e 315/317 [M+H]+.
    • Step 2: 1,1-Dimethylethyl 4-(3-fluoro-4-{[3-(1-piperidinyl)propyl]oxy}phenyl)-1-piperazinecarboxylate
  • The product of step 1 (632 mg, 2 mmol), sodium tert-butoxide (538 mg, 5.6 mmol), tert-butyl 1-piperazinecarboxylate (894 mg, 4.8 mmol), tris(dibenzylidineacetone)dipalladium(0) (18 mg, 0.01 mmol) and tris(o-tolyl)phosphine (24 mg, 0.08 mmol) were heated at reflux in toluene (10 ml) for 16 hours. The solution was loaded directly on to a SCX ion exchange resin eluting with methanol and then a mixture of 0.88 ammonia solution:methanol (1:9). The basic fractions were evaporated and the residue purified by silica gel chromatography, eluting with a mixture of 0.880 ammonia:ethanol:dichloromethane (1:9:190) to afford the title compound (468 mg, 54%); MS (ES+) m/e 422 [M+H]+.
    • Step 3: 1-(3-Fluoro-4-{[3-(1-piperidinyl)propyl]oxy}phenyl)piperazine
  • The product of step 2 (468 mg, 1.1 mmol) was dissolved in 1:1 TFA:DCM (10 ml) at 0° C. and stirred to room temperature over 2 hours. The solution was concentrated in vacuo and co-evaporated three times with dichloromethane. The residue was passed through a SCX ion exchange resin eluting with methanol and then a mixture of 0.88 ammonia solution:methanol (1:9). The basic fractions were evaporated and the residue purified by silica gel chromatography, eluting with dichloromethane then a mixture of 0.880 ammonia:ethanol:dichoromethane (1:9:90) to afford the title compound (320 mg, 90%); MS (ES+) m/e 322 [M+H]+.
    • Step 4: 1-(3-Fluoro-4-{[3-(1-piperidinyl)propyl]oxy}phenyl)-4-(phenylcarbonyl)piperazine
  • The product of step 3 (320 mg, 1 mmol) and triethylamine (140 μL, 1 mmol) were dissolved in dichloromethane (5 ml), and treated with benzoyl chloride (115 μL, 1 mmol) added. The solution was stirred at room temperature overnight and concentrated in vacuo to a crude solid. The solid was purified by silica gel chromatography eluting with dichloromethane then a mixture of 0.880 ammonia:ethanol:dichoromethane (1:9:90) to afford the title compound (354 mg, 83%); MS (ES+) m/e 426 [M+H]+.
    • EXAMPLE 447 4-[4-(3-Piperidin-1-yl-propoxy)-naphthalen-1-yl]-piperazine-1-carboxylic acid tert-butyl ester (E447)
  • Figure US20100075953A1-20100325-C00280
    • Step 1: 4-Bromo-naphthalen-1-ol
  • 1-naphthol (1 g, 6.94 mmol) in acetonitrile (25 ml) was treated with N-bromosuccinimide (1.6 g, 9.01 mmol) and the mixture was stirred at room temperature for 3 hours. The solvent was removed in vacuo and the residue was purified by silica gel chromatography eluting with a mixture of hexane:ethyl acetate (0.9:1) to afford the title compound (0.85 g, 57%); MS (ES−) m/e 222 [M−H]−.
    • Step 2: 1-[3-(4-Bromo-naphthalen-1-yl oxy)-propyl]-piperidine
  • The product from step 1 (0.85 g, 3.83 mMol) in 2-Butanone (30 ml), was treated with 1-(3-Chloro-propyl)-piperidine (0.74 g, 4.59 mMol), potassium carbonate (1.2 g, 9.19 mMol), followed by potassium iodide (1.5 g, 9.19 mMol) and heated under reflux for 6 hours. After cooling to room temperature, the reaction mixture was treated with sodium thiosulphate (1M, 10 ml) the product was extracted into ethyl acetate, washed with water (×3), brine (×1), dried over magnesium sulphate and concentrated in vacuo. The residue was purified on silica gel eluting with a mixture of 0.88 ammonia solution:methanol:dichloromethane (0.5:4.5:95) to furnish the title compound (0.88 g, 68%); MS (ES+) m/e 350 [M+H]+.
    • Step 3: 4-[4-(3-Piperidin-1-yl-propoxy)-naphthalen-1-yl]-piperazine-1-carboxylic acid tert-butyl ester
  • Palladium bis-tert-butyl phosphine (0.033 g, 0.064 mmol) in ortho-xylene (20 ml) was treated with the product from step 2 (0.45 g, 1.28 mmol), piperazine-1-carboxylic acid tert-butyl ester (1.47 g, 7.67 mMol), followed by sodium tert-butoxide (0.17 g, 1.79 mMol) and heated at 120° C. for 2 hours. After cooling to room temperature the reaction mixture was diluted with ethyl acetate, washed with water (×3), brine (×1), dried over magnesium sulphate and concentrated in vacuo. The residue was purified on silica gel eluting with a mixture of 0.88 ammonia solution:methanol:dichloromethane (0.1:0.9:99) to furnish the title compound (0.40 g, 56%); MS (ES+) m/e 454 [M+H]+.
    • EXAMPLE 448 4-(1-{4-[4-(3-Piperidin-1-yl-propoxy)-naphthalen-1-yl]-piperazin-1-yl}-methanoyl)-benzonitrile (E448)
  • Figure US20100075953A1-20100325-C00281
    • Step 1: 1-[4-(3-Piperidin-1-yl-propoxy)-naphthalene-1-yl]-piperazine
  • A solution of the product from Examples 447, step 3 (0.40 g, 0.89 mmol) in anhydrous dichloromethane (5 ml) was treated with trifluoroacetic acid (10 ml), and stirred at room temperature for 1 hour. The solvent was removed in vacuo, dissolved in methanol and applied to a SCX ion exchange column and eluted with methanol and then a mixture of methanol:0.880 ammonia (9:1). The basic fractions were then reduced and the residue was purified on silica gel eluting with a mixture of 0.88 ammonia solution:methanol:dichloromethane (1:9:90) to furnish the title compound (0.23 g, 73%); MS (ES+) m/e 354 [M+H]+.
    • Step 2: 4-(1-{4-[4-(3-Piperidin-1-yl-propoxy)-naphthalen-1-yl]-piperazin-1-yl}-methanoyl)-benzonitrile
  • The title compound was prepared from the product of Step 1 (0.13 g, 0.37 mmol) and 4-cyanobenzoic acid (0.11 g, 0.74 mmol) according the procedure detailed in Example 375 (0.17 g, 99%); MS (ES+) m/e 483 [M+H]+.
    • EXAMPLE 449 1-Phenyl-1-{4-[4-(3-piperidin-1-yl-propoxy)-phenyl-[1,4]diazepan-1-yl}-methanone (E449)
  • Figure US20100075953A1-20100325-C00282
    • Step 1: 4-[4-(3-Piperidin-1-yl-propoxy)-phenyl]-[1,4]diazepane-1-carboxylic acid tert butyl ester
  • A mixture of the product from Example 316, step 1 (1-[3-(4-Iodo-phenoxy)-propyl]-piperidine) (2 g, 5.8 mMol), [1,4] Diazepane-1-carboxylic acid tert butyl ester (2.7 g. 13.9 mMol), tris(dibenzylidenacetone) dipalladium(0) (0.03 g, 0.03 mMol), tri-ortho-tolyl-phosphane (0.04 g, 0.02 mMol) in dioxane (20 ml) was heated at reflux for 20 hours. After cooling to room temperature the reaction mixture was diluted with ethyl acetate, washed with water (×3), brine (×1), dried over magnesium sulphate and concentrated in vacuo. The residue was purified by column chromatography eluting with a mixture of 0.88 ammonia solution:methanol:dichloromethane (0.1:0.9:99) to furnish the title compound (0.61 g, 25%);
  • MS (ES+) m/e 418 [M+H]+.
    • Step 2: 1-[4-(3-Piperidin-1-yl-propoxy)-phenyl]-[1,4]diazepane
  • The title compound was prepared from the product of step 1 (162 mg, 0.26 mM) using the procedure detailed in description D11; MS (ES+) m/e 318 [M+H]+.
    • Step 3: 1-Phenyl-1-{4-[4-(3-piperidin-1-yl-propoxy)-phenyl-[1,4]diazepan-1-yl}-methanone
  • The title compound was prepared from the product of step 2 (0.09 g, 0.29 mmol) and benzoic acid (0.71 g, 0.58 mmol) using the procedure detailed in Example 375 (0.12 g, 95%); MS (ES+) m/e 422 [M+H]+.
    • EXAMPLES 450-453
  • E450 to E453 were prepared from Example 449 step 2 with the appropriate carboxylic acids indicated in the table below using the procedure detailed in Example 375.
  • Carboxylic MS (ES+) m/e
    Compound Acid [M + H]+.
    3-(1-{4-[4-(3-Piperidin-1-yl-propoxy)-phenyl]-[1,4]diazepan- 3-Cyano- 447
    1-yl}-methanoyl)-benzonitrile (E450) benzoic acid
    1-Cyclopropyl-1-{4-[4-(3-piperidin-1-yl-propoxy)- Cyclopropane 386
    phenyl]-[1,4]-diazepan-1-yl}-methanone (E451) carboxylic acid
    1-(4-Fluoro-phenyl)-1-{4-[4-(3-piperidin-yl-propoxy)- 4-Fluoro- 440
    phenyl]-[1,4]-diazepan-1-yl}-methanone (E452) benzoic acid
    1-{4-[4-(3-Piperidin-1-yl-propoxy)-phenyl]-[1,4]diazepan- Thiophene-2- 428
    1-yl}-1-thiopheny-2-yl-methanone (E453) carboxylic acid
    • EXAMPLE 454 4-(1-{(2S,5R)-2,5-Dimethyl-4-[4-(3-piperidin-1-yl-propoxy)-phenyl]-piperazin-1-yl}-methanoyl)-benzonitrile (E454)
  • Figure US20100075953A1-20100325-C00283
    • Step 1: (2R,5S)-2,5-Dimethyl-1-[4-(3-piperidin-1-yl-propoxy)-phenyl]-piperazine
  • A mixture of 2,2′-Bis(diphenylphosphino)-1,′-binaphthyl (0.068 g, 0.109 mmol) and palladium acetate (0.016 g, 0.072 mmol) in toluene (5 ml) were heated to 80° C. To this was added the product from example 316, step 1 (1-[3-(4-iodo-phenoxy)-propyl]-piperidine) (0.5 g, 1.45 mmol) pre-dissolved in toluene (5 ml), (2S,5R)-2,5-dimethyl-piperazine (0.20 g 1.74 mmol) predissolved in toluene (5 ml), followed by sodium tert-butoxide (0.20 g, 2.02 mmol). The mixture was heated at 100° C. for 6 hours. After cooling to room temperature the reaction mixture was diluted with ethyl acetate, washed with water (×3), brine (×1), dried over magnesium sulphate and concentrated in vacuo. The residue was purified on silica gel eluting with a mixture of 0.88 ammonia solution:methanol:dichloromethane (0.5:4.5:95) to furnish the title compound (0.98 g, 20%); MS (ES+) m/e 332 [M+H]+.
    • Step 2: 4-(1-{(2S,5R)-2,5-Dimethyl-4-[4-(3-piperidin-1-yl-propoxy)-phenyl]-piperazin-1-yl}-methanoyl)-benzonitrile
  • The title compound was prepared from the product of step 1 (0.13 g, 0.38 mmol) and 4-cyanobenzoic acid (0.11 g, 0.76 mol) using the procedure detailed in Example 375, (0.097 g, 57%); MS (ES+) m/e 461 [M+H]+.
    • EXAMPLES 455-458
  • E455 to E458 were prepared from Example 454 step 1 with the appropriate carboxylic acids indicated in the table below using the procedure detailed in Example 375.
  • MS (ES+) m/e
    Compound Carboxylic Acid [M + H]+.
    1-{(2R,5R)-2,5-Dimethyl-4-[4-(3-piperidin-1-yl- Benzoic acid 436
    propoxy)-phenyl]-piperazin-1-yl}-1-phenyl-
    methanone (E455)
    1-{(2R,5R)-2,5-Dimethyl-4-[4-(3-piperidin-1-yl- Isonicotinic acid 437
    propoxy)-phenyl]-piperazin-1-yl}-1-pyridin-4-
    yl-methanone (E456)
    1-{(2R,5R)-2,5-Dimethyl-4-[4-(3-piperidin-1-yl- 4-(1-Pyrrolidin-1-yl- 534
    propoxy)-phenyl]-piperazin-1-yl}-1-[4-(1- methanoyl)-benzoic
    pyrrolidin-1-yl-methanoyl)-phenyl]-methanone acid (J. Med. Chem.,
    (E457) 2003, 46(10), 1845-1857)
    1-{(2R,5R)-2,5-Dimethyl-4-[4-(3-piperidin-1-yl- tetrahydro-pyran-4- 444
    propoxy)-phenyl]-piperazin-1-yl}-1- carboxylic acid
    (tetrahydro-pyran-4-yl)-methanone (E458)
    • EXAMPLE 459 1-{(2R,5R)-2,5-Dimethyl-4-[4-(3-piperidin-1-yl-propoxy)-phenyl]-piperazin-1-yl}-1-morpholin-4-yl-methanone (E459)
  • Figure US20100075953A1-20100325-C00284
  • A mixture of the product from Example 454 step 1 (0.20 g, 0.60 mol), 4-morpholine carbonyl chloride (0.082 g, 0.55 mol), triethylamine (0.067 g, 0.66 mol) in dichloromethane (8 ml) was stirred at room temperature for 18 hours. The mixture was filtered through am SCX column eluting with methanol followed by 0.880 ammonia solution:methanol (1:9) to afford the title compound (0.18 g, 66%); MS (ES+) m/e 445 [M+H]+.
    • EXAMPLE 460 4-(1-{5-[4-(3-Piperidin-1-yl-propoxy)-phenyl]-2,5-diaza-bicyclo[2.2.1] hept-2-yl}-methanoyl)benzonitrile (E460)
  • Figure US20100075953A1-20100325-C00285
    • Step 1: 5-[4-(3-Piperidin-1-yl-propoxy)-phenyl]-2,5-diaza-bicyclo[2.2.1] heptane-carboxylic acid tert butyl ester
  • The title compound was prepared from example 316, step 1 (1-[3-(4-Iodo-phenoxy)-propyl]-piperidine) (0.25 g, 0.72 mmol) and 2,5-Diaza-bicyclo[2.2.1] heptane carboxylic acid tert butyl ester (0.17 g 0.87 mmol) using the procedure described for example 454, step 1(0.313 g, 84%); MS (ES+) m/e 416 [M+H]+.
    • Step 2: 2-[4-(3-Piperidin-1-yl-propoxy)-phenyl]-2,5-diaza-bicyclo[2.2.1] heptane
  • The title compound was prepared from the product of step 1 (0.31 g, 0.75 mmol) using the procedure detailed in description D11; MS (ES+) m/e 316 [M+H]+.
    • Step 3: 4-(1-{5-[4-(3-Piperidin-1-yl-propoxy)-phenyl]-2,5-diaza-bicyclo[2.2.1] hept-2-yl}-methanoyl)benzonitrile
  • The title compound was prepared from the product of step 2 (0.23 g, 0.73 mmol) and 4-cyanobenzoic acid (0.21 g, 1.45 mmol) using the procedure detailed in Example 375, (0.27 g, 83%); MS (ES+) m/e 445 [M+H]+.
    • EXAMPLE 461 4-(1-{4-[2-Chloro-4-(3-piperidin-1-yl-propoxy)-phenyl]-piperazin-1-yl}-methanoyl)-benzonitrile (E461)
  • Figure US20100075953A1-20100325-C00286
    • Step 1: 1-[3-(4-Bromo-3-chloro-phenoxy)-propyl]-piperidine
  • The title compound was prepared from 1-(3-Chloropropyl)piperidine hydrochloride (2.38 g, 12 mmol) and 4-bromo-3-chloro-phenol (2.07 g, 10 mmol) using the procedure detailed in Example 305, step 2, (3.42 g); MS (ES+) m/e 333 [M+H]+.
    • Step 2: 4-[2-Chloro-4-(3-piperidin-1-yl-propoxy)-phenyl]-piperazine-1-carboxylic acid tert-butyl ester
  • The title compound was prepared from the product of step 1 (0.6 g, 1.8 mmol) and 1,1-dimethylethyl 1-piperazinecarboxylate (0.40 g, 2.14 mmol) using the procedure detailed in Example 305, step 3 (0.46 g); MS (ES+) m/e 439 [M+H]+.
    • Step 3: 1-[2-Chloro-4-(3-piperidin-1-yl-propoxy)-phenyl]-piperazine
  • The title compound was prepared from the product of step 2 using the procedure of Example 295 Step 5 (0.240 g); MS (ES+) m/e 338 [M+H]+
    • Step 4: 4-(1-{4-[2-Chloro-4-(3-piperidin-1-yl-propoxy)-phenyl]-piperazin-1-yl}-methanoyl)-benzonitrile
  • The title compound was prepared from the product of step 3 (0.120 g, 0.36 mmol) and 4-Cyanobenzoic acid (105 mg, 0.712 mmol) using the procedure of Example 305 Step 5 (0.130 g); MS (ES+) m/e 468 [M+H]
    • EXAMPLE 462 1-Phenyl-1-{4-[4-(3-pyrrolidin-1-yl-propoxy)-phenyl]-piperazin-1-yl}-methanone (E462)
  • Figure US20100075953A1-20100325-C00287
    • Step 1: 1-{4-[4-(3-Chloro-propoxy)-phenyl]-piperazin-1-yl}-1-phenyl-methanone
  • The title compound was prepared from the product of Example 295, Step 3 (4-[4-(phenylcarbonyl)-1-piperazinyl]phenol) (1 g, 3.55 mmol) and 1-bromo-3-chloro propane (0.67 g, 4.25 mmol) using the procedure of Description 9 (1.3 g); MS (ES+) m/e 359 [M+H].
    • Step 2: 1-Phenyl-1-{4-[4-(3-pyrrolidin-1-yl-propoxy)-phenyl]-piperazin-1-yl}-methanone
  • The title compound was prepared from the product of step 1 (0.2 g, 0.56 mmol) and pyrrolidine (0.047 g, 0.67 mmol) using the procedure of Description 10 (0.15 g); MS (ES+) m/e 394 [M+H].
    • EXAMPLES 463-464
  • E463 to E464 were prepared from Example 462 step 1 with the appropriate amine indicated in the table below using the procedure detailed in Description 10.
  • MS
    (ES+)
    m/e
    Example Carboxylic Acid [M + H]+.
    1-(4-{4-[3-(3,3-Difluoro- 3,3-difluoro-pyrrolidine 430
    pyrrolidin-1-yl)-propoxy]- (Synlett, 1995, 1, 55-57)
    phenyl}-piperazin-
    1-yl)-1-phenyl-methanone (E463)
    1-(4-{4-[3-(4,4-Difluoro-piperidin- 4,4-Difluoro-piperidine 444
    1-yl)-propoxy]-phenyl}-piperazin- (Tetrahedron, 1977,
    1-yl)-1-phenyl-methanone (E464) 33(14), 1707-1710)
    • EXAMPLE 465 1-(1-Naphthalenylcarbonyl)-4-[2-(4-{[3-(1-piperidinyl)propyl]oxy}phenyl)ethyl]piperazine, formate (E465)
  • Figure US20100075953A1-20100325-C00288
    • E465a: 1-(1-Naphthalenylcarbonyl)-4-(2-{4-[(phenylmethyl)oxy]phenyl}ethyl) piperazine
  • Figure US20100075953A1-20100325-C00289
  • A mixture of 1-(2-bromoethyl)-4-[(phenylmethyl)oxy]benzene (533 mg) and 1-(1-naphthalenylcarbonyl)piperazine (440 mg) was partially dissolved in 1-methyl-2-pyrrolidinone (2 ml) and treated with diisopropylethylamine (0.956 ml). The resulting reaction mixture was heated in a microwave oven at 160° C. for a fixed hold time of 12 min. The mixture was partitioned between ethyl acetate and water and the organic phase was washed with water and saturated brine, dried (MgSO4) and evaporated. The residue was loaded on to an SCX-2 SPE cartridge, which was eluted with methanol followed by 2M methanolic ammonia. The methanolic ammonia fraction was evaporated, and the residue was further purified by chromatography on a silica SPE bond elut cartridge eluting with 3% methanol-1% triethylamine-dichloromethane to give the title compound (583 mg). LCMS RT=2.79 min.
    • E465b: 4-{2-[4-(1-Naphthalenylcarbonyl)-1-piperazinyl]ethyl}phenol
  • Figure US20100075953A1-20100325-C00290
  • 1-(1-Naphthalenylcarbonyl)-4-(2-{4-[(phenylmethyl)oxy]phenyl}ethyl)piperazine (E465a) (2.33 g) and 20% palladium hydroxide on carbon (800 mg) in ethanol (50 ml) were stirred at room temperature under an atmospheric pressure of hydrogen. After 24 h more palladium catalyst (800 mg) was added and stirring continued for an additional 72 h. The reaction mixture was filtered through celite, washed with ethanol and the filtrate and washings combined and evaporated under vacuum to give the title compound (1.84 g). LCMS RT=2.20 min.
    • E465c: 1-(2-{4-[(3-Chloropropyl)oxy]phenyl}ethyl)-4-(1-naphthalenylcarbonyl) piperazine
  • Figure US20100075953A1-20100325-C00291
  • 4-{2-[4-(1-Naphthalenylcarbonyl)-1-piperazinyl]ethyl}phenol (E465b) (500 mg), 1-bromo-3-chloropropane (0.165 ml) and potassium carbonate (481 mg) in 2-butanone (25 ml) were heated to reflux for 18 h. More 1-bromo-3-chloropropane (0.165 ml) was added and heating continued for 6 h. The reaction mixture was partitioned between ethyl acetate and water. The aqueous phase was re-extracted with ethyl acetate and the combined organic extracts were washed with saturated brine, dried (MgSO4) and evaporated. The crude material was purified by chromatography on a silica SPE bond elut cartridge eluting with cyclohexane followed by a gradient of 0-5% methanol-dichloromethane-1% triethylamine to give the title compound (582 mg). LCMS RT=2.67.
    • E465d: 1-(1-Naphthalenylcarbonyl)-4-[2-(4-{[3-(1-piperidinyl)propyl]oxy}phenyl)ethyl]piperazine, formate
  • 1-(2-{4-[(3-Chloropropyl)oxy]phenyl}ethyl)-4-(1-naphthalenylcarbonyl)piperazine (E465c) (50 mg), potassium carbonate (95 mg), potassium iodide (95 mg) and piperidine (0.067 ml) in 2-butanone (2 ml) were heated to reflux for 24 h. The reaction mixture was partitioned between dichloromethane and water. The aqueous layer was re-extracted and the combined organic extracts were concentrated and purified by mass directed preparative HPLC to give the title compound (42 mg). LCMS RT=2.02 min. ES+ve m/z 486 (M+H)+.
    • EXAMPLES 466-474 EXAMPLES 466-474 WERE PREPARED IN AN ARRAY FORMAT USING THE SAME METHOD described in Example 465d from 1-(2-{4-[(3-chloropropyl)oxy]phenyl}ethyl)-4-(1-naphthalenylcarbonyl)piperazine (0.114 mmol), the appropriate secondary amine (6 eq), potassium carbonate (6 eq) and potassium iodide (5 eq) in 2-butanone (2 ml). The products were purified by mass directed auto-preparative HPLC to provide the compounds as formate salts.
  • RT Mass Ion
    Example Structure (min) (M + H)+
    466
    Figure US20100075953A1-20100325-C00292
         		2.09 500
    467
    Figure US20100075953A1-20100325-C00293
         		2.07 500
    468
    Figure US20100075953A1-20100325-C00294
         		2.13 514
    469
    Figure US20100075953A1-20100325-C00295
         		2.08 500
    470
    Figure US20100075953A1-20100325-C00296
         		2.00 472
    471
    Figure US20100075953A1-20100325-C00297
         		2.06 500
    472
    Figure US20100075953A1-20100325-C00298
         		2.18 514
    473
    Figure US20100075953A1-20100325-C00299
         		2.19 514
    474
    Figure US20100075953A1-20100325-C00300
         		2.28 528
    • EXAMPLE 475 1-(1-Naphthalenylcarbonyl)-4-[2-(4-{[2-(1-piperidinyl)ethyl]oxy}phenyl)ethyl]piperazine (E475)
  • Figure US20100075953A1-20100325-C00301
    • E475a: 1-(2-{4-[(2-Chloroethyl)oxy]phenyl}ethyl)-4-(1-naphthalenylcarbonyl)piperazine
  • Figure US20100075953A1-20100325-C00302
  • Was prepared from 4-{2-[4-(1-naphthalenylcarbonyl)-1-piperazinyl]ethyl}phenol and 1-bromo-2-chloroethane using the same method as described in Example 465c. LCMS RT 2.52 min.
    • E475b: 1-(1-Naphthalenylcarbonyl)-4-[2-(4-{[2-(1-piperidinyl)ethyl]oxy}phenyl)ethyl]piperazine
  • 1-(2-{4-[(2-Chloroethyl)oxy]phenyl}ethyl)-4-(1-naphthalenylcarbonyl)piperazine (E475a) (23 mg) potassium carbonate (45 mg), potassium iodide (45 mg) and piperidine (0.032 ml) in 2-butanone (2 ml) were heated to reflux for 48 h. The reaction mixture was partitioned between dichloromethane and water. The aqueous layer was re-extracted and the combined organic extracts were concentrated and purified by mass directed preparative HPLC to give the title compound (9.9 mg). LCMS RT=1.97 min. ES+ve m/z 472 (M+H)+.
    • EXAMPLES 476-479
  • Examples 476-479 were prepared in an array format using the same method described in Example 465d from 1-(2-{4-[(2-chloroethyl)oxy]phenyl}ethyl)-4-(1-naphthalenylcarbonyl)piperazine (0.0544 mmol), the appropriate secondary amine (6 eq), potassium carbonate (6 eq) and potassium iodide (5 eq) in 2-butanone (2 ml). The products were purified by mass directed auto-preparative HPLC to provide the compounds as formate salts.
  • RT Mass Ion
    Example Structure (min) (M + H)+
    476
    Figure US20100075953A1-20100325-C00303
         		2.08 486
    477
    Figure US20100075953A1-20100325-C00304
         		2.13 500
    478
    Figure US20100075953A1-20100325-C00305
         		2.10 486
    479
    Figure US20100075953A1-20100325-C00306
         		1.98 486
    • EXAMPLES 480-499
  • Examples 480-499 were prepared in an analogous manner to the procedure described for Example 62
  • RT Mass Ion
    Example Structure (min) (M + H)+
    480
    Figure US20100075953A1-20100325-C00307
         		2.36 505
    481
    Figure US20100075953A1-20100325-C00308
         		2.24 464
    482
    Figure US20100075953A1-20100325-C00309
         		2.54 547
    483
    Figure US20100075953A1-20100325-C00310
         		2.61 561
    484
    Figure US20100075953A1-20100325-C00311
         		2.59 574
    485
    Figure US20100075953A1-20100325-C00312
         		2.32 524
    486
    Figure US20100075953A1-20100325-C00313
         		2.42 520
    487
    Figure US20100075953A1-20100325-C00314
         		2.43 588
    488
    Figure US20100075953A1-20100325-C00315
         		2.20 538
    489
    Figure US20100075953A1-20100325-C00316
         		2.32 534
    490
    Figure US20100075953A1-20100325-C00317
         		2.24 510
    491
    Figure US20100075953A1-20100325-C00318
         		2.36 519
    492
    Figure US20100075953A1-20100325-C00319
         		2.33 532
    493
    Figure US20100075953A1-20100325-C00320
         		2.07 482
    494
    Figure US20100075953A1-20100325-C00321
         		2.24 478
    495
    Figure US20100075953A1-20100325-C00322
         		2.20 496
    496
    Figure US20100075953A1-20100325-C00323
         		2.50 546
    497
    Figure US20100075953A1-20100325-C00324
         		2.38 492
    498
    Figure US20100075953A1-20100325-C00325
         		2.42 492
    499
    Figure US20100075953A1-20100325-C00326
         		2.40 546
    • EXAMPLE 500 1-Phenyl-4-{2-[4-(3-piperidin-1-ylpropoxy)phenyl]ethyl}piperazine trifluoroacetate (E500)
  • Figure US20100075953A1-20100325-C00327
  • The title compound was prepared from D42 using the procedure described in Example 229d.
  • RT=1.86 min, ES+ve m/z 408
    • EXAMPLE 501 1-(5-tert-Butyl-2-methoxybenzoyl)-4-[4-(3-piperidin-1-ylpropoxy)phenyl]piperazine (E501)
  • Figure US20100075953A1-20100325-C00328
  • The title compound was prepared from D11 using the procedure described in Example 76c. RT=2.61 min, ES+ve m/z 494
    • EXAMPLE 502 1-(3-{4-[4-(5-Isopropyl-2-methylbenzoyl)piperazin-1-yl]phenoxy}propyl)azepane (E502)
  • Figure US20100075953A1-20100325-C00329
    • E502a: 1-[3-(4-piperazin-1-ylphenoxy)propyl]azepane
  • The title compound was prepared using an analogous method to that described in Example 76b.
  • RT=1.42 min, ES+ve m/z 318
    • E502b: 1-(3-{4-[4-(5-Isopropyl-2-methylbenzoyl)piperazin-1-yl]phenoxy}propyl)azepane
  • The title compound was prepared from E502a using the procedure described in Example 76c. RT=2.65 min, ES+ve m/z 478
    • EXAMPLE 503 1-(3-{4-[4-(5-Ethyl-2-methylbenzoyl)piperazin-1-yl]phenoxy}propyl)azepane (E503)
  • Figure US20100075953A1-20100325-C00330
  • The title compound was prepared from E502a using the procedure described in Example 76c.
  • RT=2.57 min, ES+ve m/z 464
  • All publications, including but not limited to patents and patent applications, cited in this specification are herein incorporated by reference as if each individual publication were specifically and individually indicated to be incorporated by reference herein as though fully set forth.
    • Biological Data
  • A membrane preparation containing histamine H3 receptors may be prepared in accordance with the following procedures:
    • (i) Generation of Histamine H3 Cell Line
  • DNA encoding the human histamine H3 gene (Huvar, A. et al. (1999) Mol. Pharmacol. 55(6), 1101-1107) was cloned into a holding vector, pcDNA3.1 TOPO (InVitrogen) and its cDNA was isolated from this vector by restriction digestion of plasmid DNA with the enzymes BamH1 and Not-1 and ligated into the inducible expression vector pGene (InVitrogen) digested with the same enzymes. The GeneSwitch™ system (a system where in transgene expression is switched off in the absence of an inducer and switched on in the presence of an inducer) was performed as described in U.S. Pat. Nos. 5,364,791; 5,874,534; and 5,935,934. Ligated DNA was transformed into competent DH5α E. coli host bacterial cells and plated onto Luria Broth (LB) agar containing Zeocin™ (an antibiotic which allows the selection of cells expressing the sh ble gene which is present on pGene and pSwitch) at 50 μg ml−1. Colonies containing the re-ligated plasmid were identified by restriction analysis. DNA for transfection into mammalian cells was prepared from 250 ml cultures of the host bacterium containing the pGeneH3 plasmid and isolated using a DNA preparation kit (Qiagen Midi-Prep) as per manufacturers guidelines (Qiagen).
  • CHO K1 cells previously transfected with the pSwitch regulatory plasmid (InVitrogen) were seeded at 2×10e6 cells per T75 flask in Complete Medium, containing Hams F12 (GIBCOBRL, Life Technologies) medium supplemented with 10% v/v dialysed foetal bovine serum, L-glutamine, and hygromycin (100 μg ml−1), 24 hours prior to use. Plasmid DNA was transfected into the cells using Lipofectamine plus according to the manufacturer's guidelines (InVitrogen). 48 hours post transfection cells were placed into complete medium supplemented with 500 μg ml−1 Zeocin™.
  • 10-14 days post selection 10 nM Mifepristone (InVitrogen), was added to the culture medium to induce the expression of the receptor. 18 hours post induction cells were detached from the flask using ethylenediamine tetra-acetic acid (EDTA; 1:5000; InVitrogen), following several washes with phosphate buffered saline pH 7.4 and resuspended in Sorting Medium containing Minimum Essential Medium (MEM), without phenol red, and supplemented with Earles salts and 3% Foetal Clone II (Hyclone). Approximately 1×10e7 cells were examined for receptor expression by staining with a rabbit polyclonal antibody, 4a, raised against the N-terminal domain of the histamine H3 receptor, incubated on ice for 60 minutes, followed by two washes in sorting medium. Receptor bound antibody was detected by incubation of the cells for 60 minutes on ice with a goat anti rabbit antibody, conjugated with Alexa 488 fluorescence marker (Molecular Probes). Following two further washes with Sorting Medium, cells were filtered through a 50 μm Filcon™ (BD Biosciences) and then analysed on a FACS Vantage SE Flow Cytometer fitted with an Automatic Cell Deposition Unit. Control cells were non-induced cells treated in a similar manner. Positively stained cells were sorted as single cells into 96-well plates, containing Complete Medium containing 500 μg ml−1 Zeocin™ and allowed to expand before reanalysis for receptor expression via antibody and ligand binding studies. One clone, 3H3, was selected for membrane preparation.
  • (ii) Membrane Preparation from Cultured Cells
  • All steps of the protocol are carried out at 4° C. and with pre-cooled reagents. The cell pellet is resuspended in 10 volumes of buffer A2 containing 50 mM N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid (HEPES) (pH 7.40) supplemented with 10e-4M leupeptin (acetyl-leucyl-leucyl-arginal; Sigma L2884), 25 μg/ml bacitracin (Sigma B0125), 1 mM ethylenediamine tetra-acetic acid (EDTA), 1 mM phenylmethylsulfonyl fluoride (PMSF) and 2×10e-6M pepstain A (Sigma). The cells are then homogenised by 2×15 second bursts in a 1 litre glass Waring blender, followed by centrifugation at 500 g for 20 minutes. The supernatant is then spun at 48,000 g for 30 minutes. The pellet is resuspended in 4 volumes of buffer A2 by vortexing for 5 seconds, followed by homogenisation in a Dounce homogeniser (10-15 strokes). At this point the preparation is aliquoted into polypropylene tubes and stored at −70° C.
  • (iii) Generation of Histamine H1 Cell Line
  • The human H1 receptor was cloned using known procedures described in the literature [Biochem. Biophys. Res. Commun. 1994, 201(2), 894]. Chinese hamster ovary cells stably expressing the human H1 receptor were generated according to known procedures described in the literature [Br. J. Pharmacol. 1996, 117(6), 1071].
  • Compounds of the invention may be tested for in vitro biological activity in accordance with the following assays:
    • (I) Histamine H3 Binding Assay
  • For each compound being assayed, in a white walled clear bottom 96 well plate, is added:—
  • (a) 100 μl of test compound (or 100 of iodophenpropit (a known histamine H3 antagonist) at a final concentration of 10 mM) diluted to the required concentration in 10% DMSO;
    (b) 100 μl 125I 4-[3-(4-iodophenylmethoxy)propyl]-1H-imidazolium (iodoproxyfan) (Amersham; 1.85 MBq/μl or 50 μCi/ml; Specific Activity ˜2000 Ci/mmol) diluted to 200 pM in assay buffer (50 mM Tris(hydroxymethyl)aminomethane buffer (TRIS) pH 7.4, 0.5 mM ethylenediamine tetra-acetic acid (EDTA)) to give 20 pM final concentration; and
    (c) 800 bead/membrane mix prepared by suspending Scintillation Proximity Assay (SPA) bead type WGA-PVT at 100 mg/ml in assay buffer followed by mixing with membrane (prepared in accordance with the methodology described above) and diluting in assay buffer to give a final volume of 800 which contains 7.5 μg protein and 0.25 mg bead per well-mixture was pre-mixed at room temperature for 60 minutes on a roller.
  • The plate is shaken for 5 minutes and then allowed to stand at room temperature for 3-4 hours prior to reading in a Wallac Microbeta counter on a 1 minute normalised tritium count protocol. Data was analysed using a 4-parameter logistic equation.
    • (II) Histamine H3 Functional Antagonist Assay
  • For each compound being assayed, in a white walled clear bottom 96 well plate, is added:—
  • (a) 100 of test compound (or 100 of guanosine 5′-triphosphate (GTP) (Sigma) as non-specific binding control) diluted to required concentration in assay buffer (20 mM N-2-Hydroxyethylpiperazine-N′-2-ethanesulfonic acid (HEPES)+100 mM NaCl+10 mM MgCl2, pH7.4 NaOH);
    (b) 600 bead/membrane/GDP mix prepared by suspending wheat germ agglutinin-polyvinyltoluene (WGA-PVT) scintillation proximity assay (SPA) beads at 100 mg/ml in assay buffer followed by mixing with membrane (prepared in accordance with the methodology described above) and diluting in assay buffer to give a final volume of 600 which contains 10′4 protein and 0.5 mg bead per well-mixture is pre-mixed at 4° C. for 30 minutes on a roller and just prior to addition to the plate, 10 μM final concentration of guanosine 5′ diphosphate (GDP) (Sigma; diluted in assay buffer) is added;
  • The plate is incubated at room temperature to equilibrate antagonist with receptor/beads by shaking for 30 minutes followed by addition of:
  • (c) 100 histamine (Tocris) at a final concentration of 0.3 μM; and
    (d) 200 guanosine 5′ [γ35-S] thiotriphosphate, triethylamine salt (Amersham; radioactivity concentration=37 kBq/μl or 1 mCi/ml; Specific Activity 1160 Ci/mmol) diluted to 1.9 nM in assay buffer to give 0.38 nM final. The plate is then incubated on a shaker at room temperature for 30 minutes followed by centrifugation for 5 minutes at 1500 rpm. The plate is read between 3 and 6 hours after completion of centrifuge run in a Wallac Microbeta counter on a 1 minute normalised tritium count protocol. Data is analysed using a 4-parameter logistic equation. Basal activity used as minimum i.e. histamine not added to well.
    • (III) Histamine H1 Functional Antagonist Assay
  • Compounds are assayed in a black walled clear bottom 384-well plate with cells seeded at 10000 cells/well. Tyrodes buffer is used throughout (NaCl 145 mM, KCl 2.5 mM, HEPES 10 mM, glucose 10 mM, MgCl2 1.2 mM, CaCl21.5 mM, probenecid 2.5 mM, pH adjusted to 7.40 with NaOH 1.0 M). Each well is treated with 10 μl of a solution of FLUO4AM (10 μM in Tyrodes buffer at pH 7.40) and plates are then incubated for 60 minutes at 37° C. Wells are then washed with Tyrodes buffer using a EMBLA cell washer system, leaving 400 buffer in each well, and then treated with 10 μl of test compound in Tyrodes buffer. Each plate is incubated for 30 min to allow equilibration of the test compound with the receptor. Each well is then treated with 10 μl of histamine solution in Tyrodes buffer.
  • Functional antagonism is indicated by a suppression of histamine induced increase in fluorescence, as measured by the FLIPR system (Molecular Devices). By means of concentration effect curves, functional potencies are determined using standard pharmacological mathematical analysis.
    • Results
  • The compounds of Examples E1-260, 263-479 and E499-503 were tested in the histamine H3 functional antagonist assay and exhibited antagonism>6.5 pKb. More particularly, the compounds of Examples E1, E3, E10, E12-14, E16-20, E21, E23, E24, E31, E33, E35-37, E40-42, E46-48, E51, E255-256, E258-260, E263, E265-267, E268-271, E273-274, E277-280, E284-288, E290-293, E295, E309, E311, E314-315, E317, E319-329, E331, E333, E342, E344, E346-348, E350, E352, E354-355, E361-363, E368, E374, E378, E380, E384, E386, E389, E391-393, E396-E399, E405, E407, E410-411, E414-415, E420-421, E423-424, E429-431, E434-435, E436-445, E449, E452-453 and E455-459 exhibited antagonism>8.4 pKb. Yet more particularly, the compounds of Examples E255, E259, E263, E269, E271, E274, E285-287, E292-293, E333, E344, E346 and E374 exhibited antagonism>9.0 pKb.
  • The compounds of Examples E53-254, E465-479 and E499-503 were tested in the histamine H1 functional antagonist assay and exhibited antagonism>6.5 pKb. More particularly, the compounds of Examples E60, E64-65, E67, E70, E84, E87, E91, E93, E95, E98, E100, E108-110, E112, E114-115, E135-136, E162, E171, E188-189, E195, E199, E206-212, E214-219, E224, E229, E231, E235, E242, E244, E466, E468-474 and E500-503 exhibited antagonism>7.3 pKb.

Claims (9)

1. A compound of formula (I)
Figure US20100075953A1-20100325-C00331
wherein:
R1 represents heteroaryl, optionally substituted by one or more: halogen; trifluoromethyl; —C1-6alkyl optionally substituted by COOR15; —C1-6alkoxy optionally substituted by COOR15; C1-6 alkenyl; NR15R16; or C1-6alkylthio groups, and in which
R15 and R16 independently represent hydrogen, C1-6alkyl or C3-8cycloalkyl or together may be fused to form a 5- to 7-membered non-aromatic heterocyclic ring optionally interrupted by an O or S atom and optionally substituted by halogen, C1-6alkyl or —C1-6alkylC1-6alkoxy group;
wherein R15 and R16 independently represent hydrogen, C1-6alkyl or C3-8cycloalkyl or together may be fused to form a 5- to 7-membered non-aromatic heterocyclic ring optionally interrupted by an O or S atom and optionally substituted by a halogen, C1-6alkyl or C1-6alkylC1-6alkoxy group;
Z is a bond or CO;
m is 0 or 2;
p is 1;
R3 represents —(CH2)q—NR11R12 in which q represents 3 and
NR11R12 represents pyrrolidinyl, piperidinyl, azepanyl or azocanyl optionally substituted by one or more C1-6 alkyl groups;
or a pharmaceutically acceptable salt thereof.
2. A compound according to claim 1, in which R1 represents optionally substituted benzofuranyl, indolyl, or quinolinyl.
3. A compound according to claim 1, wherein m is 0.
4. A compound according to claim 1, wherein R1 is optionally substituted by 1, 2 or 3 substituents selected from chlorine, fluorine, bromine, trifluoromethyl, methyl, ethyl, isopropyl, propyl or t-butyl (wherein the methyl, ethyl, isopropyl, propyl or t-butyl is optionally substituted by COOR15), methoxy (optionally substituted by COOR15), ethenyl, N(Me)2 or —S-ethyl.
5. A compound according to claim 1, wherein NR11R12 represents pyrrolidinyl, piperidinyl, azepanyl or azocanyl optionally substituted by one or more methyl or ethyl groups.
6. A compound according to claim 1 in which NR11R12 represents unsubstituted pyrrolidinyl, piperidinyl, azepanyl or azocanyl.
7. A pharmaceutical composition which comprises a compound of formula (I) as defined in claim 1 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient.
8. A method of treatment of diseases of the upper respiratory tract which comprises administering to a host in need thereof an effective amount of a compound of formula (I) as defined in claim 1 or a pharmaceutically acceptable salt thereof.
9. A method of treatment according to claim 8 in which the disease is allergic rhinitis.
US12/562,285 2002-10-16 2009-09-18 Substituted piperazines, (1,4) diazepines, and 2,5-diazabicyclo (2.2.1) heptanes as histamine h1 and/or h3 antagonists or histamine h3 reverse antagonists Abandoned US20100075953A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US12/562,285 US20100075953A1 (en) 2002-10-16 2009-09-18 Substituted piperazines, (1,4) diazepines, and 2,5-diazabicyclo (2.2.1) heptanes as histamine h1 and/or h3 antagonists or histamine h3 reverse antagonists

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB0224084.4A GB0224084D0 (en) 2002-10-16 2002-10-16 Novel compounds
GB0224084.4 2002-10-16
US10/531,758 US7615550B2 (en) 2002-10-16 2003-10-14 Substituted piperazines,(1,4) diazepines, and 2,5-diazabicyclo (2.2.1)iieptanes as histamine H1 and/or H3 antagonists or histamine H3 reverse antagonists
PCT/EP2003/011423 WO2004035556A1 (en) 2002-10-16 2003-10-14 Substituted piperazines, (1,4) diaszepines, and 2,5-diazabicyclo (2.2.1) heptanes as histamine h1 and/or h3 antagonists or histamine h3 reverse antagonists
US12/562,285 US20100075953A1 (en) 2002-10-16 2009-09-18 Substituted piperazines, (1,4) diazepines, and 2,5-diazabicyclo (2.2.1) heptanes as histamine h1 and/or h3 antagonists or histamine h3 reverse antagonists

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
US10/531,758 Continuation US7615550B2 (en) 2002-10-16 2003-10-14 Substituted piperazines,(1,4) diazepines, and 2,5-diazabicyclo (2.2.1)iieptanes as histamine H1 and/or H3 antagonists or histamine H3 reverse antagonists
PCT/EP2003/011423 Continuation WO2004035556A1 (en) 2002-10-16 2003-10-14 Substituted piperazines, (1,4) diaszepines, and 2,5-diazabicyclo (2.2.1) heptanes as histamine h1 and/or h3 antagonists or histamine h3 reverse antagonists

Publications (1)

Publication Number Publication Date
US20100075953A1 true US20100075953A1 (en) 2010-03-25

Family

ID=9946029

Family Applications (2)

Application Number Title Priority Date Filing Date
US10/531,758 Expired - Fee Related US7615550B2 (en) 2002-10-16 2003-10-14 Substituted piperazines,(1,4) diazepines, and 2,5-diazabicyclo (2.2.1)iieptanes as histamine H1 and/or H3 antagonists or histamine H3 reverse antagonists
US12/562,285 Abandoned US20100075953A1 (en) 2002-10-16 2009-09-18 Substituted piperazines, (1,4) diazepines, and 2,5-diazabicyclo (2.2.1) heptanes as histamine h1 and/or h3 antagonists or histamine h3 reverse antagonists

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US10/531,758 Expired - Fee Related US7615550B2 (en) 2002-10-16 2003-10-14 Substituted piperazines,(1,4) diazepines, and 2,5-diazabicyclo (2.2.1)iieptanes as histamine H1 and/or H3 antagonists or histamine H3 reverse antagonists

Country Status (18)

Country Link
US (2) US7615550B2 (en)
EP (1) EP1567511A1 (en)
JP (2) JP2006508935A (en)
KR (1) KR20050049553A (en)
CN (2) CN101070309A (en)
AU (1) AU2003280380A1 (en)
BR (1) BR0315283A (en)
CA (1) CA2502249A1 (en)
GB (1) GB0224084D0 (en)
IS (1) IS7782A (en)
MA (1) MA27482A1 (en)
MX (1) MXPA05004078A (en)
NO (1) NO20051689L (en)
NZ (2) NZ539446A (en)
PL (1) PL376477A1 (en)
RU (1) RU2328494C2 (en)
WO (1) WO2004035556A1 (en)
ZA (2) ZA200502873B (en)

Families Citing this family (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7842693B2 (en) 2002-06-12 2010-11-30 Chemocentryx, Inc. Substituted piperazines
US7589199B2 (en) 2002-06-12 2009-09-15 Chemocentryx, Inc. Substituted piperazines
US20050256130A1 (en) * 2002-06-12 2005-11-17 Chemocentryx, Inc. Substituted piperazines
GB0224084D0 (en) * 2002-10-16 2002-11-27 Glaxo Group Ltd Novel compounds
GB0224557D0 (en) 2002-10-22 2002-11-27 Glaxo Group Ltd Novel compounds
US20070293216A1 (en) * 2003-02-14 2007-12-20 Roamware Inc. Method and system for providing PLN service to inbound roamers in a VPMN using a standalone approach when no roaming relationship exists between HPMN and VPMN
CA2521000A1 (en) * 2003-04-03 2004-10-21 Kyowa Hakko Kogyo Co., Ltd. Preventive and/or therapeutic agent for neuropathic pain
US20060293298A1 (en) * 2003-04-10 2006-12-28 Bamford Mark J Compounds
GB0316915D0 (en) 2003-07-18 2003-08-20 Glaxo Group Ltd Compounds
GB0324159D0 (en) 2003-10-15 2003-11-19 Glaxo Group Ltd Novel compounds
CA2561791A1 (en) * 2004-03-31 2005-10-20 Janssen Pharmaceutica, N.V. Non-imidazole heterocyclic compounds
WO2005110982A2 (en) 2004-04-07 2005-11-24 Neurogen Corporation Substituted 1-benzyl-4-substituted piperazine analogues
CA2564068A1 (en) * 2004-04-15 2005-11-17 Samaritan Pharmaceuticals, Inc. Use of (4-alkylpiperazinyl) (phenyl) methanones in the treatment of alzheimer's disease
JP2007538011A (en) * 2004-05-07 2007-12-27 メモリー・ファーマシューティカルズ・コーポレイション 1H-indazole, benzothiazole, 1,2-benzisoxazole, 1,2-benzisothiazole, and chromone, and their preparation and use
CA2588867A1 (en) * 2004-12-01 2006-06-08 Banyu Pharmaceutical Co., Ltd. Substituted pyridone derivative
EP1851201A1 (en) * 2005-02-24 2007-11-07 Glaxo Group Limited 1-{4-[(1-cyclobutyl-4-piperidinyl)oxy]phenyl}-4-{[4-(methylsulfonyl)phenyl]carbonyl}piperazine as histamine h3 antagonist
MX2007011374A (en) * 2005-03-17 2007-11-23 Lilly Co Eli Pyrrolidine derivatives as histamine h3 receptor antagonists.
EP1717235A3 (en) * 2005-04-29 2007-02-28 Bioprojet Phenoxypropylpiperidines and -pyrrolidines and their use as histamine H3-receptor ligands
CN101228127B (en) * 2005-05-30 2012-05-16 Msdk.K.公司 Piperidine derivatives
NZ562766A (en) 2005-05-30 2011-03-31 Banyu Pharma Co Ltd Piperidine derivatives as histamine-H3 receptor antagonists
GB0514811D0 (en) * 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
GB0514812D0 (en) * 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
GB0521563D0 (en) 2005-10-21 2005-11-30 Glaxo Group Ltd Novel compounds
WO2007048595A1 (en) * 2005-10-27 2007-05-03 Ucb Pharma, S.A. Compounds comprising a lactam or a lactam derivative moiety, processes for making them, and their uses
CA2629232A1 (en) * 2005-11-18 2007-05-24 F. Hoffmann-La Roche Ag Azaindole-2-carboxamide derivatives
KR101124156B1 (en) * 2005-11-30 2012-03-23 에프. 호프만-라 로슈 아게 1,5-substituted indol-2-yl amide derivatives
BRPI0619266A2 (en) * 2005-11-30 2011-09-27 Hoffmann La Roche compounds, process for their manufacture, pharmaceutical compositions, methods for treating and / or preventing diseases that are associated with h3 receptor modulation, obesity, type ii diabetes and their use
CN101331131A (en) * 2005-12-16 2008-12-24 霍夫曼-拉罗奇有限公司 Pyrrolo[2,3-b]pyridine derivatives useful as H3 receptor modulators
AR058109A1 (en) * 2005-12-20 2008-01-23 Glaxo Group Ltd ACID 3 - (4 - {[4 - (4 - {[3 - (3, 3 - DIMETILE - 1 - PIPERIDINIL) PROPIL] OXI} PHENYL) - 1 - PIPERIDINIL] CARBONIL} - 1 - NAFTALENIL) PROPANOIC AS ANTAGONISTS OF THE RECEIVERS OF HISTAMINE H1 / H3, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND THEIR USE IN THE PREPARATION OF MEDICINES FOR THE TREATMENT
PE20080360A1 (en) * 2006-04-20 2008-05-22 Glaxo Group Ltd 2-SUBSTITUTED 4-BENZYLFTALAZINONE DERIVATIVES AS HISTAMINES H1 AND H3 ANTAGONISTS
MX2008013411A (en) 2006-04-20 2008-11-04 Glaxo Group Ltd Novel compounds.
GB0609897D0 (en) * 2006-05-18 2006-06-28 Glaxo Group Ltd Compounds
JP5285603B2 (en) * 2006-05-30 2013-09-11 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Substituted pyridylamide compounds as modulators of histamine H3 receptors
GB0611587D0 (en) 2006-06-12 2006-07-19 Glaxo Group Ltd Novel compounds
US9108948B2 (en) 2006-06-23 2015-08-18 Abbvie Inc. Cyclopropyl amine derivatives
NZ611323A (en) 2006-06-23 2014-10-31 Abbvie Bahamas Ltd Cyclopropyl amine derivatives as histamin h3 receptor modulators
US20080045507A1 (en) * 2006-06-29 2008-02-21 Allison Brett D Substituted benzamide modulators of the histamine h3 receptor
KR101007469B1 (en) 2006-12-22 2011-01-12 성균관대학교산학협력단 Homopiperazine compounds that bind to the RNA-like knotted structure of SARS coronavirus to inhibit ribosomal translocation
PE20081889A1 (en) 2007-03-23 2009-03-05 Smithkline Beecham Corp INDOL CARBOXAMIDES AS INHIBITORS OF IKK2
ATE554081T1 (en) 2007-09-06 2012-05-15 Glaxo Group Ltd PIPERAZINE DERIVATIVES WITH AFFINITY FOR HISTAMINE H3 RECEPTOR
CN101801954B (en) 2007-09-20 2013-10-09 Irm责任有限公司 Compounds and compositions as modulators of GPR119 activity
EP2222664B1 (en) 2007-11-20 2014-10-29 Janssen Pharmaceutica, N.V. Cycloalkyloxy- and heterocycloalkyloxypyridine compounds as modulators of the histamine h3 receptor
EP2271619A1 (en) * 2008-04-07 2011-01-12 Irm Llc Compounds and compositions as modulators of gpr119 activity
MX2010012814A (en) 2008-05-23 2010-12-20 Amira Pharmaceuticals Inc 5-lipoxygenase-activating protein inhibitor.
WO2009147187A1 (en) 2008-06-05 2009-12-10 Glaxo Group Limited 4-carboxamide indazole derivatives useful as inhibitors of p13-kinases
WO2010094643A1 (en) 2009-02-17 2010-08-26 Glaxo Group Limited Quinoline derivatives and their uses for rhinitis and urticaria
WO2010102958A1 (en) 2009-03-09 2010-09-16 Glaxo Group Limited 4-oxadiazol-2 -yl- indazoles as inhibitors of p13 kinases
US8354539B2 (en) 2009-03-10 2013-01-15 Glaxo Group Limited Indole derivatives as IKK2 inhibitors
US20120058984A1 (en) 2009-03-17 2012-03-08 Catherine Mary Alder Pyrimidine derivatives used as itk inhibitors
WO2010107952A2 (en) 2009-03-19 2010-09-23 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF CONNECTIVE TISSUE GROWTH FACTOR (CTGF) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US20120029054A1 (en) 2009-03-19 2012-02-02 Merck Sharp & Dohme Corp. RNA Interference Mediated Inhibition of GATA Binding Protein 3 (GATA3) Gene Expression Using Short Intefering Nucleic Acid (siNA)
US20120035247A1 (en) 2009-03-19 2012-02-09 Merck Sharp & Dohme Corp. RNA Interference Mediated Inhibition of Signal Transducer and Activator of Transcription 6 (STAT6) Gene Expression Using Short Interfering Nucleic Acid (siNA)
US20120016010A1 (en) 2009-03-19 2012-01-19 Merck Sharp & Dohme Corp RNA Interference Mediated Inhibition of BTB and CNC Homology 1, Basic Leucine Zipper Transcription Factor 1 (BACH1) Gene Expression Using Short Interfering Nucleic Acid (siNA)
EP2411019A2 (en) 2009-03-27 2012-02-01 Merck Sharp&Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 1 (STAT1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
WO2010111468A2 (en) 2009-03-27 2010-09-30 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF THE NERVE GROWTH FACTOR BETA CHAIN (NGFß) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (SINA)
US20120022143A1 (en) 2009-03-27 2012-01-26 Merck Sharp & Dohme Corp RNA Interference Mediated Inhibition of the Thymic Stromal Lymphopoietin (TSLP) Gene Expression Using Short Interfering Nucliec Acid (siNA)
JP2012524754A (en) 2009-04-24 2012-10-18 グラクソ グループ リミテッド Pyrazole and triazolcarboxamides as CRAC channel inhibitors
AR076373A1 (en) 2009-04-24 2011-06-08 Glaxo Group Ltd N-PIRAZOLIL CARBOXAMIDS AS CALCIUM CHANNEL INHIBITORS
US9186353B2 (en) 2009-04-27 2015-11-17 Abbvie Inc. Treatment of osteoarthritis pain
PL2899191T3 (en) 2009-04-30 2018-01-31 Glaxo Group Ltd Oxazole substituted indazoles as pi3-kinase inhibitors
WO2011002984A1 (en) 2009-07-02 2011-01-06 Cephalon, Inc. Substituted phenoxypropylcycloamine derivatives as histamine-3 (h3) receptor ligands
CN102686579A (en) * 2009-10-09 2012-09-19 Irm责任有限公司 Compounds and compositions as modulators of GPR119 activity
WO2011067365A1 (en) 2009-12-03 2011-06-09 Glaxo Group Limited Benzpyrazole derivatives as inhibitors of p13 kinases
EP2507231A1 (en) 2009-12-03 2012-10-10 Glaxo Group Limited Indazole derivatives as pi 3 - kinase inhibitors
US20120238559A1 (en) 2009-12-03 2012-09-20 Glaxo Group Limited Novel compounds
WO2011110575A1 (en) 2010-03-11 2011-09-15 Glaxo Group Limited Derivatives of 2-[2-(benzo- or pyrido-) thiazolylamino]-6-aminopyridine, useful in the treatment of respiratoric, allergic or inflammatory diseases
GB201007203D0 (en) 2010-04-29 2010-06-16 Glaxo Group Ltd Novel compounds
WO2012025474A1 (en) 2010-08-24 2012-03-01 Glaxo Group Limited Indazole compounds
WO2012025473A1 (en) 2010-08-24 2012-03-01 Glaxo Group Limited Cc.chemokine receptor 4 antagonists
DE112010005848B4 (en) * 2010-09-06 2016-03-10 Guangzhou Institutes Of Biomedicine And Health, Chinese Academy Of Sciences amide compounds
HUE026059T2 (en) 2010-09-08 2016-05-30 Glaxosmithkline Ip Dev Ltd POLYMORPHS AND SALTS OF N-[5-[4-(5-{[(2R,6S)-2,6-DIMETHYL-4-MORPHOLINYL]METHYL}-& xA;1,3-OXAZOL-2-YL)-1H-INDAZOL-6-YL]-2-(METHYLOXY)-3-PYRIDINYL]METHANESULFONAMIDE
US8853390B2 (en) 2010-09-16 2014-10-07 Abbvie Inc. Processes for preparing 1,2-substituted cyclopropyl derivatives
WO2012035055A1 (en) 2010-09-17 2012-03-22 Glaxo Group Limited Novel compounds
US9149462B2 (en) 2010-10-21 2015-10-06 Glaxo Group Limited Pyrazole compounds acting against allergic, inflammatory and immune disorders
WO2012052458A1 (en) 2010-10-21 2012-04-26 Glaxo Group Limited Pyrazole compounds acting against allergic, immune and inflammatory conditions
GB201018124D0 (en) 2010-10-27 2010-12-08 Glaxo Group Ltd Polymorphs and salts
EP2683716A1 (en) 2011-03-11 2014-01-15 Glaxo Group Limited Pyrido[3,4-b]pyrazine derivatives as syk inhibitors
GB201104153D0 (en) 2011-03-11 2011-04-27 Glaxo Group Ltd Novel compounds
US9428478B2 (en) 2011-06-13 2016-08-30 Emory University Piperazine derivatives, compositions, and uses related thereto
WO2013151982A1 (en) 2012-04-03 2013-10-10 Arena Pharmaceuticals, Inc. Methods and compounds useful in treating pruritus, and methods for identifying such compounds
JP6494634B2 (en) 2013-09-22 2019-04-03 キャリター・サイエンシーズ・リミテッド・ライアビリティ・カンパニーＣａｌｉｔｏｒ Ｓｃｉｅｎｃｅｓ， Ｌｌｃ Aminopyrimidine compounds substituted and methods of use
US9233953B2 (en) * 2013-10-16 2016-01-12 Boehringer Ingelheim International Gmbh Derivatives of 4-(piperazinylcarbonyl)thiane-1, 1-dione which inhibit GlyT1
WO2015055691A1 (en) 2013-10-17 2015-04-23 Glaxosmithkline Intellectual Property Development Limited Pi3k inhibitor for treatment of respiratory disease
CA2923995A1 (en) 2013-10-17 2015-04-23 Glaxosmithkline Intellectual Property Development Limited Pi3k inhibitor for treatment of respiratory disease
WO2015069110A1 (en) * 2013-11-07 2015-05-14 Aapa B.V. Multiple d2 a(nta)gonists/h3 antagonists for treatment of cns-related disorders
EP3312164B1 (en) 2014-03-28 2020-12-09 Calitor Sciences, LLC Substituted heteroaryl compounds and methods of use
TW201625247A (en) 2014-05-12 2016-07-16 葛蘭素史密斯克藍智慧財產權有限公司 Pharmaceutical composition for treating infectious diseases
JP2018527362A (en) 2015-09-11 2018-09-20 サンシャイン・レイク・ファーマ・カンパニー・リミテッドＳｕｎｓｈｉｎｅ Ｌａｋｅ Ｐｈａｒｍａ Ｃｏ．，Ｌｔｄ． Substituted heteroaryl compounds and methods of use
GB201602527D0 (en) 2016-02-12 2016-03-30 Glaxosmithkline Ip Dev Ltd Chemical compounds
EP3497100A1 (en) 2016-08-08 2019-06-19 GlaxoSmithKline Intellectual Property Development Limited Chemical compounds
CA3034211A1 (en) 2016-08-18 2018-02-22 Vidac Pharma Ltd. Piperazine derivatives, pharmaceutical compositions and methods of use thereof
GB201706102D0 (en) 2017-04-18 2017-05-31 Glaxosmithkline Ip Dev Ltd Chemical compounds
CN109232549B (en) * 2017-07-11 2022-07-12 江苏恩华药业股份有限公司 Compound for treating schizophrenia and application thereof
GB201712081D0 (en) 2017-07-27 2017-09-13 Glaxosmithkline Ip Dev Ltd Chemical compounds
US10683297B2 (en) 2017-11-19 2020-06-16 Calitor Sciences, Llc Substituted heteroaryl compounds and methods of use
US10751339B2 (en) 2018-01-20 2020-08-25 Sunshine Lake Pharma Co., Ltd. Substituted aminopyrimidine compounds and methods of use
US11744833B2 (en) 2019-04-12 2023-09-05 LA PharmaTech Inc. Pharmaceutical compositions and methods for treatment of insomnia
US10898493B2 (en) 2019-04-12 2021-01-26 LA PharmaTech Inc. Pharmaceutical compositions and methods for psychiatric symptoms of patients with Alzheimer's disease
US11690849B2 (en) 2019-04-12 2023-07-04 LA PharmaTech Inc. Method of treating dementia
US11938139B2 (en) 2019-04-12 2024-03-26 LA PharmaTech Inc. Pharmaceutical compositions and methods for anxiety, depression and other psychiatric disorders
US11389458B2 (en) 2019-04-12 2022-07-19 LA PharmaTech Inc. Pharmaceutical compositions and methods for treating parkinson's and huntington's disease
US11318144B2 (en) 2019-04-12 2022-05-03 LA PharmaTech Inc. Compositions and methods for treating Alzheimer's disease and Parkinson's disease
US10639314B1 (en) 2019-04-30 2020-05-05 LA PharmaTech Inc. Method of treating Alzheimer's disease
US10639315B1 (en) 2019-05-21 2020-05-05 LA PharmaTech Inc. Pharmaceutical compositions and methods for treating Alzheimer's disease
US10966989B2 (en) 2019-04-12 2021-04-06 LA PharmaTech Inc. Pharmaceutical compositions and methods for treating mental, behavioral, cognitive disorders
CA3137393A1 (en) * 2019-04-30 2020-11-05 Jianmin Wang A method of treating mental, behavioral, cognitive disorders
WO2021191875A1 (en) 2020-03-26 2021-09-30 Glaxosmithkline Intellectual Property Development Limited Cathepsin inhibitors for preventing or treating viral infections
US11351179B1 (en) 2021-08-05 2022-06-07 LA PharmaTech Inc. Pharmaceutical compositions and methods for treatment of psychiatric disorders

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3996361A (en) * 1974-01-11 1976-12-07 Boehringer Mannheim G.M.B.H. N6 -Substituted-9-[3-(4-phenyl-piperazino)-propyl]-adenines
US4405620A (en) * 1980-01-19 1983-09-20 Beecham Group Limited Piperazine derivatives
US5364791A (en) * 1992-05-14 1994-11-15 Elisabetta Vegeto Progesterone receptor having C. terminal hormone binding domain truncations
US5874534A (en) * 1992-05-14 1999-02-23 Baylor College Of Medicine Mutated steroid hormone receptors, methods for their use and molecular switch for gene therapy
US5880128A (en) * 1996-05-08 1999-03-09 Schering Corporation Carbonyl piperazinyl and piperidinyl compounds
US20020137931A1 (en) * 2000-07-13 2002-09-26 Bennani Yousseff L. 1,3-disubstituted and 1,3,3-trisubstituted pyrrolidines as histamine-3 receptor ligands and their therapeutic applications
US20060019964A1 (en) * 2002-10-16 2006-01-26 Ancliff Ranchael A Compounds
US20090181950A1 (en) * 2006-05-18 2009-07-16 Glaxo Group Limited Histamine Receptor Antagonists Comprising an Azepin Core

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4410822A1 (en) 1994-03-24 1995-09-28 Schering Ag New piperidine derivatives
US5464788A (en) 1994-03-24 1995-11-07 Merck & Co., Inc. Tocolytic oxytocin receptor antagonists
USH2007H1 (en) 1996-01-19 2001-12-04 Fmc Corporation Insecticidal N-heterocyclylalkyl-or N-[(polycyclyl)alkyl]-N′substituted piperazines
WO1999041242A1 (en) 1998-02-13 1999-08-19 Rhone-Poulenc Rorer S.A. Di-substituted naphthyl derivatives, preparation thereof, pharmaceutical compositions containing them
CA2415396C (en) * 2000-07-13 2011-03-08 Abbott Laboratories 1,3-disubstituted and 1,3,3-trisubstituted pyrrolidines as histamine-3 receptor ligands and their therapeutic applications
CA2416192A1 (en) 2000-07-18 2003-01-15 Basf Aktiengesellschaft 1-aryl-4-alkyl halide-2(1h)-pyridones and their use as herbicides
CN1468227A (en) * 2000-08-08 2004-01-14 ����-������ҩƷ��˾ Non-imidazole aryloxyalkylamines
DE60126785T2 (en) * 2000-08-08 2007-10-25 Ortho-Mcneil Pharmaceutical, Inc. NON-IMIDAZOLE ARYLOXYPIPERIDINE AS H3 RECEPTOR LIGANDEN
JP2002173426A (en) 2000-12-05 2002-06-21 Ss Pharmaceut Co Ltd Hypoglycemic agent
JP2004520347A (en) 2001-01-15 2004-07-08 グラクソ　グループ　リミテッド Arylpiperidine and piperazine derivatives as inducers of LDL-receptor expression
EP1379493A2 (en) 2001-03-23 2004-01-14 Eli Lilly and Company Non-imidazole aryl alkylamines compounds as histamine h3 receptor antagonists, preparation and therapeutic uses
JP4186518B2 (en) * 2001-06-15 2008-11-26 アステラス製薬株式会社 Phenylpyridine derivatives
US7459461B2 (en) 2001-10-19 2008-12-02 Ortho-Mcneil Pharmaceutical, Inc. Phosphonic acid compounds as inhibitors of serine proteases
IL162859A0 (en) * 2002-02-05 2005-11-20 Novo Nordisk As Novel aryl-and heteroarylpiperazines
GB0224084D0 (en) * 2002-10-16 2002-11-27 Glaxo Group Ltd Novel compounds

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3996361A (en) * 1974-01-11 1976-12-07 Boehringer Mannheim G.M.B.H. N6 -Substituted-9-[3-(4-phenyl-piperazino)-propyl]-adenines
US4405620A (en) * 1980-01-19 1983-09-20 Beecham Group Limited Piperazine derivatives
US5364791A (en) * 1992-05-14 1994-11-15 Elisabetta Vegeto Progesterone receptor having C. terminal hormone binding domain truncations
US5874534A (en) * 1992-05-14 1999-02-23 Baylor College Of Medicine Mutated steroid hormone receptors, methods for their use and molecular switch for gene therapy
US5935934A (en) * 1992-05-14 1999-08-10 Baylor College Of Medicine Mutated steroid hormone receptors, methods for their use and molecular switch for gene therapy
US5880128A (en) * 1996-05-08 1999-03-09 Schering Corporation Carbonyl piperazinyl and piperidinyl compounds
US20020137931A1 (en) * 2000-07-13 2002-09-26 Bennani Yousseff L. 1,3-disubstituted and 1,3,3-trisubstituted pyrrolidines as histamine-3 receptor ligands and their therapeutic applications
US20060019964A1 (en) * 2002-10-16 2006-01-26 Ancliff Ranchael A Compounds
US20090181950A1 (en) * 2006-05-18 2009-07-16 Glaxo Group Limited Histamine Receptor Antagonists Comprising an Azepin Core

Also Published As

Publication number Publication date
CA2502249A1 (en) 2004-04-29
GB0224084D0 (en) 2002-11-27
BR0315283A (en) 2005-08-30
JP2006508935A (en) 2006-03-16
NO20051689D0 (en) 2005-04-05
CN1726201A (en) 2006-01-25
ZA200502873B (en) 2006-07-26
EP1567511A1 (en) 2005-08-31
PL376477A1 (en) 2005-12-27
NZ549963A (en) 2008-03-28
ZA200603604B (en) 2007-04-25
KR20050049553A (en) 2005-05-25
IS7782A (en) 2005-03-31
MA27482A1 (en) 2005-08-01
NZ539446A (en) 2006-11-30
MXPA05004078A (en) 2005-06-08
AU2003280380A1 (en) 2004-05-04
RU2328494C2 (en) 2008-07-10
NO20051689L (en) 2005-07-07
US7615550B2 (en) 2009-11-10
CN101070309A (en) 2007-11-14
WO2004035556A1 (en) 2004-04-29
JP2007016041A (en) 2007-01-25
US20060025404A1 (en) 2006-02-02
RU2005110061A (en) 2006-01-20
CN100400523C (en) 2008-07-09

Similar Documents

Publication Publication Date Title
US20100075953A1 (en) Substituted piperazines, (1,4) diazepines, and 2,5-diazabicyclo (2.2.1) heptanes as histamine h1 and/or h3 antagonists or histamine h3 reverse antagonists
US8492375B2 (en) 1-benzoyl substituted diazepine derivatives as selective histamine H3 receptor agonists
JP4584831B2 (en) Benzazepine derivatives for the treatment of diseases of the nervous system
US7446103B2 (en) Bicyclic benzamide compound as histamine H3 receptor ligand useful in the treatment of neurological diseases
US7538121B2 (en) Vanilloid receptor modulators
US7592347B2 (en) Piperazine derivates and their use for the treatment of neurological and psychiatric diseases
US20050124626A1 (en) Novel compounds
US20060247227A1 (en) Substituted piperidines as histamine h3 receptor ligands
US7439243B2 (en) Piperazinyl-quinoline derivatives useful for the treatment of CNS disorders
US20080039499A1 (en) Chemical Compounds
US20070191345A1 (en) 3-((Hetero)arylsulfonyl)-8-'(aminoalkyl)oxyquinolines as 5-ht6 receptor antagonists for the treatment of cns disorders
US20080009479A1 (en) Tetrahydrobenzazepines as Histamine H3 Receptor Ligands
US5466691A (en) Thiophene compound
WO2004035544A1 (en) Benzo[d]azepine derivatives for the treatment of neurological and psychiatric disorders
US8518947B2 (en) (Heterocycle/tetrahydropyridine)-(piperazinyl)-1-alcanone and (heterocycle/dihydropyrrolidine)-(piperazinyl)-1-alcanone derivatives, and use thereof as p75 inhibitors
CA2093516A1 (en) Thiophene compound

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION